{
    "url": "https://www.sec.gov/Archives/edgar/data/1133818/000155837024002730/bpth-20231231x10k.htm",
    "report_type": "10-K",
    "context": [
        {
            "id": 0,
            "context": "ITEM 1. BUSINESS\nOverview We are a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize\u00ae, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body\u2019s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize\u00ae delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Through testing in numerous animal studies and dosing in clinical trials, our DNAbilize\u00ae drug candidates have demonstrated an excellent safety profile. DNAbilize\u00ae is a registered trademark of the Company.",
            "type": "paragraph"
        },
        {
            "id": 1,
            "context": "Using DNAbilize\u00ae as a platform for drug development and manufacturing, we currently have four drug candidates in development to treat at least five different cancer disease indications (Figure 1). Our lead drug candidate, prexigebersen (pronounced prex\u201d i je ber\u2019 sen), which targets growth factor receptor-bound protein 2 (\u201cGrb2\u201d), initially started the efficacy portion of a Phase 2 clinical trial for untreated acute myeloid leukemia (\u201cAML\u201d) patients in combination with low-dose cytarabine (\u201cLDAC\u201d). The interim data presented in the 2018 American Society of Hematology (\u201cASH\u201d) Annual Meeting showed that 11 (65%) of the 17 evaluable patients had a response, including five (29%) who achieved complete remission (\u201cCR\u201d), inclusive of one CR with incomplete hematologic recovery (\u201cCRi\u201d) and one morphologic leukemia-free state, and six (35%) stable disease responses, including two patients who had greater than a 50% reduction in bone marrow blasts. However, DNA hypomethylating agents are now the most frequently used agents in the treatment of elderly AML patients in the U.S. and Europe. As a result, Stage 2 of the Phase 2 trial in AML was amended to remove the combination treatment of prexigebersen and LDAC and replace it with the combination treatment of prexigebersen and decitabine, a DNA hypomethylating agent, for treatment of a second cohort of untreated AML patients. Since decitabine is also used as a treatment for relapsed/refractory AML patients, a cohort of relapsed/refractory AML patients was also added to the study.",
            "type": "paragraph"
        },
        {
            "id": 2,
            "context": "The U.S. Food and Drug Administration (\u201cFDA\u201d) granted approval of venetoclax in combination with LDAC, decitabine or azacytidine (the latter two drugs are DNA hypomethylating agents) as frontline therapy for newly diagnosed AML in adults who are 75 years or older, or who have comorbidities precluding intensive induction chemotherapy. We believe this approval of the frontline venetoclax and decitabine combination therapy provides an opportunity for combining prexigebersen with the combination therapy for the treatment of newly diagnosed AML patients. Preclinical efficacy studies for the triple combination treatment of prexigebersen, decitabine and venetoclax in AML have been successfully completed. In the preclinical efficacy studies, four AML cancer cell lines were treated with three different combinations of decitabine, venetoclax and prexigebersen. Decrease in AML cell viability was the primary measure of efficacy. The triple combination of decitabine, venetoclax and prexigebersen showed significant improvement in efficacy in three of the four AML cell lines. Based on these results, we believe that adding prexigebersen to the treatment combination of decitabine and venetoclax could lead to improved efficacy in AML patients. Accordingly, we further amended Stage 2 of this Phase 2 clinical trial to add the triple combination treatment comprised of prexigebersen, decitabine and venetoclax.",
            "type": "paragraph"
        },
        {
            "id": 3,
            "context": "Our approved amended Stage 2 for this Phase 2 clinical trial currently has three cohorts of patients. The first two cohorts will treat patients with the triple combination of prexigebersen, decitabine and venetoclax. The first cohort will include untreated AML patients, and the second cohort will include relapsed/refractory AML patients. Finally, the third cohort will treat relapsed/refractory AML patients, who are venetoclax-resistant or -intolerant, with the two-drug combination of prexigebersen and decitabine. The full trial design plans have approximately 98 evaluable patients for the first cohort having untreated AML patients with a preliminary review performed after 19 evaluable patients and a formal interim analysis after 38 evaluable patients. The full trial design plans have approximately 54 evaluable patients for each of the second cohort, having relapsed/refractory AML patients, and the third cohort, having AML patients who are venetoclax-resistant or -intolerant, in each case with a review performed after 19 evaluable patients. The study is anticipated to be conducted at up to ten clinical sites in the U.S., and Gail J. Roboz, MD, is the national coordinating Principal Investigator for the Phase 2 trial. Dr. Roboz is a professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University (the \u201cWeill Medical College\u201d) and the New York-Presbyterian Hospital in New York City. On August 13, 2020, we announced the enrollment and dosing of the first patient in this approved amended Stage 2 of the Phase 2 clinical trial.",
            "type": "paragraph"
        },
        {
            "id": 4,
            "context": "2 The safety run-in of Stage 2 of the Phase 2 clinical study was successfully completed, and the preliminary data was presented at the 2021 ASH Annual Meeting. In the safety run-in of the triple combination, six evaluable patients were treated with the combination of prexigebersen, decitabine and venetoclax. These patients included four relapsed/refractory AML patients, and two newly diagnosed AML patients. Five patients (83%) responded to treatment, including four (67%) achieving CR and one (17%) achieving CRi. Recent publications provide that response (CR + CRi) rates to combination treatment with decitabine and venetoclax (but without prexigebersen) are 42 to 52% for relapsed/refractory AML patients and 0 to 39% for relapsed/refractory secondary AML patients. Response rates to frontline treatment with decitabine and venetoclax (but without prexigebersen) are 62 to 71% for newly diagnosed AML patients. These preliminary data showed the treatment was well-tolerated and there were no dose limiting toxicities attributed to prexigebersen. Three patients remained on treatment for more than one cycle.On August 1, 2023, we announced interim data for the first two cohorts of the amended Stage 2 of the Phase 2 clinical trial. Fourteen newly diagnosed patients were evaluable in the first cohort and treated with at least one cycle of the prexigebersen, decitabine and venetoclax combination therapy. All patients in the first cohort (median age 75) were adverse risk by 2017 European LeukemiaNet (\u201cELN\u201d) guidelines (n=10) or secondary AML (n=4). Prexigebersen was well-tolerated, and adverse events (\u201cAEs\u201d) were generally consistent with decitabine and venetoclax treatment and/or for AML. Twelve of the 14 evaluable patients (86%) achieved CR/CRi and two (14%) achieved partial remission (\u201cPR\u201d). In total, 100% of the evaluable patients had a response to treatment. The CR/CRi rates of 86% for the evaluable patients in the first cohort is significantly higher than the CR/CRi rates of 62% for newly diagnosed patients treated with the frontline combination treatment of decitabine and venetoclax. Fourteen refractory/relapsed evaluable AML patients in the second cohort were treated with at least one cycle of the prexigebersen, decitabine and venetoclax combination therapy. Substantially all of the patients in the second cohort (median age 56.5) were adverse risk by 2017 ELN guidelines (n=11) or secondary AML (n=2). Prexigebersen was well-tolerated, and AEs were generally consistent with decitabine and venetoclax treatment and/or for AML. Eight of the 14 evaluable refractory/relapsed patients (57%) achieved CR/CRi, two (14%) achieved PR and two (22%) achieved stable disease. In total, 93% of the evaluable patients in the second cohort had a response to treatment. The CR/CRi rates of 57% for the evaluable refractory and relapsed patients in the second cohort is significantly higher than the CR/CRi rates of 21% for refractory/relapsed patients treated with the combination treatment of decitabine and venetoclax. Based on this interim data, we currently plan to pursue FDA expedited programs for Fast Track designation, and we are evaluating whether to seek to expand Stage 2 of the Phase 2 clinical trial in Europe.Our second drug candidate, Liposomal Bcl-2 (\u201cBP1002\u201d), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. A Phase 1 clinical trial to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia (\u201cCLL\u201d) patients has been initiated. The Phase 1 clinical trial is being conducted at the Georgia Cancer Center while two additional clinical trial sites are currently being activated for inclusion in the study, The University of Texas Southwestern and New York Medical College. On January 10, 2024, we announced the successful completion of the first dose cohort in the Phase 1 clinical trial. A total of six evaluable patients are scheduled to be treated with BP1002 monotherapy in a standard 3+3 design, unless there is a dose limiting toxicity which would require an additional three patients to be tested. There were no dose limiting toxicities in the first dose cohort (20 mg/m2). Enrollment is now open for patients for the second BP1002 dose cohort of 40 mg/m2.Additionally, preclinical studies suggest that the combination of BP1002 with decitabine is efficacious in venetoclax-resistant leukemia and lymphoma cells. An abstract of the preclinical study was presented at the 2021 American Association for Cancer Research (\u201cAACR\u201d) Annual Meeting. A Phase 1/1b clinical trial to investigate the ability of BP1002 to treat refractory/relapsed AML patients, including venetoclax-resistant patients, is being studied. A recent study1 found that AML patients who had relapsed from frontline venetoclax-based treatment had a very poor prognosis, with a median survival of less than three months. Since venetoclax and BP1002 utilize different mechanisms of action, we believe that BP1002 may be a potential treatment for venetoclax-relapsed AML patients. The Phase 1/1b clinical trial is being conducted at several leading cancer centers in the United States, including the Weill Medical College, The University of Texas MD Anderson Cancer Center (\u201cMD Anderson\u201d), Scripps Health and The University of California at Los Angeles Cancer Center. On December 14, 2023, we announced the successful completion of the first dose cohort of the dose escalation portion of the Phase 1/1b clinical trial of BP1002. A total of three evaluable patients per dosing cohort are scheduled to be treated with BP1002 monotherapy in a standard 3+3 design. The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities. Enrollment is now open for patients for the second BP1002 dose cohort of 40 1 (Maiti A, Ruasch C, Cortes JE, et.al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 2021; 106: 894-898.)3",
            "type": "paragraph"
        },
        {
            "id": 5,
            "context": "mg/m2. The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and is intended to assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.Our third drug candidate, Liposomal STAT3 (\u201cBP1003\u201d), targets the STAT3 protein and is currently in IND enabling studies as a potential treatment of pancreatic cancer, non-small cell lung cancer (\u201cNSCLC\u201d) and AML. Preclinical models have shown BP1003 to inhibit cell viability and STAT3 protein expression in NSCLC and AML cell lines. Further, BP1003 successfully penetrated pancreatic tumors ex vivo and significantly enhanced the efficacy of gemcitabine, a treatment for patients with advanced pancreatic cancer, in a pancreatic cancer patient derived tumor model. An abstract of the preclinical study was presented at the 2019 AACR Annual Meeting. Our lead indication for BP1003 is pancreatic cancer due to the severity of this disease and the lack of effective, life-extending treatments. For example, pancreatic adenocarcinoma is projected to be the second most lethal cancer behind lung cancer by 2030. Typical survival for a metastatic pancreatic cancer patient is about three to six months from diagnosis. Additionally, an abstract of the preclinical study demonstrating that BP1003 enhanced the sensitivity of breast and ovarian cancer cells to chemotherapy was presented at the 2022 AACR Annual Meeting. We have successfully completed several IND enabling studies of BP1003 and have one additional IND enabling study to complete. Once the additional study is successfully completed, our goal is to file an IND application and initiate the first-in-humans Phase 1 study of BP1003 in patients with refractory, metastatic solid tumors, including pancreatic cancer and NSCLC.In addition, a modified product named BP1001-A, our fourth drug candidate, has shown to enhance chemotherapy efficacy in preclinical solid tumor models. Results of the preclinical study were published in the scientific journal Oncotarget in July 2020. BP1001-A incorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticle properties. A BP1001-A Phase 1/1b clinical trial in patients with advanced or recurrent solid tumors has been initiated. The Phase 1/1b clinical trial is being conducted at several leading cancer centers in the United States, including MD Anderson, Karmanos Cancer Institute, Mary Crowley Cancer Research and Holy Cross Hospital, Maryland. On July 17, 2023, we announced completion of the first cohort of the dose escalation portion of the Phase 1/1b clinical trial. A total of nine evaluable patients are scheduled to be treated with BP1001-A monotherapy in a standard 3+3 dose escalation design. The first dose cohort consisted of a starting dose of 60 mg/m2, and there were no dose limiting toxicities. Enrollment is now open for patients for the second dose cohort of 90 mg/m2. The Phase 1b portion of the study is expected to commence after successful completion of BP1001-A monotherapy cohorts and is intended to assess the safety and efficacy of BP1001-A in combination with paclitaxel in patients with recurrent ovarian or endometrial tumors.Our DNAbilize\u00ae technology-based products are available for out-licensing or partnering. We intend to apply our drug technology template to new disease-causing protein targets to develop new liposomal antisense drug candidates for inclusion in our pipeline that meet scientific, preclinical and commercial criteria and file new patents on these targets. We expect that these efforts will include collaboration with key scientific opinion leaders in the field of study and include developing drug candidates for diseases other than cancer. As we expand our drug development programs, we will look at indications where a systemic delivery is needed and antisense RNAi nanoparticles can be used to slow, reverse or cure a disease, either alone or in combination with another drug.We have certain intellectual property as the basis for our current drug products in clinical development, prexigebersen, BP1002, BP1003 and BP1001-A. We are developing RNAi antisense nanoparticle drug candidates based on our own patented technology to treat cancer and autoimmune disorders where targeting a single protein may be advantageous and result in reduced patient adverse effects as compared to small molecule inhibitors with off-target and non-specific effects. We have composition of matter and method of use intellectual property for the design and manufacture of antisense RNAi nanoparticle drug products.4",
            "type": "paragraph"
        },
        {
            "id": 6,
            "context": "Our pipeline for development of antisense therapeutics is set forth in Figure 1 below:Figure 1. Bio-Path Pipeline for Development of Therapeutics* Received orphan drug designation from the U.S. FDA and from the European Medicines Agency (\u201cEMA\u201d) for AML\u200bOur basic drug development concept is to block expression of proteins associated with disease. Messenger RNA (\u201cmRNA\u201d) is essential in the process of creating proteins. We have developed DNAbilize\u00ae nanoparticle drug delivery systems to deliver short strands of antisense DNA drugs to cells and block the production of proteins associated with disease progression.Antisense DNA therapeutics is the field of designing short DNA sequences that are complementary to a mRNA for a protein of interest with the intention of inhibiting the production of the targeted protein. The DNA will find the matching RNA and form a complex. The complexed RNA will not have access to the protein-making machinery, which prevents the cell from translating it into a protein. Thus, protein production is turned off and levels of the targeted protein are reduced in the cell. This gene-specific process of controlling protein expression has led to great interest in using antisense DNA to shut off the production of proteins involved in disease. Antisense therapeutics have been in development for over 20 years. However, challenges to antisense therapeutics, such as instability of antisense drugs inside of the body and inefficient delivery of antisense to disease cells, have thawed antisense therapeutic potential.We believe our DNAbilize\u00ae technology, which is the combination of the protected P-ethoxy antisense DNA backbone with the neutral liposome nanoparticle, is the ideal approach for antisense DNA therapeutics because it overcomes the challenges associated with both antisense stability and intracellular delivery. The P-ethoxy modification used in our DNAbilize\u00ae technology is completely sulfur free. We avoid using sulfur-containing antisense because it has been associated with causing liver toxicity and life-threatening bleeding and clotting complications. We prefer neutral lipids to cationic lipids for intracellular delivery because encapsulating the antisense DNA inside a neutral charged lipid bilayer facilitates the delivery and transfer of DNA into the cell to be fluid and gentle. While many companies have focused research on either the DNA stabilization problem or the lipid delivery problem, 5",
            "type": "paragraph"
        },
        {
            "id": 7,
            "context": "| \u25cf | Developing prexigebersen for treatment of AML in combination therapies. |\n| \u25cf | Developing BP1002 for treatment of lymphoma and CLL. |\n| \u25cf | Developing BP1002 for refractory/relapsed AML patients, including venetoclax-resistant patients. |\n| \u25cf | Developing BP1003 for pancreatic cancer, NSCLC and AML. |\n| \u25cf | Developing BP1001-A for treatment of solid tumors. |\n| \u25cf | Expanding DNAbilize\u00ae to evaluate targets beyond cancer. |\n| \u25cf | Establishing DNAbilize\u00ae as the antisense drug delivery method of choice by forming partnerships with pharmaceutical and academic clinical research labs. |",
            "type": "table"
        },
        {
            "id": 8,
            "context": "Indications for Acute Myeloid Leukemia (AML)AML - Background and Common Treatments. AML is the rapid accumulation of immature myeloid cells in the blood, resulting in a drop of the other cell types such as red blood cells and platelets. AML incidence increases with age, with more than 50% of the cases in people aged 60 or older. AML is the most common acute leukemia in adults, and the National Cancer Institute estimated that approximately 20,380 new cases occurred in 2023 (Table 1). The five-year survival rate is approximately 11% in older adults (ages 65+). Prior to venetoclax approval, the frontline low-intensity therapies for elderly AML patients were LDAC, decitabine or azacytidine. The Bcl-2 inhibitor venetoclax is approved for newly diagnosed AML patients aged 75 years and older or adults who cannot be treated with intensive induction chemotherapy. Venetoclax is used in combination with LDAC, decitabine or azacytidine. Mutation in the Bcl-2 binding domain, which reduces venetoclax\u2019s ability to bind to Bcl-2, has been linked with venetoclax resistance in CLL patients. Such venetoclax resistance may also occur in AML patients. AML remains an area of high unmet need for both the relapsed and the newly diagnosed elderly population who are typically ineligible for induction therapy.Table 1. Basic Statistics for AML Prexigebersen Development and Treatment for Leukemia. The safety, pharmacokinetics and efficacy of our lead DNAbilize\u00ae antisense drug candidate, prexigebersen, was assessed in patients having AML, CML, myelodysplastic syndrome (MDS) or acute lymphoblastic leukemia (\u201cALL\u201d) in a Phase 1 trial. The Phase 1 clinical trial was a dose-escalating study to determine the safety and tolerability of escalating doses of prexigebersen. After completion of dose-escalation monotherapy, the safety and toxicity of prexigebersen in combination with LDAC was assessed in patients with refractory/relapsed AML. Additionally, the pharmacokinetics and anti-leukemic effects, including down-regulation of the target Grb2 protein in patient samples, of the drug candidate were determined. Results of the clinical study were published in the scientific journal Lancet Haematology in 2018.Phase 1 Clinical TrialAmong the 39 patients enrolled in the study, 12 patients were removed from study before the end of cycle 1 because of disease progression or death, without dose-limiting toxicity, and were replaced per protocol guidelines. The approved prexigebersen treatment cycle is two doses per week over four weeks, resulting in eight doses administered over 28 days. Among the 27 evaluable patients, 21 patients were treated with escalating doses of prexigebersen monotherapy and six patients were treated with prexigebersen plus LDAC (Figure 2). The dose-limiting toxicity was not reached in the prexigebersen monotherapy cohorts, up to the maximum dose of 90 mg/m2. The prexigebersen plus LDAC combination was also well tolerated, with a toxicity profile similar to that of prexigebersen monotherapy, including the absence of identifiable dose-limiting toxicity. Lack of toxicity is a major advantage for the drug candidate prexigebersen since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.\u200bPatients could receive additional cycles of prexigebersen if they exhibited stable disease or had improvement of their disease. In the prexigebersen monotherapy cohorts, four patients completed two cycles of treatment and three patients completed five cycles of treatment. Among the six patients who received prexigebersen plus LDAC combination therapy, three received three cycles of treatment and one received five cycles of treatment. Furthermore, five patients receiving prexigebersen plus LDAC combination experienced at least a 50% reduction in bone marrow blasts; two patients achieved a CR, one achieved CRi, and two had stable disease. These results demonstrate the potential anti-leukemic activity of prexigebersen and its potential to stabilize patients for extended treatments.\u200bOne of the assays developed in the Phase 1 clinical trial was the flow cytometry scientific assay which was used to provide critical proof that DNAbilize\u00ae neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb2 protein. The extent by which prexigebersen inhibited the expression of the target Grb2 protein and the expression of phosphorylated extracellular signal related kinase (pERK), a 7",
            "type": "paragraph"
        },
        {
            "id": 9,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Peripheral or bone | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | marrow blast % | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Off- | \u200b | Reason | \u200b | Cycles |\n| Patients | Diagnosis | Baseline | Nadir | Tx | Discontinued | Completed |\n| 1 | CML | 51 | No | 97 | DLT | <1 |\n| 6 | AML | 15 | 2 | 5 | PD | 5 |\n| 7 | MDS | 8 | 4 | 6 | PD | 5 |\n| 10 | AML | 23 | 10 | 10 | PD | 1 |\n| 11 | CML | 7 | No | 50 | PD | 1 |\n| 14 | AML | 48 | 5 | 21 | PD | 1 |\n| 15 | AML | 54 | 31 | 72 | PD | 1 |\n| 20 | AML | 76 | 5 | 63 | PD | 1 |\n| 21 | AML | 71 | 43 | 74 | PD | 2 |\n| 22 | AML | 1 | \u2014 | 1 | PD | 2 |\n| 23 | MDS | NE | NE | NE | PD | 1 |\n| 24 | MDS | \u2014 | \u2014 | \u2014 | PD | 5 |\n| 25 | AML | 10 | 3 | 19 | PD | 2 |\n| 26 | AML | 11 | No | 80 | PD | 1 |\n| 27 | AML | 93 | No | 97 | PD | 1 |\n| 28 | AML | 96 | 93 | 98 | PD | 1 |\n| 29 | AML | 35 | 7 | 24 | PD | 1 |\n| 30 | AML | 51 | 17 | 82 | PD | 1 |\n| 31 | AML | 17 | No | 17 | PD | 1 |\n| 32 | AML | 24 | 22 | 22 | PD | 2 |\n| 34 | AML | 66 | ND | ND | PD | 1 |\n| 35 | AML | 17 | 2 | 2 | CRi | 1 |\n| 37 | AML | 25 | 33 | ND | PD | 1 |\n| 38 | AML | 23 | 2 | 3 | CR | 5 |\n| 39 | AML | 36 | 16 | 58 | SD | 3 |\n| 40 | AML | 31 | 2 | 2 | CR | 3 |\n| 41 | AML | 18 | 9 | 14 | SD | 3 |",
            "type": "table"
        },
        {
            "id": 10,
            "context": "Phase 2 Clinical TrialsResults from the Phase 1b clinical trial demonstrated it is safe to add prexigebersen to LDAC, which appears to yield better response rates in this AML patient population. A Phase 2 study was initiated to assess the efficacy of prexigebersen plus LDAC in newly diagnosed AML patients. Thirty patients were enrolled and 17 patients were deemed evaluable (Table 2). The interim data showed that 11 (65%) of the 17 evaluable patients had a response, including five (29%) who achieved CR, including one CRi and one morphologic leukemia free state, and six (35%) stable disease responses, including two patients who had greater than a 50% reduction in bone marrow blasts. The efficacy data from the 17 evaluable patients was very favorable compared to the reported CR, CRp and CRi rates of 7 to 13% with LDAC treatment alone. Importantly, through investigation by the principal investigators, it was observed that 68% of patients were secondary AML patients, a difficult class to treat.Table 2. Outcome of evaluable patients who were treated with prexigebersen + LDAC Results to date have shown prexigebersen, with its efficacy and excellent safety profile, to be an effective combination candidate with frontline therapy. However, DNA hypomethylating agents are now the most frequently used agents in the treatment of elderly AML patients in the U.S. and Europe. As a result, we amended Stage 2 of the Phase 2 trial in AML to remove the combination treatment of prexigebersen and LDAC and replace it with the combination treatment of prexigebersen and decitabine. Since decitabine is also used as a treatment for relapsed/refractory AML patients, a cohort of relapsed/refractory AML patients was also added to the study.We believe the approval of the frontline venetoclax and decitabine combination therapy provides an opportunity for combining prexigebersen with the combination therapy for the treatment of newly diagnosed AML patients. Preclinical testing of prexigebersen with venetoclax and decitabine demonstrated the potential to enhance efficacy of the frontline treatment combination. The triple combination of prexigebersen, venetoclax and decitabine showed significant improvement in decreasing the viability of three of the four AML cell lines tested. Bio-Path\u2019s approved amended Stage 2 for this Phase 2 clinical trial has three cohorts of patients. The first two cohorts will treat patients with the triple combination of prexigebersen, decitabine and venetoclax with the first cohort including untreated AML patients and the second cohort including relapsed/refractory AML patients. Finally, the third cohort will treat relapsed/refractory AML patients who are venetoclax-resistant or -intolerant with the two-drug combination of prexigebersen and decitabine.The first step in establishing the amended Stage 2 of the Phase 2 trial in AML was demonstrating the safety of treating patients with the two-drug combination of prexigebersen and decitabine. Results of the six evaluable patients, who were treated with the combination of prexigebersen and decitabine, in Stage 2 of the Phase 2 clinical trial were presented in the 2021 ASH Annual Meeting (Table 3). Although the treatment combination of prexigebersen and decitabine was not the treatment planned for the efficacy evaluation of Stage 2 of the Phase 2 clinical trial, the efficacy profile in this safety segment of the study was encouraging with 50% of patients having a response, including two complete responses (33%) with incomplete hematologic recovery and one patient (17%) 9",
            "type": "paragraph"
        },
        {
            "id": 11,
            "context": "showing partial response. For reference, in this class of AML patients, the complete response rate to treatment with decitabine alone is approximately 20%.Additionally, results of the six evaluable patients, who were treated with the triple combination of prexigebersen, decitabine and venetoclax, in Stage 2 of the Phase 2 clinical trial were also presented in the 2021 ASH Annual Meeting (Table 3). These patients included four relapsed/refractory AML patients, and two newly diagnosed AML patients. In the preliminary safety data review, five of the patients (83%) responded to treatment, including four (67%) achieving CR and one (17%) achieving CRi. Recent publications provide that CR rates to combination treatment with decitabine and venetoclax (but without prexigebersen) are 42 to 52% for relapsed/refractory AML patients and 0 to 39% for relapsed/refractory secondary AML patients. Response rates to frontline treatment with decitabine and venetoclax (but without prexigebersen) are 62 to 71% for newly diagnosed AML patients. These preliminary data showed the treatment was well-tolerated and there were no dose limiting toxicities attributed to prexigebersen. Three patients remained on treatment for more than one cycle.Table 3. Outcome of evaluable patients who were treated with the two-drug prexigebersen + decitabine combination or the triple prexigebersen + decitabine + venetoclax combination On August 1, 2023, we announced interim data for the first two cohorts of the amended Stage 2 of the Phase 2 clinical trial (Table 4). Fourteen newly diagnosed patients were evaluable in the first cohort and treated with at least one cycle of the prexigebersen, decitabine and venetoclax combination therapy. All patients in the first cohort (median age 75) were adverse risk by 2017 ELN guidelines (n=10) or secondary AML (n=4). Prexigebersen was well-tolerated, and AEs were generally consistent with decitabine and venetoclax treatment and/or for AML. Twelve of the 14 evaluable patients (86%) achieved CR/CRi and two (14%) achieved PR. In total, 100% of the evaluable patients had a response to treatment. The CR/CRi rates of 86% for the evaluable patients in the first cohort is significantly higher than the CR/CRi rates of 62% for newly diagnosed patients treated with the frontline combination treatment of decitabine and venetoclax. Fourteen refractory/relapsed evaluable AML patients in the second cohort were treated with at least one cycle of the prexigebersen, decitabine and venetoclax combination therapy. Substantially all of the patients in the second cohort (median age 56.5) were adverse risk by 2017 ELN guidelines (n=11) or secondary AML (n=2). Prexigebersen was well-tolerated, and AEs were generally consistent with decitabine and venetoclax treatment and/or for AML. Eight of the 14 evaluable refractory/relapsed patients (57%) achieved CR/CRi, two (14%) achieved PR and two (22%) achieved stable disease. In total, 93% of the evaluable patients in the second cohort had a response to treatment. The CR/CRi rates of 57% for the evaluable refractory and relapsed patients in the second cohort is significantly higher than the CR/CRi rates of 21% for refractory/relapsed patients treated with the combination treatment of decitabine and venetoclax. Based on this interim data, we currently plan to pursue FDA expedited programs for Fast Track designation, and we are evaluating whether to seek to expand Stage 2 of the Phase 2 clinical trial in Europe.10",
            "type": "paragraph"
        },
        {
            "id": 12,
            "context": "Table 4. Interim data of evaluable patients who were treated with the triple prexigebersen + decitabine + venetoclax combinationDevelopment of new therapeutics for AML can meet currently unmet needs for patients who have very few treatment options due to age, fitness or treatment-resistance of advanced genetically unstable cells. Elderly patients unfit to receive a stem cell transplant or induction therapy face a likelihood of relapse to a more resistant leukemia. Prexigebersen and DNAbilize\u00ae technology offer new hope for achieving remission for fragile populations. We believe that the combination of prexigebersen with frontline chemotherapy can provide a way to treat cancer without added toxicity so that the patient can remain under treatment long enough to reach complete remission.BP1002BP1002, also known by its scientific name as Liposomal Bcl-2, is our second liposome delivered antisense drug candidate. BP1002 is intended to target lymphoma, CLL, AML and certain solid tumor markets. We believe that BP1002 has the potential to treat 40 to 60% of solid tumors.Bcl-2 is a protein that is involved in regulating apoptosis, or programmed cell death. Apoptosis is a physiologic mechanism of cell turnover by which cells actively commit suicide in response to aberrant external signals. Over-expression of Bcl-2 prevents the induction of apoptosis in response to cellular insults such as treatment with chemotherapeutic agents. Bcl-2, initially discovered in transformed follicular lymphoma (\u201cFL\u201d) was found to contribute to the pathophysiology of various subtypes of non-Hodgkin\u2019s lymphoma (\u201cNHL\u201d).Non-Hodgkin\u2019s Lymphoma - Background and Common Treatments. Lymphoma can start anywhere in the body where lymph tissue is found. The major sites of lymph tissue are lymph nodes, bone marrow, spleen, thymus, adenoids and tonsils and the digestive tract. NHL is a term used for many different types of lymphoma that share some common characteristics. In the U.S., approximately 86,550 new cases of and 20,180 deaths from NHL were expected in 2023 (Table 5). Approximately 60% of NHLs are aggressive lymphomas which usually need to be treated right away, as they grow and can spread quickly to other parts of the lymph system or to other parts of the body, such as the liver, brain or bone marrow.Table 5. Basic statistics of Non-Hodgkin\u2019s Lymphoma \u200b11",
            "type": "paragraph"
        },
        {
            "id": 13,
            "context": "BP1002 - Development and Treatment for lymphoma Therapies that directly and specifically block or inhibit protein synthesis of Bcl-2 could be transformative for NHL. The Bcl-2 inhibitor venetoclax was approved by the FDA for the treatment of patients with CLL and small lymphocytic leukemia (\u201cSLL\u201d). However, treatment with venetoclax can lead to the development of drug resistance, resulting in disease recurrence. One of the proposed mechanisms of venetoclax resistance is acquired mutations in Bcl-2, which reduce venetoclax\u2019s ability to bind and inhibit Bcl-2. Because BP1002 activity is based on blocking the Bcl-2 messenger RNA and BP1002 targets Bcl-2 at a site different from venetoclax, we expect BP1002 to overcome such venetoclax resistance mechanism and be an effective approach for patients who have relapsed from venetoclax. Preclinical studies suggest that the combination of BP1002 with decitabine is efficacious in venetoclax-resistant lymphoma cells. An abstract of the preclinical study was presented at the 2021 American Association for Cancer Research Annual Meeting. We believe BP1002 provides a new tool for cancer treatment for not just lymphomas, but also many cancers for which Bcl-2 expression is driving cell survival. The introduction of a new, non-toxic, and specific Bcl-2 inhibitor could be a major advance in cancer therapeutics.On January 10, 2024, we announced the successful completion of the first dose cohort in the Phase 1 clinical trial evaluating the ability of BP1002 to treat refractory/relapsed lymphoma and refractory/relapsed CLL patients. The Phase 1 clinical trial is being conducted at the Georgia Cancer Center while two additional clinical trial sites are currently being processed for inclusion in the study, The University of Texas Southwestern and New York Medical College. Initially, a total of six evaluable patients are scheduled to be treated with BP1002 monotherapy in a standard 3+3 design, with a starting dose of 20 mg/m2. The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days. Enrollment is now open for patients for the second dose cohort of 40 mg/m2.BP1002 - Development and Treatment for AMLThe Bcl-2 inhibitor venetoclax is used in frontline combination therapies to treat elderly AML patients; however, venetoclax resistance has been observed. A recent study2 found that AML patients who had relapsed from frontline venetoclax-based treatment had a very poor prognosis, with a median survival of less than three months. Since venetoclax and BP1002 utilize different mechanisms of action, we believe that BP1002 may be a potential treatment for venetoclax-relapsed AML patients. Preclinical studies, presented as an abstract at the 2021 American Association for Cancer Research Annual Meeting, suggest that the combination of BP1002 with decitabine is efficacious in venetoclax-resistant AML cells. A Phase 1/1b clinical trial to investigate the ability of BP1002 to treat refractory/relapsed AML patients, including venetoclax-resistant patients, is being studied. The Phase 1/1b clinical trial is being conducted at several leading cancer centers in the United States, including the Weill Medical College, MD Anderson Cancer Center, Scripps Cancer Center and The University of California at Los Angeles Cancer Center. Gail J. Roboz, M.D., is serving as the national coordinating Principal Investigator for the Phase 1/1b trial. Gary Schiller, M.D., The University of California at Los Angeles Cancer Center, Maro Ohanian, D.O., Department of Leukemia, University of Texas MD Anderson Cancer Center, and David Hermel, M.D., Scripps Health, will each serve as Principal Investigators.On December 14, 2023, we announced the successful completion of the first dose cohort of the dose escalation portion of the Phase 1/1b clinical trial of BP1002 which evaluates the ability of BP1002 to treat refractory/relapsed AML patients, including venetoclax-resistant patients. A total of three evaluable patients per dosing cohort are scheduled to be treated with BP1002 monotherapy in a standard 3+3 design, unless there is a dose limiting toxicity which would require an additional three patients tested. The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities. The approved treatment cycle is two doses per week over four weeks for a total of eight doses administered over 28 days. Enrollment is now open for patients for the second dose cohort of 40 mg/m2. The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients. BP1003BP1003 is our third liposome delivered antisense drug candidate. BP1003 is a DNAbilize\u00ae RNAi nanoparticle containing antisense DNA targeting STAT3, whose elevated expression/activity is associated with a poorer survival outcome for patients with 2 (Maiti A, Ruasch C, Cortes JE, et.al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 2021; 106: 894-898.)12",
            "type": "paragraph"
        },
        {
            "id": 14,
            "context": "solid tumors, including those of gastric cancer, lung cancer, hepatic cancer, osteosarcoma, prostate cancer and pancreatic adenocarcinoma (PDAC). We believe that a therapeutic that shuts down the STAT3 protein can have significant clinical impact for solid tumors that have elevated expression/activity of STAT3.Our lead indication for BP1003 is pancreatic cancer due to the severity of this disease and the lack of effective, life-extending treatments. PDAC is a cancer of the exocrine cells of the pancreas. In the U.S. in 2022, approximately 62,210 people were diagnosed with PDAC, and approximately 49,830 died from the disease. It is estimated that less than 11% of PDAC patients survive beyond five years, and it is projected that by 2030, PDAC will become the second most lethal cancer behind lung cancer. Treatment of the disease is hampered by the location of the pancreas, which is difficult to reach with conventional therapies and the fibrotic nature of the tumors, which protects them from penetration by chemotherapeutics. We believe a novel and unconventional therapeutic is needed to overcome these barriers to treatment.While competition for therapeutics that target the STAT3 pathway exists, the competition for specific STAT3 inhibitors is very small. Many peptides designed to bind to STAT3 suffered from poor intrinsic pharmacokinetic properties, including poor cellular permeability and lack of stability in vivo, which curtailed their further development. Even second-generation peptidomimetics have failed to overcome these limitations. Most compounds under development target the pathway upstream of STAT3, such as the JAK2 kinase. However, lack of efficacy of the JAK2 kinase inhibitors was observed in PDAC clinical studies. Ionis Pharmaceuticals, Inc. has developed an antisense DNA-based STAT3 inhibitor called IONIS-STAT3-2.5Rx. It is being evaluated in clinical trials by AstraZeneca under the name AZD9150 for solid tumors and NHL. However, due to the toxicity of the DNA chemistry, thrombocytopenia continues to limit the systemic delivery and efficacy of such compounds for the treatment of cancer. We believe BP1003 avoids these complications.We hypothesized that the natural lipid delivery vesicle would have unique characteristics that would allow for penetration of the fibrotic stroma to reach the PDAC cells. An abstract of the preclinical study was presented in the 2019 American Association for Cancer Research Annual Meeting. Our preclinical work demonstrated that BP1003 was successful in crossing the scar tissue matrix and delivering antisense drug into the tumor tissue. Subsequent studies evaluating the combination of BP1003 with gemcitabine, a standard of care for PDAC patients with metastatic disease, suggest that the regimen has synergistic anti-tumor effects. Additionally, an abstract of the preclinical study demonstrating that BP1003 enhanced the sensitivity of breast and ovarian cancer cells to chemotherapy was presented at the 2022 AACR Annual Meeting. We have successfully completed several IND enabling studies of BP1003, including safety. Body weight was used as an indicator of BP1003 safety in rodents. Mice received saline or twice weekly injections of BP1003 for four weeks. There was no difference in body weight between control mice and BP1003-treated mice (Figure 3). We have one additional IND enabling study to complete. Once the additional study is successfully completed, our goal is to file an IND and initiate the first-in-humans Phase 1 study of BP1003 in patients with refractory, metastatic solid tumors, including pancreatic cancer and NSCLC.Figure 3. No difference in mean body weight was observed between control groups and BP1003-treated groupsWe believe that the excellent safety profile of the DNAbilize\u00ae chemistry, the novel lipid formula that allows for penetration of the tumor stroma, and the ability to target a single protein with precision, makes BP1003 an ideal candidate for combination with approved treatments to extend survival while maintaining quality of life for the patient.13",
            "type": "paragraph"
        },
        {
            "id": 15,
            "context": "BP1001-AData supports a prominent role of Grb2 in the progression of solid tumors, and overexpression of Grb2 has been associated with chemosensitivity, poor prognosis and advanced disease in several malignancies including gynecologic malignancies.Indications for Solid Tumors (e.g., Ovary, Endometrium)Ovarian cancer is one of the most common types of gynecologic malignancy. In the U.S., 19,710 new cases of and 13,270 deaths from ovarian cancer were expected in 2023 (Table 6). According to the Ovarian Cancer Research Alliance, approximately 70% of patients diagnosed with ovarian cancer will have a recurrence. Recurrent ovarian cancer is treatable but rarely curable. The response rates to second-line chemotherapy are low and differ by platinum-sensitivity status: 20 to 25% for platinum-sensitive cases and 10 to 20% for platinum-resistant cases3. Given the poor outcomes of treatment for ovarian cancer, novel drug treatments are urgently needed.Table 6. Basic Statistics for Ovarian Cancer Endometrial cancer is the most common gynecologic malignancy in the U.S. In the U.S., 66,200 new cases of and 13,030 deaths from endometrial cancer were expected in 2023 (Table 7). The majority of cases are diagnosed at an early stage and are amenable to treatment with surgery alone. However, approximately 38 to 67% of advanced stage endometrial cancers will recur 4. Recurrent endometrial cancer is incurable with currently available standard therapies. The median survival for patients with recurrent endometrial carcinoma is approximately 12 to 15 months 5. Novel drug treatments for recurrent endometrial carcinoma are urgently needed.Table 7. Basic Statistics for Endometrial CancerDevelopment and Treatment for ovarian and endometrial cancerGrb2 may be a novel potential therapeutic target for ovarian and endometrial cancer, and BP1001-A may provide clinical benefit against these gynecologic malignancies. BP1001-A is a modified drug product with the same drug substance as prexigebersen but includes formulation enhancements to produce smaller drug nanoparticles. The goal of this product enhancement is to produce smaller drug nanoparticles that can pass through vasculature pore spaces, thereby enabling release of the drug product into the interior of the tumor to enhance drug effectiveness. Preclinical experiments were conducted in collaboration with leaders in the field of ovarian cancer at MD Anderson Cancer Center. Results of the preclinical study were published in the scientific journal Oncotarget in 3 (Soyama H, Takano M, Miyamoto M, et al. Factors favouring long-term survival following recurrence in ovarian cancer. Mol Clin Oncol. 2017: 7: 42-46.)4 (Huijgens ANJ, Merten HJMM. Factors predicting recurrent endometrial cancer. Facts Views Vis Obgyn. 2013; 5: 179-186.)5 (Brooks RA, Fleming GF, Lastra RR, et al. Current recommendations and progress in endometrial cancer. CA Cancer J Clin 2019; 69: 258-279.)14",
            "type": "paragraph"
        },
        {
            "id": 16,
            "context": "July 2020. BP1001-A effectively penetrated ovarian tumors and decreased target Grb2 protein level in preclinical ovarian and endometrial tumor models. BP1001-A was demonstrated to reduce tumor burden both as a monotherapy and in combination with paclitaxel, a therapy commonly used to treat patients with advanced ovarian or endometrial cancer. A Phase 1/1b clinical trial of BP1001-A in patients with advanced or recurrent solid tumors has been initiated. The dose escalation portion of the Phase 1/1b clinical trial is ongoing at more than eight leading cancer centers in the United States, including MD Anderson, The Mary Crowley Cancer Research Center, and Karmanos Cancer Center. Initially, a total of nine evaluable patients are scheduled to be treated with BP1001-A monotherapy in a standard 3+3 design, with a starting dose of 60 mg/m2 and continuing with 90 mg/m2 and 135 mg/m2. The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over 28 days. The Phase 1b portion of the study is expected to commence after successful completion of BP1001-A monotherapy cohorts and is intended to assess the safety and efficacy of BP1001-A in combination with paclitaxel in patients with recurrent ovarian or endometrial tumors.On July 17, 2023, we announced successful completion of the first dose cohort of BP1001-A in the Phase 1/1b study. Three patients were enrolled into the first dose cohort of BP1001-A at three different centers in the study, including one patient with hepatic lesions (and lung metastases) and two with advanced gynecologic lesions. All three patients had undergone extensive previous chemotherapies and/or surgeries for their disease prior to enrollment in this study. No patient experienced any treatment related adverse events or any adverse events deemed related to the study drug. Enrollment is now open for patients for the second dose cohort.Indications for Triple Negative Breast Cancer (TNBC) and Inflammatory Breast Cancer (IBC)TNBC and IBC - Background and Common Treatments. Approximately 15 to 20% of breast cancers fall into the category of triple-negative. TNBC tumors do not express estrogen receptors, progesterone receptors, and low human epidermal growth factor receptor 2 (\u201cHER2\u201d). These negative indicators mean that the growth of the cancer is not supported by the hormones estrogen and progesterone, or by the presence of HER2 receptors. Therefore, TNBC does not respond to hormonal therapy or therapies that target HER2 receptors. In addition, TNBC tumors are very aggressive. IBC is a rare and very aggressive type of breast cancer that accounts for 2 to 5% of all breast cancers. A lack of targeted treatments for these types of breast cancer has led to development of new therapeutics currently in clinical trials. Overexpression of receptor tyrosine kinases has been reported for TNBC and IBC. Since Grb2 is vital in the cancer signaling of receptor tyrosine kinases, the Company and collaborators at MD Anderson Cancer Center are interested in developing BP1001-A as a potential treatment for TNBC and IBC.DNABILIZE\u00aeDNAbilize\u00ae technology is available for out-licensing. We intend to apply our drug delivery technology template to new disease-causing protein targets to develop new liposomal antisense drug candidates for inclusion in our pipeline that meet scientific, preclinical and commercial criteria and file new patents on these targets. We expect that these efforts will include collaboration with scientific key opinion leaders in the field of study and include developing drug candidates for diseases other than cancer. A significant amount of capital is expected to be allocated to in-license promising protein targets that can be developed as new liposomal antisense drug candidates. As we expand, we will look at indications where a systemic delivery is needed and antisense can be used to slow, reverse or cure a disease, either alone or in combination with another drug. Our patent portfolio currently includes three issued patents in the U.S. that protect the platform technology for DNAbilize\u00ae, the Company\u2019s novel RNAi nanoparticle drugs. We plan to continue our efforts to build protection around our technology as it safeguards our platform technology and target-specific technology, is a deterrent to would-be competitors and creates value around our core competencies.We are interested in pursuing a wide-ranging, proactive licensing program to include co-development of specific liposomal antisense drug candidates, sub-licensing our delivery template for outside development of liposomal antisense drug candidates or out-licensing a partially-developed drug candidate for final development and marketing.Research and DevelopmentOur research and development expense primarily consists of third-party clinical, preclinical and manufacturing development activities, salaries and benefits expense and stock-based compensation. As we advance and expand our pipeline of drug candidates, we anticipate our research and development expenses will continue to increase in conjunction with these activities. Research and 15",
            "type": "paragraph"
        },
        {
            "id": 17,
            "context": "development expenses incurred during the years ended December 31, 2023 and 2022 were $11.6 million and $9.2 million, respectively.ManufacturingWe do not own or operate, and currently have no plans to establish, any manufacturing facilities. Accordingly, we have no ability to internally manufacture the drug candidates that we need to conduct our clinical trials. For the foreseeable future, we expect to continue to rely on third-party manufacturers and other third parties to produce, package and store sufficient quantities of our drug candidates and any future drug candidates for use in our clinical trials. We have entered into agreements with third-party manufacturers for the manufacture of our drug requirements, including agreements for the manufacture of prexigebersen for use in our Phase 2 clinical trial in AML, as well as agreements for the manufacture of BP1002, BP1003 and BP1001-A for use in our Phase 1 clinical trials. However, we may face various risks and uncertainties in connection with our reliance on third-party manufacturers, as discussed in \u201cItem 1A. Risk Factors\u201d of this Annual Report on Form 10-K under the heading \u201cRisks Related to Manufacturing Our Drug Candidates.\u201d If the FDA or other regulatory agencies approve any of our drug candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-party manufacturers to produce commercial quantities of such approved drug candidates. However, we may in the future elect to manufacture certain of our drug candidates in our own manufacturing facilities. If we do so, we will require substantial additional funds and need to recruit qualified personnel in order to build or lease and operate any manufacturing facilities.Sales and MarketingWe currently do not have any commercial drug products or an organization for the sales and marketing of pharmaceutical products. In order to successfully commercialize any drug candidates that may be approved in the future by the FDA or comparable foreign regulatory authorities, we must build our sales and marketing capabilities or make arrangements with third parties to perform these services. For certain drug candidates in selected indications where we believe that an approved product could be commercialized by a specialty sales force that calls on a limited but focused group of physicians, we may commercialize these products ourselves. However, in therapeutic indications that require a large sales force selling to a large and diverse prescribing population, we may enter into arrangements with other companies for commercialization. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable.Intellectual PropertyPatents, trademarks, trade secrets, technology, know-how and other proprietary rights are important to our business. Our success depends in large part on our ability to obtain and maintain patent protection both in the U.S. and in other countries for our drug candidates and on our ability to operate without infringing the proprietary rights of third parties. Our ability to protect our drug candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents.We rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. In order to protect our proprietary technology and processes, we also rely in part on confidentiality and intellectual property assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators, sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information nor result in the effective assignment to us of intellectual property, and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information or other breaches of the agreements. In addition, others may independently discover our trade secrets and proprietary information, and in such case we could not assert any trade secret rights against such party. To the extent that we enter into out-license and in-license agreements in the future, our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for their intellectual property, in particular, any patents to which we secure exclusive rights.We have expanded our intellectual property portfolio by filing patent applications that are applicable to our technology and business strategy. Our patent portfolio currently includes five issued patents in the U.S. and 17 issued patents in foreign jurisdictions:16",
            "type": "paragraph"
        },
        {
            "id": 18,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Patent No. | Title | Date Issued |\n| US 9,744,187 | P-ethoxy nucleic acids for liposomal formulation | \u200b | August 29, 2017 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| US 10,335,428 | P-ethoxy nucleic acids for liposomal formulation | \u200b | July 2, 2019 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| US 10,898,506 | P-ethoxy nucleic acids for liposomal formulation | \u200b | January 26, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| SG 11201802718P | P-ethoxy nucleic acids for liposomal formulation | \u200b | May 12, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EA 038277(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM) | P-ethoxy nucleic acids for liposomal formulation | \u200b | August 4, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| AU 2016340123 | \u200b | P-ethoxy nucleic acids for liposomal formulation | \u200b | January 5, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| MX 403603 | \u200b | P-ethoxy nucleic acids for liposomal formulation | \u200b | June 20, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| IN 472686 | \u200b | P-ethoxy nucleic acids for liposomal formulation | \u200b | November 24, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Patent No. | Title | Date Issued |\n| US 10,927,379 | Combination therapy with liposomal antisense oligonucleotides | \u200b | February 23, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| US 11,041,153 | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | June 22, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EP 3 512 525(in force in DE, ES, FR, GB, and NL) | \u200b | Combination therapy with liposomal antisense oligonucleotides | \u200b | July 27, 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| JP 7132911 | \u200b | Combination therapy with liposomal antisense oligonucleotides | \u200b | August 30, 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| JP 7186721 | \u200b | P-ethoxy nucleic acids for IGF-1R inhibition | \u200b | December 1, 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| CN ZL 201880033244.6 | \u200b | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | December 16, 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EA 041953(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM) | \u200b | Combination therapy with liposomal antisense oligonucleotides | \u200b | December 19, 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| JP 7237009 | \u200b | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | March 2, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EA 042663(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM) | \u200b | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | March 9, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| HK 400 11951 | \u200b | Combination therapy with liposomal antisense oligonucleotides | \u200b | April 6, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| JP 7284709 | \u200b | P-ethoxy nucleic acids for BCL2 inhibition | \u200b | May 23, 2023 |",
            "type": "table"
        },
        {
            "id": 19,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EA 044637 | \u200b | P-ethoxy nucleic acids for BCL2 inhibition | \u200b | September 19, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| MX 408790 | \u200b | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | December 7, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| MX 408785 | \u200b | P-ethoxy nucleic acids for BCL2 inhibition | \u200b | December 7, 2023 |\n| \u25cf | significantly greater capital, technical and human resources than we have and may be better equipped to discover, develop, manufacture and commercialize drug candidates; |\n| \u25cf | more experience in drug discovery, development and commercialization, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products; |\n| \u25cf | drug candidates that have been approved or are in late-stage clinical development; and/or |\n| \u25cf | collaboration arrangements in our target markets with leading companies and research institutions. |",
            "type": "table"
        },
        {
            "id": 20,
            "context": "| \u25cf | completion of preclinical laboratory tests, animal studies and formulation studies according to FDA\u2019s Good Laboratory Practice regulations; |\n| \u25cf | submission of an IND, which must become effective before human clinical trials may begin and which must include approval by an institutional review board at each clinical site before the trials are initiated; |\n| \u25cf | performance of adequate and well-controlled human clinical trials according to FDA\u2019s Good Clinical Practice (\u201cGCP\u201d) regulations to establish the safety and efficacy of the proposed drug for its intended use; |\n| \u25cf | submission to, and acceptance by, the FDA of a new drug application (an \u201cNDA\u201d); |\n| \u25cf | completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice (\u201ccGMP\u201d) regulations to assure that the facilities, methods and controls are adequate to preserve the drug\u2019s identity, strength, quality and purity; and |\n| \u25cf | FDA review and approval of the NDA. |",
            "type": "table"
        },
        {
            "id": 21,
            "context": "| \u25cf | Phase 1: The drug candidate is initially introduced into human subjects or patients with the disease and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some drug candidates for severe or life-threatening diseases, the initial human testing is often conducted in patients. |\n| \u25cf | Phase 2: Involves studies in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the drug candidate for specific targeted diseases and to determine dosage tolerance and optimal dosage. |\n| \u25cf | Phase 3: Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, typically at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the drug candidate and provide, if appropriate, an adequate basis for product labeling. |",
            "type": "table"
        },
        {
            "id": 22,
            "context": "Approval ProcessAfter successful completion of the required clinical trials, an NDA is generally submitted, which is required before marketing of the product may begin in the U.S. The NDA must include the results of drug development, preclinical studies and clinical studies, together with other detailed information, including information on the chemistry, manufacture and composition of the drug. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA that has been accepted for filing to determine, among other things, whether a product is safe and effective for its intended use. The approval process for an NDA is lengthy and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA may also refer applications for drug candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee. Before approving an NDA, the FDA will also inspect the facility or facilities where the product is manufactured to determine whether its manufacturing is cGMP-compliant to assure and preserve the product\u2019s identity, strength, quality, purity and stability.There are various programs that are intended to expedite the development and review of drug candidates, and/or provide for approval on the basis of surrogate endpoints, including Fast Track, breakthrough therapy, priority review and accelerated approval. Even if a drug candidate qualifies for one or more of these programs, the FDA may later decide that the drug candidate no longer meets the conditions for qualification or that the time period for FDA review or approval will not be shortened. Generally, drug candidates that may be eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs or those that offer meaningful benefits over existing treatments.Fast Track is a process designed to facilitate the development and expedite the review of drug candidates to treat serious diseases and fill an unmet medical need. Breakthrough therapy requires preliminary clinical evidence that demonstrates the drug candidate may have substantial improvement on at least one clinically significant endpoint over available therapy. A breakthrough therapy designation conveys all of the Fast Track program features, as well as more intensive FDA guidance on an efficient drug development program. Priority review is designed to give drug candidates that offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months as compared to a standard review time of 10 months. Although Fast Track, breakthrough therapy and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated drug candidate and expedite review of the application for a drug candidate designated for priority review. Accelerated approval provides an earlier approval of drugs to treat serious diseases and that fill an unmet medical need based on a surrogate endpoint, which is a laboratory measurement or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome. As a condition of approval, the FDA may require that a sponsor of a product receiving accelerated approval perform post-marketing clinical trials.If the FDA evaluations of the application and the manufacturing facilities are favorable, the FDA may issue an approval letter or an \u201capprovable\u201d letter. An approvable letter will usually contain a number of conditions that must be met in order to secure final approval of the NDA and authorization of commercial marketing of the drug for certain indications. An approval letter authorizes commercial marketing of the drug with specific prescribing information for a specific indication. As a condition of NDA approval, the FDA may require post-approval testing, including Phase 4 trials, and surveillance to monitor the drug\u2019s safety or efficacy and may impose other conditions, including labeling or distribution restrictions which can materially impact the potential market and profitability of the drug. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems occur after the product reaches the market. The FDA may also refuse to approve the NDA or issue a \u201cnot approvable\u201d letter outlining the deficiencies in the submission and often requiring additional testing or information.To date, we have not submitted a marketing application for any drug candidate to the FDA or any foreign regulatory agency, and none of our drug candidates have been approved for commercialization in any country. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to complete clinical trials and for the FDA\u2019s review processes is uncertain and typically takes many years. Our analysis of data obtained from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unanticipated delays or increased costs due to government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials, and FDA 21",
            "type": "paragraph"
        },
        {
            "id": 23,
            "context": "| \u25cf | record-keeping requirements; |\n| \u25cf | reporting of adverse experiences with the drug; |\n| \u25cf | providing the FDA with updated safety and efficacy information; |\n| \u25cf | drug sampling and distribution requirements; |\n| \u25cf | notifying the FDA and gaining its approval of specified manufacturing or labeling changes; |\n| \u25cf | complying with certain electronic records and signature requirements; and |\n| \u25cf | complying with FDA promotion and advertising requirements. |",
            "type": "table"
        },
        {
            "id": 24,
            "context": "To obtain regulatory approval of an investigational drug under E.U. regulatory systems, we must submit a marketing authorization application. This application is similar to the NDA in the U.S., with the exception of, among other things, country-specific document requirements. Drugs can be authorized in the E.U. by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the decentralized procedure or (iv) national authorization procedures.The EMA implemented the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are valid throughout the E.U. This procedure results in a single marketing authorization granted by the European Commission that is valid across the E.U., as well as in Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for certain human drugs including those that are: (i) derived from biotechnology processes, such as genetic engineering, or (ii) contain a new active substance indicated for the treatment of certain diseases.ReimbursementSales of pharmaceutical products depend in significant part on the availability of third-party reimbursement, which is time consuming and expensive. Reimbursement may not be available or sufficient to allow us to sell our future products, if any, on a competitive and profitable basis.The passage of the Medicare Prescription Drug and Modernization Act of 2003 (the \u201cMMA\u201d) imposed requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries, which may affect the marketing of our future products, if any. The MMA also introduced a reimbursement methodology, part of which went into effect in 2004, and a prescription drug plan, which went into effect on January 1, 2006. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the E.U. provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market.There have been and we expect that there will continue to be frequent federal and state proposals to impose governmental pricing controls or cost containment measures for prescription drugs. While we cannot predict whether such legislative or regulatory proposals will be adopted, the adoption of such proposals could have a material adverse effect on our business, financial condition and profitability. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, contains provisions that may reduce the profitability of drugs, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies\u2019 share of sales to federal health care programs. Even if favorable coverage and reimbursement status is attained for one or more of our drug candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.Other RegulationsPursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, under certain conditions a sponsor may be granted marketing exclusivity for a period of five years following FDA approval. During this period, third parties would not be permitted to obtain FDA approval for a similar or identical drug through an Abbreviated NDA, which is the application form typically used by manufacturers seeking approval of a generic drug. The Hatch-Waxman Act also permits a patent extension term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent extension cannot extend the remaining term of a patent beyond a total of 14 years. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA, plus time of active FDA review between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and it must be applied for prior to expiration of the patent and within 60 days of the approval of the NDA.23",
            "type": "paragraph"
        },
        {
            "id": 25,
            "context": "In April 2015 and October 2016, prexigebersen received orphan drug designations for AML in the U.S. from the FDA and in the E.U. from the EMA, respectively. Orphan designation is available in the U.S. to drugs intended to treat, diagnose or prevent a rare disease or condition that affects fewer than 200,000 people in the U.S. at the time of application for orphan designation. Orphan drug designation must be requested before submitting an application for marketing authorization. Orphan designation qualifies the sponsor of the product for a tax credit and marketing incentives. The first sponsor to receive FDA marketing approval for a drug with an orphan designation is entitled to a seven-year exclusive marketing period in the U.S. for that product for that indication and, typically, a waiver of the prescription drug user fee for its marketing application. However, a drug that the FDA considers to be clinically superior to, or different from, the approved orphan drug, even though for the same indication, may also obtain approval in the U.S. during the seven-year exclusive marketing period. Orphan drug exclusive marketing rights may also be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. To receive orphan drug designation from the EMA, a therapy must be intended for the treatment of a life-threatening or chronically debilitating rare condition with a prevalence of less than five in 10,000 in the E.U. Orphan drug designation provides incentives designed to facilitate development, including fee reductions for protocol assistance, scientific advice and importantly, may provide up to ten years of market exclusivity in the E.U. following product approval.There is no guarantee that any of our other drug candidates will receive orphan drug designation or that, even if such drug candidate is granted such status, the drug candidate\u2019s clinical development and regulatory approval process will not be delayed or will be successful.Pharmaceutical companies are also subject to various federal and state laws pertaining to health care \u201cfraud and abuse,\u201d including anti-kickback laws and false claims laws. Anti-kickback laws make it illegal for any entity or person to solicit, offer, receive, or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase or prescription of a particular drug. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third party payors, including Medicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services.Company History and Available InformationThe Company was incorporated in May 2000 as a Utah corporation. In February 2008, Bio-Path Subsidiary completed a reverse merger with the Company, which at the time was traded over the counter and had no current operations. The prior name of the Company was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path Subsidiary became the directors and officers of Bio-Path Holdings, Inc. On March 10, 2014, our common stock ceased trading on the OTCQX and commenced trading on the Nasdaq Capital Market under the ticker symbol \u201cBPTH.\u201d Effective December 31, 2014, we changed our state of incorporation from Utah to Delaware through a statutory conversion pursuant to the Utah Revised Business Corporation Act and the Delaware General Corporation Law.On February 22, 2024, we effected a reverse stock split of our outstanding shares of common stock at a ratio of 1-for-20, and our common stock began trading on the spilt-adjusted basis on the Nasdaq Capital Market at the commencement of trading on February 23, 2024. All common stock share and per share amounts in this Annual Report on Form 10-K have been adjusted to give effect to the 1-for-20 reverse stock split. Our principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401, and our telephone number is (832) 742-1357. Our Internet address is www.biopathholdings.com. We are not including the information contained in our website as part of, or incorporating it by reference into, this Annual Report on Form 10-K. We make available free of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such materials with, or furnish it to, the SEC. We also make available on our website our Corporate Governance Guidelines; the charters for our Audit Committee, Nominating/Corporate Governance Committee and Compensation Committee; our Employee Code of Business Conduct and Ethics, which applies to all of our employees, including our executive officers; and our Code of Business Conduct and Ethics for Members of the Board of Directors. All such information is also available in print and free of charge to any of our stockholders who request it. In addition, we intend to disclose on our website any amendments to, or waivers from, our codes of business conduct and ethics that are required to be publicly disclosed pursuant to rules of the SEC.\u200b24",
            "type": "paragraph"
        },
        {
            "id": 26,
            "context": "ITEM 1A. RISK FACTORS\nRisk Factor Summary We are providing the following summary of the risk factors disclosed in this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the risk factors disclosed in this Form 10-K in their entirety for additional information regarding the material factors that make an investment in the Company speculative or risky.",
            "type": "paragraph"
        },
        {
            "id": 27,
            "context": "25\n\n| us to potential criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. |\n| \u25cf | Inadequate funding for the FDA, the SEC and other government agencies, or a work slowdown or stoppage at those agencies as part of a broader federal government shutdown, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. |\n| \u25cf | Our business and operations have been affected by and could be materially and adversely affected in the future by the effects of health epidemics and pandemics, including the evolving and ongoing effects of the COVID-19 pandemic. |\n| \u25cf | Unstable market and economic conditions may have serious adverse effects on our ability to raise funds, which may cause delays, restructuring or cessation of our operations. |\n| \u25cf | We must complete extensive clinical trials to demonstrate the safety and efficacy of our drug candidates. If we are unable to demonstrate the safety and efficacy of our drug candidates, we will not be successful. |\n| \u25cf | Delays in the commencement of clinical trials of our drug candidates could result in increased costs to us and delay our ability to generate revenues. |\n| \u25cf | Delays in the completion of, or the termination of, clinical trials of our drug candidates could result in increased costs to us and could delay or prevent us from generating revenues. |\n| \u25cf | If we are unable to obtain U.S. and/or foreign regulatory approval, we will be unable to commercialize our drug candidates. |\n| \u25cf | In addition to regulations in the U.S., we may be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products, if approved. |\n| \u25cf | Changes in existing laws and regulations affecting the healthcare industry could increase our costs and otherwise adversely affect our business. |\n| \u25cf | We rely on third parties to conduct clinical trials for our drug candidates, and their failure to timely and properly perform their obligations may result in costs and delays that prevent us from obtaining regulatory approval or successfully commercializing our drug candidates. |\n| \u25cf | We may not be able to obtain or maintain orphan drug exclusivity for our product candidates. |\n| \u25cf | We rely on third parties for manufacturing of our clinical drug supplies; our dependence on these manufacturers may impair the development of our drug candidates. |\n| \u25cf | There are underlying risks associated with the manufacture of our drug candidates, which have never been manufactured in large scale. Furthermore, we anticipate continued reliance on third-party manufacturers if we are successful in obtaining marketing approval from the FDA or other regulatory agencies for any of our drug candidates. |\n| \u25cf | Identification of previously unknown problems with respect to a drug candidate, manufacturer or facility may result in restrictions on the drug candidate, manufacturer or facility. |\n| \u25cf | We may experience delays in the development of our drug candidates if the third-party manufacturers of our drug candidates cannot meet FDA requirements relating to current Good Manufacturing Practices. |",
            "type": "table"
        },
        {
            "id": 28,
            "context": "| \u25cf | If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may not generate product revenue. |\n| \u25cf | If our future drugs do not achieve market acceptance, we may be unable to generate significant revenue, if any. |\n| \u25cf | If third-party payors do not adequately reimburse patients for any of our drug candidates that are approved for marketing, they might not be purchased or used, and our revenues and profits will not develop or increase. |\n| \u25cf | If our patent position does not adequately protect our drug candidates, others could compete against us more directly, which would harm our business. |\n| \u25cf | If any third-party owners of intellectual property we may license in the future do not properly maintain or enforce the patents underlying such licenses, our competitive position and business prospects will be harmed. |\n| \u25cf | If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. |\n| \u25cf | Litigation regarding patents, intellectual property and other proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing drug candidates to market and harm our ability to operate. |\n| \u25cf | Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property. |\n| \u25cf | Raising additional capital may cause dilution to existing stockholders, restrict our operations or require us to relinquish rights. Additionally, sales of a substantial number of shares of our common stock or other securities in the public market could cause our stock price to fall. |\n| \u25cf | We may issue additional shares of our common stock in accordance with our equity incentive plans or upon exercise or conversion of outstanding securities that are exercisable for or convertible into shares of our common stock, which may cause dilution to existing stockholders. |\n| \u25cf | The trading price of our common stock has been volatile and is likely to be volatile in the future. |\n| \u25cf | Our common stock is thinly traded and in the future may continue to be thinly traded, and our stockholders may be unable to sell at or near asking prices or at all if they need to sell their shares to raise money or otherwise desire to liquidate such shares. |\n| \u25cf | Our certificate of incorporation grants our Board of Directors the power to designate and issue additional shares of common and/or preferred stock. |\n| \u25cf | We do not anticipate paying cash dividends, and accordingly stockholders must rely on stock appreciation for any return on their investment in us. |\n| \u25cf | Our management is required to devote substantial time and incur additional expense to comply with public company regulations. |\n| \u25cf | Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on the price of our common stock. |\n| \u25cf | Our common stock may be delisted from The Nasdaq Capital Market which could negatively impact the price of our common stock and our ability to access the capital markets. |",
            "type": "table"
        },
        {
            "id": 29,
            "context": "| \u25cf | the rate of progress, results and costs of completion of ongoing clinical trials of our drug candidates; |\n| \u25cf | the rate of progress, results and costs of completion of ongoing preclinical testing of our drug candidates; |\n| \u25cf | the size, scope, rate of progress, results and costs of completion of any potential future clinical trials and preclinical tests of our drug candidates that we may initiate; |\n| \u25cf | the costs to obtain adequate supply of the compounds necessary for our drug candidates; |\n| \u25cf | the costs of obtaining regulatory approval of our drug candidates; |\n| \u25cf | the scope, prioritization and number of drug development programs we pursue; |\n| \u25cf | the costs for preparing, filing, prosecuting, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; |\n| \u25cf | the extent to which we acquire or in-license other products and technologies and the costs to develop those products and technologies; |\n| \u25cf | the costs of future commercializing activities, including product sales, marketing, manufacturing and distribution, of any of our drug candidates or other products for which marketing approval has been obtained; |\n| \u25cf | our ability to establish strategic collaborations and licensing or other arrangements on terms favorable to us; and |\n| \u25cf | competing technological and market developments. |",
            "type": "table"
        },
        {
            "id": 30,
            "context": "| \u25cf | delay, reduce the scope of or eliminate one or more of our drug development programs; |\n| \u25cf | relinquish, license or otherwise dispose of rights to technologies, drug candidates or products that we would otherwise seek to develop or commercialize ourselves at an earlier stage or on terms that are less favorable than might otherwise be available; or |\n| \u25cf | liquidate and dissolve the Company. |\n| \u25cf | significantly greater capital, technical and human resources than we have and may be better equipped to discover, develop, manufacture and commercialize drug candidates; |",
            "type": "table"
        },
        {
            "id": 31,
            "context": "| \u25cf | more experience in drug discovery, development and commercialization, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products; |\n| \u25cf | drug candidates that have been approved or are in late-stage clinical development; and/or |\n| \u25cf | collaboration arrangements in our target markets with leading companies and research institutions. |\n| \u25cf | inability to integrate the resources or capabilities of collaborators; |\n| \u25cf | collaborators may prove difficult to work with or less skilled than we originally expected; |\n| \u25cf | disputes may arise with respect to the ownership of rights to technology developed with collaborators; |\n| \u25cf | disagreements with collaborators could delay or terminate the research, development or commercialization of products or result in litigation or arbitration; |\n| \u25cf | difficulty enforcing our arrangements if one of our collaborators fails to perform; |\n| \u25cf | termination of our collaboration arrangements by collaborators, which could make it difficult for us to attract new collaborators or adversely affect the perception of us in the business or financial communities; |\n| \u25cf | collaborators may have considerable discretion in electing whether to pursue the development of any additional drug candidates and may pursue technologies or products either on their own or in collaboration with our competitors that are similar to or competitive with our technologies; and |",
            "type": "table"
        },
        {
            "id": 32,
            "context": "Our business has a substantial risk of product liability claims. If we are unable to obtain or maintain appropriate levels of insurance, a product liability claim could adversely affect our business.Our business exposes us to significant potential product liability risks that are inherent in the development, manufacturing and sales and marketing of human therapeutic products. Although we do not currently commercialize any products, claims could be made against us based on the use of our drug candidates in clinical trials. Product liability claims could delay or prevent completion of our clinical development programs. We currently have product liability insurance, but we may not be able to maintain such insurance on acceptable terms. However, even if we maintain or obtain other product liability insurance, our insurance may not provide adequate coverage against potential liabilities. As a result, we may be unable to obtain or maintain insurance coverage at a reasonable cost to protect against losses that could harm our business and financial condition. If any claims are brought against us, and we are not successful in defending ourselves, those claims could result in damage awards against us, which could materially adversely affect our business and financial condition. Whether or not we are successful in defending against such claims, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims.We are increasingly dependent on information technology systems to operate our business and a cyber-attack or other breach of our systems, or those of third parties on whom we may rely, could subject us to liability or interrupt the operation of our business.We are increasingly dependent on information technology systems to operate our business. A breakdown, invasion, corruption, destruction or interruption of critical information technology systems by employees, others with authorized access to our systems or unauthorized persons could negatively impact operations. In the ordinary course of business, we collect, store and transmit confidential information and it is critical that we do so in a secure manner to maintain the confidentiality and integrity of such information. Additionally, we outsource certain elements of our information technology systems to third parties. As a result of this outsourcing, our third party vendors may or could have access to our confidential information making such systems vulnerable. Data breaches of our information technology systems, or those of our third party vendors, may pose a risk that sensitive data may be exposed to unauthorized persons or to the public. For example, the loss of clinical trial data from completed or ongoing clinical trials or preclinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. While we believe that we have taken appropriate security measures to protect our data and information technology systems, and have been informed by our third party vendors that they have as well, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems, or those of our third party vendors, that could materially adversely affect our business and financial condition.Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.Under Section 382 of the Internal Revenue Code of 1986, as amended (the \u201cCode\u201d), if a corporation experiences an \u201cownership change,\u201d generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation\u2019s ability to utilize its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income or taxes may be limited. Our prior and potential future equity offerings and other changes in our stock ownership, some of which are outside of our control, may have resulted or could in the future result in an ownership change under Section 382 of the Code. If a limitation were to apply, utilization of a portion of our domestic net operating loss and tax credit carryforwards could be limited in future periods and a portion of the carryforwards could expire before being available to reduce future income tax liabilities.On December 22, 2017, the U.S. government enacted legislation referred to as the Tax Cuts and Jobs Act (the \u201cTax Act\u201d). Under the Tax Act, net operating losses generated prior to 2018 will continue to be governed by the net operating loss tax rules as they existed prior to the adoption of the new Tax Act, which means that generally they will expire 20 years after they were generated if not used prior thereto. Accordingly, our net operating losses could expire unused and be unavailable to offset future income tax liabilities, if any. Under the Tax Act, net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such net operating losses is limited to 80% of current year taxable income. We continue to examine the impact that this provision of the Tax Act, among other provisions, may have on our business.32",
            "type": "paragraph"
        },
        {
            "id": 33,
            "context": "| \u25cf | limitations on our stockholders\u2019 ability to call special meetings of stockholders; |\n| \u25cf | an advance notice requirement for stockholder proposals and nominations for members of our Board; |\n| \u25cf | the authority of our Board to determine the number of director seats on our Board; |\n| \u25cf | the authority of our Board to fill vacancies occurring on the Board; |\n| \u25cf | the authority of our Board to issue preferred stock with such terms as our Board may determine. |",
            "type": "table"
        },
        {
            "id": 34,
            "context": "| \u25cf | the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs; |\n| \u25cf | federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which may be pursued through civil whistleblower or qui tam actions, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or other third-party payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; |\n| \u25cf | federal criminal statutes under the Health Insurance Portability and Accountability Act of 1996, which prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; |\n| \u25cf | the federal transparency requirements under The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (known collectively as the \u201cAffordable Care Act\u201d), including the provision commonly referred to as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies for which payment is available under Medicare, Medicaid or the Children\u2019s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and |\n| \u25cf | State law equivalents of each of the healthcare laws described above, some of which may be broader in scope and apply regardless of the type of payor, such as state anti-kickback statutes and false claims acts, and state pricing, marketing, and transparency statutes that require us to adopt compliance programs, report pricing information, or disclose payments or other transfers of value to physicians or other covered recipients. |",
            "type": "table"
        },
        {
            "id": 35,
            "context": "Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.Efforts to ensure that our business arrangements comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our existing or future business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. Any such actions instituted against us could have a significant adverse impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Even if we are successful in defending against such actions, we may nonetheless be subject to substantial costs, reputational harm and adverse effects on our ability to operate our business.If any of our employees, agents, or the physicians or other providers or entities with whom we expect to do business are found to have violated applicable laws, we may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, or, if we are not subject to such actions, we may suffer reputational harm for conducting business with persons or entities found, or accused of being, in violation of such laws. Any such events could adversely affect our ability to operate our business and our results of operations.Inadequate funding for the FDA, the SEC and other government agencies, or a work slowdown or stoppage at those agencies as part of a broader federal government shutdown, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which could adversely affect our business. For example, over the last several years, including December 22, 2018 to January 25, 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough employees and stop critical activities. If a prolonged government shutdown or a series of shutdowns occurs, it could significantly affect the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to gain access to the public markets and obtain necessary capital in order to properly capitalize and continue our operations, which could have a material adverse effect on our business and financial condition.Our business and operations have been affected by and could be materially and adversely affected in the future by the effects of health epidemics and pandemics, including the evolving and ongoing effects of the COVID-19 pandemic.Our business and operations could be adversely affected by health epidemics and pandemics, including the ongoing COVID-19 pandemic, which has presented a substantial public health and economic challenge around the world and has affected, and continues to affect, our employees, clinical trial participants, communities, and business operations, as well as the U.S. and global economy and financial markets. To date, COVID 19\u2019s impact on our operations has been limited to the inability to travel to clinical trial sites, clinical trial sites not allowing nonessential personnel on site for the purpose of monitoring activity, delays in the manufacture of our drug requirements by contracted third-party manufacturers and limitations on patient recruiting and enrollment. There can be no guarantee we will not experience other impacts, such as being forced to further delay or pause enrollment, experiencing potential interruptions to our supply chain, facing difficulties or additional costs in enrolling patients in future clinical trials or being able to achieve full enrollment of our studies within the timeframes we anticipate, or at all.35",
            "type": "paragraph"
        },
        {
            "id": 36,
            "context": "The negative impacts caused by the COVID-19 pandemic have been and may continue to be extensive in many aspects of society and could continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. The full extent to which the COVID-19 pandemic could ultimately impact our business, preclinical studies, clinical trials and financial results will depend on future developments, which are highly uncertain and cannot be accurately predicted, including the emergence of new variants and subvariants of the virus that causes COVID-19.Other public health crises, including any future outbreaks of contagious diseases, could have additional material adverse effects on our business. The extent to which any future public health crises may impact our business, results of operations, and financial condition depends on many factors which are highly uncertain and are difficult to predict. These factors include, but are not limited to, the duration and spread of any outbreak, its severity, the actions to contain or address the impact of the outbreak, the timing, distribution, and efficacy of vaccines and other treatments, United States and foreign government actions to respond to possible reductions in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume.Unstable market and economic conditions may have serious adverse effects on our ability to raise funds, which may cause delays, restructuring or cessation of our operations.From time to time, global and domestic credit and financial markets have experienced extreme disruptions, including severely diminished liquidity and credit availability, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make a debt or equity financing more difficult to complete, costlier, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms will have a material adverse effect on our business strategy and financial condition, and could require us to liquidate and dissolve the Company.Risks Related to the Development of Our Drug CandidatesWe must complete extensive clinical trials to demonstrate the safety and efficacy of our drug candidates. If we are unable to demonstrate the safety and efficacy of our drug candidates, we will not be successful.To date, none of our drug candidates have been approved for sale in the U.S. or any foreign country. While antisense therapeutics have been in development for over 20 years, only a limited number of antisense drugs have been successfully developed to date. Further, the development of liposomal antisense therapeutics, which comprise our drug therapeutics technology, has faced many challenges and generally remains unproven in the treatment of cancers. The success of our business depends primarily on our ability to develop and commercialize our drug candidates successfully. Our drug candidates must satisfy rigorous standards of safety and efficacy before they can be approved for sale. To satisfy these standards, we must engage in expensive and lengthy testing of our drug candidates.We may not be able to obtain authority from the FDA or other equivalent foreign regulatory agencies to move on to further efficacy segments of our ongoing clinical trials or commence and complete any other clinical trials for any of our drug candidates. Positive results in preclinical studies of a drug candidate may not be predictive of similar results in human clinical trials, and promising results from early clinical trials of a drug candidate may not be replicated in later clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stage development. Accordingly, the results from the preclinical tests or clinical trials for our drug candidates may not be predictive of the results we may obtain in later stage trials. The failure of clinical trials to demonstrate safety and efficacy of one or more of our drug candidates will have a material adverse effect on our business and financial condition.Delays in the commencement of clinical trials of our drug candidates could result in increased costs to us and delay our ability to generate revenues.Our drug candidates will require continued extensive clinical trials prior to the submission of a regulatory application for commercial sales. Because of the nature of clinical trials, we do not know whether future planned clinical trials will begin on time, if at all. Delays in the commencement of clinical trials could significantly increase our drug development costs and delay any commercialization of our drug candidates. In addition, many of the factors that may cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to denial of regulatory approval of a drug candidate.36",
            "type": "paragraph"
        },
        {
            "id": 37,
            "context": "| \u25cf | demonstrating sufficient safety and efficacy in past clinical trials to obtain regulatory approval to commence a further clinical trial; |\n| \u25cf | convincing the FDA that we have selected valid endpoints for use in proposed clinical trials; |\n| \u25cf | reaching agreements on acceptable terms with prospective contract manufacturers for manufacturing sufficient quantities of our drug candidates; and |\n| \u25cf | obtaining institutional review board approval to conduct a clinical trial at a prospective site. |\n| \u25cf | regulators or institutional review boards may not authorize us to commence or conduct a clinical trial at a prospective trial site; |\n| \u25cf | our preclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical testing or clinical trials or we may abandon projects that we expect may not be promising; |\n| \u25cf | we might have to suspend or terminate our clinical trials if the participating patients are being exposed to unacceptable health risks; |\n| \u25cf | regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements; |\n| \u25cf | the cost of our clinical trials may be greater than we currently anticipate and we may lack adequate funding to continue the clinical trial; |\n| \u25cf | the timing of our clinical trials may be longer than we currently anticipate; |\n| \u25cf | our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner (including delays or inability to manufacture or obtain sufficient quantities of materials for use in clinical trials); |\n| \u25cf | inadequacy of or changes in our manufacturing process or compound formulation; |\n| \u25cf | slower than expected rates of patient recruitment and enrollment or lower than expected patient retention rates; |\n| \u25cf | the effects of our drug candidates may not be the desired effects or may include undesirable side effects or our drug candidates may have other unexpected characteristics; |\n| \u25cf | changes in applicable regulatory policies and regulations; |",
            "type": "table"
        },
        {
            "id": 38,
            "context": "| \u25cf | delays in identifying and reaching agreement on acceptable terms with prospective clinical trial sites; |\n| \u25cf | uncertainty regarding proper dosing; |\n| \u25cf | failure of our clinical research organizations to comply with all regulatory and contractual requirements or otherwise fail to perform their services in a timely or acceptable manner; |\n| \u25cf | scheduling conflicts with participating clinicians and clinical institutions; |\n| \u25cf | failure to construct appropriate clinical trial protocols; |\n| \u25cf | insufficient data to support regulatory approval; |\n| \u25cf | inability or unwillingness of medical investigators to follow our clinical protocols; and |\n| \u25cf | the timing of discussions and meetings with the FDA or other regulatory authorities regarding the scope or design of our clinical trials. |\n| \u25cf | the drug candidate may not prove to be sufficiently efficacious; |\n| \u25cf | the drug candidate may not prove to be safe; |\n| \u25cf | the drug candidate may not be readily co-administered or combined with other drugs or drug candidates; |\n| \u25cf | the results may not confirm the positive results from earlier preclinical studies or clinical trials; |\n| \u25cf | the results may not meet the level of statistical significance required by the FDA or other regulatory agencies; and |\n| \u25cf | the FDA or other regulatory agencies may require us to carry out additional studies. |",
            "type": "table"
        },
        {
            "id": 39,
            "context": "| \u25cf | new laws, regulations, or judicial decisions related to healthcare availability or the payment for healthcare products and services, including prescription drugs, that would make it more difficult for us to market and sell products once they are approved by the FDA or foreign regulatory agencies; |\n| \u25cf | changes in FDA and foreign regulations that may require additional safety monitoring prior to or after the introduction of new products to market, which could materially increase our costs of doing business; and |\n| \u25cf | changes in FDA and foreign current cGMP that would make it more difficult for us to manufacture our drug candidates in accordance with cGMP. |",
            "type": "table"
        },
        {
            "id": 40,
            "context": "| \u25cf | reliance on third-party manufacturers for regulatory compliance and quality assurance; |\n| \u25cf | the possibility of breach of the manufacturing agreement by the third-party manufacturer because of factors beyond our control; |\n| \u25cf | the possibility of termination or nonrenewal of our manufacturing agreement by the third-party manufacturer at a time that is costly or inconvenient for us; |\n| \u25cf | the potential that third-party manufacturers will develop know-how owned by such third-party manufacturer in connection with the production of our drug candidates that is necessary for the manufacture of our drug candidates; and |\n| \u25cf | reliance on third-party manufacturers to assist us in preventing inadvertent disclosure or theft of our proprietary knowledge. |",
            "type": "table"
        },
        {
            "id": 41,
            "context": "facilities due to events such as equipment malfunction or failure or damage to the facility by natural disasters could result in the cancellation of shipments, loss of product in the manufacturing process or a shortfall in available drug candidates.We may in the future elect to manufacture certain of our drug candidates in our own manufacturing facilities. If we do so, we will require substantial additional funds and need to recruit qualified personnel in order to build or lease and operate any manufacturing facilities.There are underlying risks associated with the manufacture of our drug candidates, which have never been manufactured in large scale. Furthermore, we anticipate continued reliance on third-party manufacturers if we are successful in obtaining marketing approval from the FDA or other regulatory agencies for any of our drug candidates.To date, our drug candidates have been manufactured in relatively small quantities for preclinical testing and clinical trials by third-party manufacturers, and have never been manufactured in large scale. Additionally, as in the development of any new compound, there are underlying risks associated with their manufacture. These risks include, but are not limited to, cost, process scale-up, process reproducibility, construction of a suitable process plant, timely availability of raw materials, as well as regulatory issues associated with the manufacture of an active pharmaceutical agent. Any of these risks may prevent us from successfully developing our drug candidates. Our failure, or the failure of our third-party manufacturers to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors and reliable product packaging for diverse environmental conditions, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could materially adversely affect our business and financial condition.If the FDA or other regulatory agencies approve any of our drug candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-party manufacturers to produce commercial quantities of such approved drug candidates. These manufacturers may not be able to successfully increase the manufacturing capacity for any of our approved drug candidates in a timely or economic manner, or at all. Significant scale-up of manufacturing may require additional validation studies, which the FDA or other regulatory authorities must review and approve. If our third-party manufacturers are unable to successfully increase the manufacturing capacity for a drug candidate, or we are unable to establish our own manufacturing capabilities, the commercial launch of any approved products may be delayed or there may be a shortage in supply.Identification of previously unknown problems with respect to a drug candidate, manufacturer or facility may result in restrictions on the drug candidate, manufacturer or facility.The FDA stringently applies regulatory standards for the manufacturing of our drug candidates. Identification of previously unknown problems with respect to a drug candidate, manufacturer or facility may result in restrictions on the drug candidate, manufacturer or facility, including warning letters, suspensions of regulatory approvals, operating restrictions, delays in obtaining new product approvals, withdrawal of the product from the market, product recalls, fines, injunctions and criminal prosecution. Any of the foregoing could have a material adverse effect on our business and financial condition.We may experience delays in the development of our drug candidates if the third-party manufacturers of our drug candidates cannot meet FDA requirements relating to current Good Manufacturing Practices.Our third-party manufacturers are required to produce our drug candidates under FDA cGMP in order to meet acceptable standards for our preclinical testing and clinical trials. If such standards change, the ability of third-party manufacturers to produce our drug candidates on the schedule we require for our preclinical tests and clinical trials may be affected. In addition, third-party manufacturers may not perform their obligations under their agreements with us or may discontinue their business before the time required by us to gain approval for or commercialize our drug candidates. Any difficulties or delays in the manufacturing and supply of our drug candidates could increase our costs or cause us to lose revenue or postpone or cancel clinical trials.The FDA also requires that we demonstrate structural and functional comparability of a drug candidate produced by different third-party manufacturers. Because we may use multiple sources to manufacture our drug candidates, we may need to conduct comparability studies to assess whether manufacturing changes have affected the safety, identity, purity or potency of any drug candidate compared to the drug candidate produced by another manufacturer. If we are unable to demonstrate comparability, the FDA could require us to conduct additional clinical trials, which would be expensive and significantly delay commercialization of our drug candidates.42",
            "type": "paragraph"
        },
        {
            "id": 42,
            "context": "| \u25cf | the timing of market introduction of competitive drugs; |\n| \u25cf | the demonstrated clinical safety and efficacy of our drug candidates compared to other drugs and other drug candidates; |\n| \u25cf | the suitability of our drug candidates to be co-administered or combined with other drugs or drug candidates; |\n| \u25cf | the durability of our drug candidates in their ability to prevent the emergence of drug-resistant viral mutants; |\n| \u25cf | the convenience and ease of administration of our drug candidates; |\n| \u25cf | the existence, prevalence and severity of adverse side effects; |\n| \u25cf | other potential advantages of alternative treatment methods; |\n| \u25cf | the effectiveness of marketing and distribution support; |\n| \u25cf | the cost-effectiveness of our drug candidates; and |\n| \u25cf | the availability of reimbursement from managed care plans, the government and other third-party payors. |\n| \u25cf | new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete; |\n| \u25cf | unforeseen complications arise with respect to the use of our products; or |\n| \u25cf | sufficient third-party insurance coverage or reimbursement does not remain available. |",
            "type": "table"
        },
        {
            "id": 43,
            "context": "| \u25cf | a covered benefit under its health plan; |\n| \u25cf | safe, effective and medically necessary; |\n| \u25cf | appropriate for the specific patient; |\n| \u25cf | cost effective; and |\n| \u25cf | neither experimental nor investigational. |",
            "type": "table"
        },
        {
            "id": 44,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Patent No. | Title | Date Issued |\n| US 9,744,187 | P-ethoxy nucleic acids for liposomal formulation | \u200b | August 29, 2017 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| US 10,335,428 | P-ethoxy nucleic acids for liposomal formulation | \u200b | July 2, 2019 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| US 10,898,506 | P-ethoxy nucleic acids for liposomal formulation | \u200b | January 26, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| SG 11201802718P | P-ethoxy nucleic acids for liposomal formulation | \u200b | May 12, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EA 038277(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM) | P-ethoxy nucleic acids for liposomal formulation | \u200b | August 4, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| AU 2016340123 | \u200b | P-ethoxy nucleic acids for liposomal formulation | \u200b | January 5, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| MX 403603 | \u200b | P-ethoxy nucleic acids for liposomal formulation | \u200b | June 20, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| IN 472686 | \u200b | P-ethoxy nucleic acids for liposomal formulation | \u200b | November 24, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Patent No. | Title | Date Issued |\n| US 10,927,379 | Combination therapy with liposomal antisense oligonucleotides | \u200b | February 23, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| US 11,041,153 | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | June 22, 2021 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EP 3 512 525(in force in DE, ES, FR, GB, and NL) | \u200b | Combination therapy with liposomal antisense oligonucleotides | \u200b | July 27, 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| JP 7132911 | \u200b | Combination therapy with liposomal antisense oligonucleotides | \u200b | August 30, 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| JP 7186721 | \u200b | P-ethoxy nucleic acids for IGF-1R inhibition | \u200b | December 1, 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| CN ZL 201880033244.6 | \u200b | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | December 16, 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EA 041953(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM) | \u200b | Combination therapy with liposomal antisense oligonucleotides | \u200b | December 19, 2022 |",
            "type": "table"
        },
        {
            "id": 45,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b |\n| JP 7237009 | \u200b | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | March 2, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EA 042663(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM) | \u200b | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | March 9, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| HK 400 11951 | \u200b | Combination therapy with liposomal antisense oligonucleotides | \u200b | April 6, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| JP 7284709 | \u200b | P-ethoxy nucleic acids for BCL2 inhibition | \u200b | May 23, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| EA 044637 | \u200b | P-ethoxy nucleic acids for BCL2 inhibition | \u200b | September 19, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| MX 408790 | \u200b | P-ethoxy nucleic acids for STAT3 inhibition | \u200b | December 7, 2023 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| MX 408785 | \u200b | P-ethoxy nucleic acids for BCL2 inhibition | \u200b | December 7, 2023 |",
            "type": "table"
        },
        {
            "id": 46,
            "context": "following commercialization of our drug candidates, thereby reducing any advantages of the patent. To the extent our drug candidates based on that technology are not commercialized significantly ahead of the date of any applicable patent, or to the extent we have no other patent protection on such drug candidates, those drug candidates would not be protected by patents, and we would then rely solely on other forms of exclusivity, such as regulatory exclusivity provided by the FDCA or trade secret protection.The Leahy-Smith America Invents Act (the \u201cAmerica Invents Act\u201d) was signed into law in September 2011, and many of the substantive changes became effective in March 2013. The America Invents Act reforms U.S. patent law in part by changing the standard for patent approval from a \u201cfirst to invent\u201d standard to a \u201cfirst to file\u201d standard and developing a post-grant review system. This legislation changes U.S. patent law in a way that may weaken our ability to obtain patent protection in the U.S. for those applications filed after March 2013.If any third-party owners of intellectual property we may license in the future do not properly maintain or enforce the patents underlying such licenses, our competitive position and business prospects will be harmed.We may enter into licenses for third-party intellectual property in the future. Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for their intellectual property, in particular, those patents to which we have secured exclusive rights. If applicable, our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents issue in respect of any such patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. In addition, our licensors may terminate their agreements with us in the event we breach the applicable license agreement and fail to cure the breach within a specified period of time. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could materially adversely affect our competitive business position, business prospects and financial condition.Because our research and development of drug candidates incorporates compounds and other information that is the intellectual property of third parties, we depend on continued access to such intellectual property to conduct and complete our preclinical and clinical research and commercialize the drug candidates that result from this research. We expect that future licenses would impose, numerous obligations on us. For example, under our existing and future license agreements, we may be required to pay (i) annual maintenance fees until a drug candidate is sold for the first time, (ii) running royalties on net sales of drug candidates, (iii) minimum annual royalties after a drug candidate is sold for the first time, and (iv) one-time payments upon the achievement of specified milestones. We may also be required to reimburse patent costs incurred by the licensor, or we may be obligated to pay additional royalties, at specified rates, based on net sales of our drug candidates that incorporate the licensed intellectual property rights. We may also be obligated under some of these agreements to pay a percentage of any future sublicensing revenues that we may receive. Future license agreements may also include payment obligations such as milestone payments or minimum expenditures for research and development. We expect that any future licenses would contain reporting, insurance and indemnification requirements.If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.Our research, development and commercialization activities, including any drug candidates resulting from these activities, may infringe or be claimed to infringe patents or other proprietary rights owned by third parties and to which we do not hold licenses or other rights. There may be applications that have been filed but not published that, if issued, could be asserted against us. If a patent infringement suit were brought against us, we could be forced to stop or delay research, development or manufacturing of drug candidate that is the subject of the suit. Further, if we are found to have infringed a third- party patent, we could be obligated to pay royalties and/or other payments to the third party related to our drug candidates, which may be substantial, or we could be enjoined from selling our drug candidates that obtain approval.There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference proceedings declared by the USPTO and opposition proceedings in the European Patent Office, regarding intellectual property rights with respect to our drug candidates and technology. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business and financial condition.47",
            "type": "paragraph"
        },
        {
            "id": 47,
            "context": "| \u25cf | the patentability of our inventions relating to our drug candidates; and/or |\n| \u25cf | the enforceability, validity or scope of protection offered by our patents relating to our drug candidates. |\n| \u25cf | incur substantial monetary damages; |\n| \u25cf | encounter significant delays in bringing our drug candidates to market; and/or |\n| \u25cf | be precluded from participating in the manufacture, use or sale of our drug candidates or methods of treatment requiring licenses. |",
            "type": "table"
        },
        {
            "id": 48,
            "context": "| \u25cf | the denial or delay of regulatory approvals of our drug candidates or receipt of regulatory approval of competing products; |\n| \u25cf | our ability to accomplish clinical, regulatory and other drug development milestones; |\n| \u25cf | the ability of our drug candidates, if they receive regulatory approval, to achieve market success; |\n| \u25cf | the performance of third-party manufacturers and suppliers; |\n| \u25cf | developments with respect to patents and other intellectual property rights; |\n| \u25cf | sales of common stock or other securities by us or our stockholders in the future; |\n| \u25cf | additions or departures of key scientific or management personnel; |",
            "type": "table"
        },
        {
            "id": 49,
            "context": "| \u25cf | disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our drug candidates; |\n| \u25cf | trading volume of our common stock; |\n| \u25cf | investor perceptions about us and our industry; |\n| \u25cf | public reaction to our press releases, other public announcements and SEC and other filings; |\n| \u25cf | the failure of analysts to cover us, or changes in analysts\u2019 estimates or recommendations; |\n| \u25cf | the failure by us to meet analysts\u2019 projections or guidance; |\n| \u25cf | general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors; and |\n| \u25cf | the other factors described elsewhere in this \u201cItem 1A. Risk Factors\u201d or the section titled \u201cRisk Factors\u201d contained in our other public filings. |",
            "type": "table"
        },
        {
            "id": 50,
            "context": "Our management is required to devote substantial time and incur additional expense to comply with public company regulations.As a public reporting company, we are subject to the Sarbanes-Oxley Act of 2002, as well as to the information and reporting requirements of the SEC and other federal securities laws. We are also subject to the rules of The Nasdaq Stock Market. As a result, we incur significant legal, accounting, and other expenses that we would not incur as a private company, including costs associated with our public company reporting requirements and corporate governance requirements. Compliance with these public company obligations places significant additional demands on our limited number of finance and accounting staff and on our financial, accounting and information systems.Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on the price of our common stock.Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC require an annual management assessment of the effectiveness of our internal control over financial reporting. As a smaller reporting company as defined in Rule 12b-2 under the Exchange Act, we are currently exempt from the auditor attestation requirement of Section 404(b). If we lose this eligibility, we will incur increased personnel and audit fees in connection with the additional audit requirements. If we fail to maintain the adequacy of our internal control over financial reporting, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC. If we cannot in the future favorably assess the effectiveness of our internal control over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on the price of our common stock.Our common stock may be delisted from The Nasdaq Capital Market which could negatively impact the price of our common stock and our ability to access the capital markets.The listing standards of The Nasdaq Capital Market provide that a company, in order to qualify for continued listing, must maintain (1) a board of directors comprised of a majority of Independent Directors (as defined in Nasdaq Listing Rule 5605(a)(2)) and an audit committee of the board of directors comprised of at least three members, each of whom must be an Independent Director, and (2) a minimum stock price of $1.00 and satisfy standards relative to minimum stockholders\u2019 equity, minimum market value of publicly held shares and various additional requirements. If we fail to comply with all listing standards applicable to issuers listed on The Nasdaq Capital Market, our common stock may be delisted. If our common stock is delisted, it could reduce the price of our common stock and the levels of liquidity available to our stockholders. In addition, the delisting of our common stock could materially adversely affect our access to the capital markets and any limitation on liquidity or reduction in the price of our common stock could materially adversely affect our ability to raise capital. Delisting from The Nasdaq Capital Market could also result in other negative consequences, including the potential loss of confidence by suppliers, customers and employees, the loss of institutional investor interest and fewer business development opportunities.In the past, we have received a notice of non-compliance from the Listing Qualifications Department of The Nasdaq Stock Market LLC with respect to the $1.00 minimum closing bid price requirement. Although we have effected a reverse stock split in an effort to regained compliance with the minimum closing bid price requirement, there can be no assurance that we will be able to meet the minimum closing bid price requirement or other listing requirements in the future. \u200b",
            "type": "paragraph"
        },
        {
            "id": 51,
            "context": "ITEM 1B. UNRESOLVED STAFF COMMENTS\nNone.\nITEM 2. PROPERTIES In April 2014, we entered into a lease agreement for approximately 3,000 square feet of office space for general and administrative purposes in Bellaire, Texas, which is part of the Houston metropolitan area. The term of the lease began on August 1, 2014 and was scheduled to terminate on July 31, 2019. In May 2019, we entered into an amendment to the lease agreement to extend the term of the lease to October 31, 2024.",
            "type": "paragraph"
        },
        {
            "id": 52,
            "context": "In April 2016, we entered into a lease agreement for approximately 2,100 square feet of lab space located in Bellaire, Texas for research and development purposes. The term of the lease began on May 1, 2016 and was scheduled to terminate on April 30, 2019. In December 2018, we entered into an amendment to the lease agreement to extend the term of the lease to April 30, 2022. In January 2022, we exercised an option in the lease agreement amendment to extend the term of the lease to April 30, 2025.",
            "type": "paragraph"
        },
        {
            "id": 53,
            "context": "We do not own or lease any other real property that is materially important to our business. We believe that our current facilities are adequate for our current needs and that additional space will be available when and as needed.\n\u200b\nITEM 3. LEGAL PROCEEDINGS\nNone.\n\u200b\nITEM 4. MINE SAFETY DISCLOSURES\nNot applicable.\n\u200b\n52\nPART II\nITEM 5. MARKET FOR REGISTRANT\u2019S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES\nOur common stock is listed on The Nasdaq Capital Market under the symbol \u201cBPTH.\u201d\nHolders\nAs of March 6, 2024, there were 678,795 shares of our common stock outstanding and approximately 187 stockholders of record.\nDividends\nWe have not paid any cash dividends since our inception and do not anticipate or contemplate paying dividends in the foreseeable future.\nUnregistered Sales of Equity Securities and Use of Proceeds\nNone.\nPurchases of Equity Securities by the Issuer and Affiliated Purchasers\nNone.\nITEM 6. [RESERVED]\n\u200b\n\u200b\n53\nITEM 7. MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS In addition to historical information, this Annual Report on Form 10-K contains forward-looking statements that involve significant risks and uncertainties, which may cause our actual results to differ materially from plans and results discussed in forward-looking statements. We encourage you to review the risks and uncertainties, discussed in \u201cItem 1A. Risk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements,\u201d included elsewhere in this Annual Report on Form 10-K. The risks and uncertainties can cause actual results to differ significantly from those forecasted in forward-looking statements or implied in historical results and trends.",
            "type": "paragraph"
        },
        {
            "id": 54,
            "context": "The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report on Form 10-K.\nOverview We are a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize\u00ae, is a platform that uses P-ethoxy, which is a DNA backbone modification that is intended to protect the DNA from destruction by the body\u2019s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize\u00ae delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Through testing in numerous animal studies and dosing in clinical trials, our DNAbilize\u00ae drug candidates have demonstrated an excellent safety profile. DNAbilize\u00ae is a registered trademark of the Company.",
            "type": "paragraph"
        },
        {
            "id": 55,
            "context": "Using DNAbilize\u00ae as a platform for drug development and manufacturing, we currently have four drug candidates in development to treat at least five different cancer disease indications. Our lead drug candidate, prexigebersen (pronounced prex\u201d i je ber\u2019 sen), which targets Grb2, initially started the efficacy portion of a Phase 2 clinical trial for untreated AML patients in combination with LDAC. The interim data presented in the 2018 ASH Annual Meeting showed that 11 (65%) of the 17 evaluable patients had a response, including five (29%) who achieved CR, inclusive of one CR with CRi and one morphologic leukemia-free state, and six (35%) stable disease responses, including two patients who had greater than a 50% reduction in bone marrow blasts. However, DNA hypomethylating agents are now the most frequently used agents in the treatment of elderly AML patients in the U.S. and Europe. As a result, Stage 2 of the Phase 2 trial in AML was amended to remove the combination treatment of prexigebersen and LDAC and replace it with the combination treatment of prexigebersen and decitabine, a DNA hypomethylating agent, for treatment of a second cohort of untreated AML patients. Since decitabine is also used as a treatment for relapsed/refractory AML patients, a cohort of relapsed/refractory AML patients was also added to the study.",
            "type": "paragraph"
        },
        {
            "id": 56,
            "context": "The FDA granted approval of venetoclax in combination with LDAC, decitabine or azacytidine (the latter two drugs are DNA hypomethylating agents) as frontline therapy for newly diagnosed AML in adults who are 75 years or older, or who have comorbidities precluding intensive induction chemotherapy. We believe this approval of the frontline venetoclax and decitabine combination therapy provides an opportunity for combining prexigebersen with the combination therapy for the treatment of newly diagnosed AML patients. Preclinical efficacy studies for the triple combination treatment of prexigebersen, decitabine and venetoclax in AML have been successfully completed. In the preclinical efficacy studies, four AML cancer cell lines were treated with three different combinations of decitabine, venetoclax and prexigebersen. Decrease in AML cell viability was the primary measure of efficacy. The triple combination of decitabine, venetoclax and prexigebersen showed significant improvement in efficacy in three of the four AML cell lines. Based on these results, we believe that adding prexigebersen to the treatment combination of decitabine and venetoclax could lead to improved efficacy in AML patients. Accordingly, we further amended Stage 2 of this Phase 2 clinical trial to add the triple combination treatment comprised of prexigebersen, decitabine and venetoclax.",
            "type": "paragraph"
        },
        {
            "id": 57,
            "context": "Our approved amended Stage 2 for this Phase 2 clinical trial currently has three cohorts of patients. The first two cohorts will treat patients with the triple combination of prexigebersen, decitabine and venetoclax. The first cohort will include untreated AML patients, and the second cohort will include relapsed/refractory AML patients. Finally, the third cohort will treat relapsed/refractory AML patients, who are venetoclax-resistant or -intolerant, with the two-drug combination of prexigebersen and decitabine. The full trial design plans have approximately 98 evaluable patients for the first cohort having untreated AML patients with a preliminary",
            "type": "paragraph"
        },
        {
            "id": 58,
            "context": "54 review performed after 19 evaluable patients and a formal interim analysis after 38 evaluable patients. The full trial design plans have approximately 54 evaluable patients for each of the second cohort, having relapsed/refractory AML patients, and the third cohort, having AML patients who are venetoclax-resistant or -intolerant, in each case with a review performed after 19 evaluable patients. The study is anticipated to be conducted at up to ten clinical sites in the U.S., and Gail J. Roboz, MD, is the national coordinating Principal Investigator for the Phase 2 trial. Dr. Roboz is a professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College and the New York-Presbyterian Hospital in New York City. On August 13, 2020, we announced the enrollment and dosing of the first patient in this approved amended Stage 2 of the Phase 2 clinical trial.The safety run-in of Stage 2 of the Phase 2 clinical study was successfully completed, and the preliminary data was presented at the 2021 ASH Annual Meeting. In the safety run-in of the triple combination, six evaluable patients were treated with the combination of prexigebersen, decitabine and venetoclax. These patients included four relapsed/refractory AML patients, and two newly diagnosed AML patients. Five patients (83%) responded to treatment, including four (67%) achieving CR and one (17%) achieving CRi. Recent publications provide that response (CR + CRi) rates to combination treatment with decitabine and venetoclax (but without prexigebersen) are 42 to 52% for relapsed/refractory AML patients and 0 to 39% for relapsed/refractory secondary AML patients. Response rates to frontline treatment with decitabine and venetoclax (but without prexigebersen) are 62 to 71% for newly diagnosed AML patients. These preliminary data showed the treatment was well-tolerated and there were no dose limiting toxicities attributed to prexigebersen. Three patients remained on treatment for more than one cycle.On August 1, 2023, we announced interim data for the first two cohorts of the amended Stage 2 of the Phase 2 clinical trial. Fourteen newly diagnosed patients were evaluable in the first cohort and treated with at least one cycle of the prexigebersen, decitabine and venetoclax combination therapy. All patients in the first cohort (median age 75) were adverse risk by 2017 ELN guidelines (n=10) or secondary AML (n=4). Prexigebersen was well-tolerated, and AEs were generally consistent with decitabine and venetoclax treatment and/or for AML. Twelve of the 14 evaluable patients (86%) achieved CR/CRi and two (14%) achieved PR. In total, 100% of the evaluable patients had a response to treatment. The CR/CRi rates of 86% for the evaluable patients in the first cohort is significantly higher than the CR/CRi rates of 62% for newly diagnosed patients treated with the frontline combination treatment of decitabine and venetoclax. Fourteen refractory/relapsed evaluable AML patients in the second cohort were treated with at least one cycle of the prexigebersen, decitabine and venetoclax combination therapy. Substantially all of the patients in the second cohort (median age 56.5) were adverse risk by 2017 ELN guidelines (n=11) or secondary AML (n=2). Prexigebersen was well-tolerated, and AEs were generally consistent with decitabine and venetoclax treatment and/or for AML. Eight of the 14 evaluable refractory/relapsed patients (57%) achieved CR/CRi, two (14%) achieved PR and two (22%) achieved stable disease. In total, 93% of the evaluable patients in the second cohort had a response to treatment. The CR/CRi rates of 57% for the evaluable refractory and relapsed patients in the second cohort is significantly higher than the CR/CRi) rates of 21% for refractory/relapsed patients treated with the combination treatment of decitabine and venetoclax. Based on this interim data, we currently plan to pursue FDA expedited programs for Fast Track designation, and we are evaluating whether to seek to expand Stage 2 of the Phase 2 clinical trial in Europe.Our second drug candidate, BP1002, targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. A Phase 1 clinical trial to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and CLL patients has been initiated. The Phase 1 clinical trial is being conducted at the Georgia Cancer Center while two additional clinical trial sites are currently being activated for inclusion in the study, The University of Texas Southwestern and New York Medical College. On January 10, 2024, we announced the successful completion of the first dose cohort in the Phase 1 clinical trial. A total of six evaluable patients are scheduled to be treated with BP1002 monotherapy in standard 3+3 design, unless there is a dose limiting toxicity which would require an additional three patients to be tested. There were no dose limiting toxicities in the first dose cohort (20 mg/m2). Enrollment is now open for patients for the second BP1002 dose cohort of 40 mg/m2.Additionally, preclinical studies suggest that the combination of BP1002 with decitabine is efficacious in venetoclax-resistant leukemia and lymphoma cells. An abstract of the preclinical study was presented at the 2021 AACR Annual Meeting. A Phase 1/1b clinical trial to investigate the ability of BP1002 to treat refractory/relapsed AML patients, including venetoclax-resistant patients, is being studied. A recent study6 found that AML patients who had relapsed from frontline venetoclax-based treatment had a very poor prognosis, with a median survival of less than 3 months. Since venetoclax and BP1002 utilize different mechanisms of action, we believe that BP1002 may be a potential treatment for venetoclax-relapsed AML patients. The Phase 1/1b clinical trial is being 6 (Maiti A, Ruasch C, Cortes JE, et.al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 2021; 106: 894-898.)55",
            "type": "paragraph"
        },
        {
            "id": 59,
            "context": "conducted at several leading cancer centers in the United States, including the Weill Medical College, MD Anderson, Scripps Cancer Center and The University of California at Los Angeles Cancer Center. On December 14, 2023, we announced the successful completion of the first dose cohort of the dose escalation portion of the Phase 1/1b clinical trial of BP1002. A total of three evaluable patients per dosing cohort are scheduled to be treated with BP1002 monotherapy in a standard 3+3 design. The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities. Enrollment is now open for patients for the second BP1002 dose cohort of 40 mg/m2. The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and is intended to assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients. Our third drug candidate, BP1003, targets the STAT3 protein and is currently in IND enabling studies as a potential treatment of pancreatic cancer, NSCLC and AML. Preclinical models have shown BP1003 to inhibit cell viability and STAT3 protein expression in NSCLC and AML cell lines. Further, BP1003 successfully penetrated pancreatic tumors ex vivo and significantly enhanced the efficacy of gemcitabine, a treatment for patients with advanced pancreatic cancer, in a pancreatic cancer patient derived tumor model. An abstract of the preclinical study was presented at the 2019 AACR Annual Meeting. Our lead indication for BP1003 is pancreatic cancer due to the severity of this disease and the lack of effective, life-extending treatments. For example, pancreatic adenocarcinoma is projected to be the second most lethal cancer behind lung cancer by 2030. Typical survival for a metastatic pancreatic cancer patient is about three to six months from diagnosis. Additionally, an abstract of the preclinical study demonstrating that BP1003 enhanced the sensitivity of breast and ovarian cancer cells to chemotherapy was presented at the 2022 AACR Annual Meeting. We have successfully completed several IND enabling studies of BP1003 and have one additional IND enabling study to complete. Once the additional study is successfully completed, our goal is to file an IND application and initiate the first-in-humans Phase 1 study of BP1003 in patients with refractory, metastatic solid tumors, including pancreatic cancer and NSCLC.In addition, a modified product named BP1001-A, our fourth drug candidate, has shown to enhance chemotherapy efficacy in preclinical solid tumor models. Results of the preclinical study were published in the scientific journal Oncotarget in July 2020. BP1001-A incorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticle properties. A BP1001-A Phase 1/1b clinical trial in patients with advanced or recurrent solid tumors has been initiated. The Phase 1/1b clinical trial is being conducted at several leading cancer centers in the United States, including MD Anderson, Karmanos Cancer Institute, Mary Crowley Cancer Research and Holy Cross Hospital, Maryland. On July 17, 2023, we announced completion of the first cohort of the dose escalation portion of the Phase 1/1b clinical trial. A total of nine evaluable patients are scheduled to be treated with BP1001-A monotherapy in a standard 3+3 dose escalation design. The first dose cohort consisted of a starting dose of 60 mg/m2, and there were no dose limiting toxicities. Enrollment is now open for patients for the second dose cohort of 90 mg/m2. The Phase 1B portion of the study is expected to commence after successful completion of BP1001-A monotherapy cohorts and is intended to assess the safety and efficacy of BP1001-A in combination with paclitaxel patients with recurrent ovarian or endometrial tumors. Our DNAbilize\u00ae technology-based products are available for out-licensing or partnering. We intend to apply our drug technology template to new disease-causing protein targets to develop new liposomal antisense drug candidates for inclusion in our pipeline that meet scientific, preclinical and commercial criteria and file new patents on these targets. We expect that these efforts will include collaboration with key scientific opinion leaders in the field of study and include developing drug candidates for diseases other than cancer. As we expand our drug development programs, we will look at indications where a systemic delivery is needed and antisense RNAi nanoparticles can be used to slow, reverse or cure a disease, either alone or in combination with another drug.We have certain intellectual property as the basis for our current drug products in clinical development, prexigebersen, BP1002, BP1003 and BP1001-A. We are developing RNAi antisense nanoparticle drug candidates based on our own patented technology to treat cancer and autoimmune disorders where targeting a single protein may be advantageous and result in reduced patient adverse effects as compared to small molecule inhibitors with off-target and non-specific effects. We have composition of matter and method of use intellectual property for the design and manufacture of antisense RNAi nanoparticle drug products.As of December 31, 2023, we had an accumulated deficit of $107.6 million. Our net loss was $16.1 million and $13.9 million for the years ended December 31, 2023 and 2022, respectively. We expect to continue to incur significant operating losses, and we anticipate that our losses may increase substantially as we expand our drug development programs and commercialization efforts. To achieve profitability, we must enter into license or development agreements with third parties or successfully develop and obtain regulatory approval for one or more of our drug candidates and effectively commercialize any drug candidates we develop. In 56",
            "type": "paragraph"
        },
        {
            "id": 60,
            "context": "| \u25cf | expenses related to research and development personnel, including salaries and benefits, travel and stock-based compensation; |\n| \u25cf | external research and development expenses incurred under arrangements with third parties, such as contract research organizations, clinical investigative sites, laboratories, manufacturing organizations and consultants; and |\n| \u25cf | costs of materials used during research and development activities. |\n| \u25cf | the rate of progress, results and costs of completion of ongoing clinical trials of our drug candidates; |\n| \u25cf | the size, scope, rate of progress, results and costs of completion of any potential future clinical trials and preclinical tests of our drug candidates that we may initiate; |\n| \u25cf | competing technological and market developments; |",
            "type": "table"
        },
        {
            "id": 61,
            "context": "| \u25cf | the performance of third-party manufacturers and suppliers; |\n| \u25cf | the ability of our drug candidates, if they receive regulatory approval, to achieve market success; |\n| \u25cf | disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our drug candidates; and |\n| \u25cf | the impact, risks and uncertainties related to global pandemics and actions taken by governmental authorities or others in connection therewith. |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Year ended |\n| \u200b | \u200b | December 31, |\n| \u200b | \u200b | 2023 | 2022 |\n| Research and development expense | \u200b | $ | 11,425 | \u200b | $ | 8,969 |\n| Non-cash stock-based compensation expense | \u200b | 183 | \u200b | 196 |\n| Total research and development expense | \u200b | $ | 11,608 | \u200b | $ | 9,165 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Year ended |\n| \u200b | \u200b | December 31, |\n| \u200b | \u200b | 2023 | 2022 |\n| General and administrative expense | \u200b | $ | 3,684 | \u200b | $ | 4,081 |\n| Non-cash stock-based compensation expense | \u200b | 551 | \u200b | 655 |\n| Total general and administrative expense | \u200b | $ | 4,235 | \u200b | $ | 4,736 |",
            "type": "table"
        },
        {
            "id": 62,
            "context": "Net Operating Loss. Our net loss from operations was $15.8 million for the year ended December 31, 2023, an increase of $1.9 million compared to the year ended December 31, 2022.Change in Fair Value of Warrant Liability. The change in fair value of the warrant liability for the year ended December 31, 2023 resulted in non-cash expense of $0.3 million.Net Loss. Our net loss was $16.1 million for the year ended December 31, 2023, an increase of $2.2 million compared to the year ended December 31, 2022.Net Loss per Share. Net loss per share, both basic and diluted, was $33.63 per share for the year ended December 31, 2023, compared to $38.12 per share for the year ended December 31, 2022. Net loss per share is calculated using the weighted average number of shares of common stock outstanding during the applicable periods and excludes stock options and warrants because they are antidilutive.Liquidity and Capital ResourcesOverviewWe have not generated significant revenues to date. Since our inception, we have funded our operations primarily through public and private offerings of our capital stock and other securities. We expect to finance our foreseeable cash requirements through cash on hand, cash from operations, debt financings and public or private equity offerings. We may seek to access the public or private equity markets whenever conditions are favorable; however, there can be no assurance that we will be able to raise additional capital when needed or on terms that are favorable to us, if at all. Additionally, we may seek collaborations and license arrangements for our drug candidates. We currently have no lines of credit or other arranged access to debt financing.We had a cash balance of $1.1 million at December 31, 2023, a decrease of $9.3 million compared to December 31, 2022. We do not believe that our available cash at December 31, 2023 will be sufficient to fund current liabilities and capital expenditure requirements. The Company\u2019s ability to continue as a going concern is dependent upon obtaining funding through one or more sources as described above to meet its planned obligations and pay its liabilities. Cash FlowsFor the Year Ended December 31, 2023Operating Activities. Net cash used in operating activities for the year ended December 31, 2023 was $11.5 million. Excluding non-cash stock-based compensation expense of $0.7 million, change in fair value of the warrant liability of $0.3 million and depreciation and amortization expenses of $0.2 million, net cash used in operating activities consisted primarily of the net loss for the period of $16.1 million. These are partially offset by a decrease in prepaid drug product of $3.0 million, a decrease in other current assets of $0.3 million and an increase in operating liabilities of $0.1 million.Investing Activities. There were no investing activities for the year ended December 31, 2023.Financing Activities. Net cash provided by financing activities for the year ended December 31, 2023 consisted of net proceeds of $1.7 million from the 2023 Public Offering as described below, as well as net proceeds of $0.5 million from the exercise of warrants to purchase shares of our common stock.For the Year Ended December 31, 2022Operating Activities. Net cash used in operating activities for the year ended December 31, 2022 was $15.1 million. Excluding non-cash stock-based compensation expense of $0.9 million and depreciation and amortization expenses of $0.2 million, net cash used in operating activities consisted primarily of the net loss for the period of $13.9 million and an increase in current assets of $2.9 million which was partially offset by an increase in accounts payable and accrued expenses of $0.7 million.59",
            "type": "paragraph"
        },
        {
            "id": 63,
            "context": "Investing Activities. Net cash used in investing activities for the year ended December 31, 2022 consisted of a capital expenditure totaling $21,000 which was related to a research and development equipment purchase.Financing Activities. Net cash provided by financing activities for the year ended December 31, 2022 consisted of net proceeds of $1.7 million from the 2022 Registered Direct Offering and the 2022 Private Placement, each as described below.2022 Shelf Registration StatementOn May 27, 2022, we filed a shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC on June 14, 2022 (File No. 333-265282) (the \u201c2022 Shelf Registration Statement\u201d), at which time the offering of unsold securities under a previous shelf registration statement on Form S-3 filed with the SEC, which was declared effective by the SEC on June 5, 2019 (File No. 333-231537) (the \u201c2019 Shelf Registration Statement\u201d), was deemed terminated pursuant to Rule 415(a)(6) under the Securities Act. The 2022 Shelf Registration Statement was filed to register the offering, issuance and sale of (i) up to $110.0 million of our common stock, preferred stock, warrants to purchase common stock or preferred stock or any combination thereof, either individually or in units, (ii) up to $9.0 million of our common stock under the Offering Agreement (as defined below), which $9.0 million was subsequently reduced to $3.0 million pursuant to a prospectus supplement filed with the SEC on July 29, 2022, and (iii) up to 11,895 shares of our common stock pursuant to the exercise of warrants outstanding on May 27, 2022. The $3.0 million of our common stock that could previously be offered, issued and sold under the Offering Agreement was included in the $110.0 million of our securities that may be offered, issued and sold. On December 7, 2022, we received written notice from Wainwright (as defined below) that Wainwright had elected, pursuant to Section 8(b) of the Offering Agreement, to terminate the Offering Agreement effective as of December 7, 2022. As of immediately prior to the termination of the Offering Agreement, all $3.0 million of shares of our common stock remained available for sale pursuant to the ATM Prospectus (as defined below) and the Offering Agreement. As a result of the termination of the Offering Agreement, we will not offer or sell any additional shares of our common stock under the ATM Prospectus or the Offering Agreement, and the entire $3.0 million of shares of our common stock included in the ATM Prospectus will be available for sale in other offerings pursuant to the 2022 Shelf Registration Statement. Because our public float is less than $75.0 million, our ability to offer and sell any securities under the 2022 Shelf Registration Statement is currently limited pursuant to Instruction I.B.6 to Form S-3. For so long as our public float is less than $75.0 million, the aggregate market value of securities we sell pursuant to Instruction I.B.6 to Form S-3 during any 12 consecutive months may not exceed one-third of our public float. The foregoing does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.2022 Registered Direct Offering and 2022 Private PlacementOn November 6, 2022, we entered into a placement agency agreement with Roth Capital Partners, LLC relating to the 2022 Registered Direct Offering and the 2022 Private Placement. In addition, on November 6, 2022, we entered into securities purchase agreements with several institutional and accredited investors pursuant to which we agreed to sell, in a registered direct offering, an aggregate of 40,000 shares of our common stock for gross proceeds of approximately $2.0 million under the base prospectus contained in the 2022 Shelf Registration Statement and a related prospectus supplement filed with the SEC on November 9, 2022 (the \u201c2022 Registered Direct Offering\u201d). In a concurrent private placement, we also agreed pursuant to the securities purchase agreements to issue to such investors warrants to purchase up to 40,000 shares of our common stock (the \u201c2022 Private Placement\u201d). The 2022 Registered Direct Offering and the 2022 Private Placement closed on November 9, 2022. The net proceeds from the offerings, after deducting the placement agent\u2019s fees and expenses and our offering expenses, and excluding the proceeds, if any, from the exercise of the warrants issued in the offerings, were approximately $1.7 million. 2023 Public Offering On August 3, 2023, we entered into a placement agency agreement with Roth Capital Partners, LLC relating to a best efforts public offering of an aggregate of 175,000 shares of its common stock, together with warrants to purchase up to 175,000 shares of its common stock (the \u201c2023 Warrants\u201d), for gross proceeds of approximately $2.1 million (the \u201c2023 Public Offering\u201d). The 2023 Public Offering was made pursuant to a registration statement on Form S-1, as amended (File No. 333-272879), which was declared effective by the SEC on August 2, 2023. The 2023 Public Offering closed on August 7, 2023. The net proceeds from the 2023 Public Offering, after deducting the placement agent\u2019s fees and expenses and our offering expenses, and excluding the proceeds, if any, from the exercise of the warrants issued in such offering, were approximately $1.7 million.60",
            "type": "paragraph"
        },
        {
            "id": 64,
            "context": "Future Capital RequirementsWe expect to continue to incur significant operating expenses in connection with our ongoing activities, including conducting clinical trials, manufacturing and seeking regulatory approval of our drug candidates, prexigebersen, BP1002, BP1003 and BP1001-A. Accordingly, we will continue to require substantial additional capital to fund our projected operating requirements. Such additional capital may not be available when needed or on terms favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current and future operating plan. There can be no assurance that we will be able to continue to raise additional capital through the sale of our securities in the future. Our future capital requirements may change and will depend on numerous factors, which are discussed in detail in \u201cItem 1A. Risk Factors\u201d of this Annual Report on Form 10-K.Off-Balance Sheet ArrangementsAs of December 31, 2023, we did not have any material off-balance sheet arrangements.Critical Accounting PoliciesOur management\u2019s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in conformity with GAAP in the U.S. The preparation of such financial statements has required our management to make assumptions, estimates and judgments that affect the amounts reported in the financial statements, including the notes thereto, and related disclosures of commitments and contingencies, if any. We consider our critical accounting policies to be those that require the more significant judgments and estimates in the preparation of financial statements, including the following:Research and Development Costs \u2013 Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. If the goods will not be delivered, or services will not be rendered, then the capitalized advance payment is charged to expense.The Company estimates its clinical trial expense accrual each period based on a cost per patient calculation which is derived from estimated start-up costs, clinical trial costs based on the number of patients and length of treatment and clinical study report costs. These services are performed by the Company\u2019s third-party clinical research organizations, laboratories and clinical investigative sites. The expense accrual is recorded in research and development expense each period. Amounts that have been prepaid in advance of work performed are recorded in other current assets.For the years ended December 31, 2023 and 2022, we had $11.6 million and $9.2 million, respectively, of costs classified as research and development expense.",
            "type": "paragraph"
        },
        {
            "id": 65,
            "context": "ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK\nNot applicable.\nITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA\nOur consolidated financial statements, together with the report of our independent registered public accounting firm, are set forth beginning on page F-1 of this Annual Report on Form 10-K.\nITEM 9. CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE\nNone.\n61\nITEM 9A. CONTROLS AND PROCEDURES\nEvaluation of Disclosure Controls and Procedures It is management\u2019s responsibility to establish and maintain adequate disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC\u2019s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including the company\u2019s principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.",
            "type": "paragraph"
        },
        {
            "id": 66,
            "context": "Our management, including our Chief Executive Officer (who is also our Chief Financial Officer), has reviewed and evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Annual Report on Form 10-K. Following this review and evaluation, our management determined that as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.",
            "type": "paragraph"
        },
        {
            "id": 67,
            "context": "Management\u2019s Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act, is a process designed by, or under the supervision of, our principal executive officer and our principal financial officer, and effected by our Board, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:",
            "type": "paragraph"
        },
        {
            "id": 68,
            "context": "Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. The scope of management\u2019s assessment of the effectiveness of internal control over financial reporting includes our consolidated subsidiary.",
            "type": "paragraph"
        },
        {
            "id": 69,
            "context": "Management\u2019s assessment of the effectiveness of our internal controls is based principally on our financial reporting as of December 31, 2023. In making our assessment of internal control over financial reporting, management used the criteria set forth in Internal Control \u2013 Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Our management, with the participation of our Chief Executive Officer (who is also our Chief Financial Officer), has evaluated the effectiveness of our internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as of December 31, 2023. Based on this evaluation, management believes that, as of December 31, 2023, our internal control over financial reporting was effective.",
            "type": "paragraph"
        },
        {
            "id": 70,
            "context": "62\nChanges in Internal Control over Financial ReportingThere were no changes in our internal control over financial reporting that occurred during the fourth fiscal quarter of 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.\nITEM 9B. OTHER INFORMATION\nN o n e .\nITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE\nIdentification of Directors and Executive Officers\nOur current directors and officers are set forth below:\n\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Name | Age | Position - Committee |\n| Peter H. Nielsen | \u200b | 75 | \u200b | Chief Executive Officer; President; Chief Financial Officer; Treasurer; Chairman of the Board; Director \u2013 Business Development Committee |\n| \u200b | \u200b | \u200b | \u200b |\n| Heath W. Cleaver, CPA | \u200b | 50 | \u200b | Director \u2013 Audit Committee (Chair); Compensation Committee; Nominating/Corporate Governance Committee (Chair) |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Paul D. Aubert | 54 | Director \u2013 Audit Committee; Compensation Committee (Chair); Nominating/Corporate Governance Committee |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Aline B. Sherwood | \u200b | 54 | \u200b | Director \u2013 Audit Committee; Compensation Committee; Nominating/Corporate Governance Committee; Business Development Committee (Chair) |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Douglas P. Morris | 68 | Director \u2013 Business Development Committee; Director of Investor Relations; Secretary |",
            "type": "table"
        },
        {
            "id": 71,
            "context": "Our current directors will serve until the next annual meeting of stockholders or until their successors are elected or appointed and qualified.\nBackground Information Peter H. Nielsen. Mr. Nielsen co-founded Bio-Path and has served as Bio-Path\u2019s President, Chief Executive Officer, Chief Financial Officer/Treasurer and Chairman of the Board since 2008. At the time of Bio-Path\u2019s establishment in 2007, Mr. Nielsen licensed technology and targets from The University of Texas, MD Anderson Cancer Center and coordinated preclinical development, optimization and manufacturing of Bio-Path\u2019s lead drug candidate, prexigebersen. Since that time, Mr. Nielsen has led the clinical advancement of prexigebersen into Phase 2 studies, the introduction of additional pipeline candidates and the Company\u2019s public market debut. Prior to co-founding Bio-Path, Mr. Nielsen worked with several other companies, leading turnarounds and developing and executing on strategies for growth. Mr. Nielsen previously served as a director of Synthecon, Inc., a company developing 3D cell culture technology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He holds engineering, mathematics and M.B.A. finance degrees from the University of California at Berkeley.",
            "type": "paragraph"
        },
        {
            "id": 72,
            "context": "Heath W. Cleaver, CPA. Mr. Cleaver has served as a director of Bio-Path since 2014. Since February 2020, Mr. Cleaver has served as the President and Chief Financial Officer of Compressor Engineering Corporation (\u201cCECO\u201d), a privately-held independent manufacturer of engine and compressor replacement parts. Prior to his current roles, Mr. Cleaver served as Chief Financial Officer of CECO from July 2017 to February 2020. Mr. Cleaver was previously a consultant providing turn-around management and capital raising services to companies in the oil and gas service sector from 2016 to 2017. From 2015 to 2016, Mr. Cleaver served as the Chief Financial Officer of Global Fabrication Services, Inc. In 2014, Mr. Cleaver served as Chief Financial Officer at Tarka Resources, Inc. From 2011 until 2014, Mr. Cleaver served as Chief Financial Officer of Porto Energy Corp. From 2010 until 2011, Mr. Cleaver served as Chief Accounting Officer of Porto Energy Corp. Mr. Cleaver served as Corporate Controller and then as Vice President and Chief Accounting Officer for BPZ Energy from 2006 to 2010. Beginning in 1997 through 2004, Mr. Cleaver served in various accounting roles, including Financial Controller, at Horizon Offshore Contractors, Inc. Mr. Cleaver is a Certified Public Accountant in the state of Texas and holds a Bachelor\u2019s Degree in Business Administration - Accounting from Texas A&M University.",
            "type": "paragraph"
        },
        {
            "id": 73,
            "context": "64 Paul D. Aubert. Mr. Aubert was appointed to the Board on February 1, 2018. Mr. Aubert is currently Senior Vice President & General Counsel of Anthem Holdings Company and its subsidiaries, positions he has held since March 2018. From June 2014 to March 2018, he practiced law in a solo law practice and also served as part-time General Counsel to his current employers. From February 2012 through May 2014, Mr. Aubert served as General Counsel of Pernix Therapeutics Holdings, Inc., a Nasdaq-listed specialty pharmaceutical company. Before that, he was a Shareholder in the Corporate and Securities practice group at Winstead PC, a national law firm headquartered in Dallas, Texas, from 2007 to 2012. Mr. Aubert also served as an attorney in the Corporate and Securities practice groups of several national and international law firms prior to joining Winstead in 2004, including at Andrews Kurth LLP from 1999 to 2004, Weil, Gotshal & Manges LLP from 1998 to 1999 and Jones Walker LLP from 1996 to 1998. Mr. Aubert holds a Juris Doctor and an M.B.A. from Tulane University in New Orleans, Louisiana and a B.A. in History from Louisiana State University - Baton Rouge.Aline B. Sherwood. Ms. Sherwood was appointed to the Board on March 31, 2022. Ms. Sherwood is currently the senior director of strategic communications at Cognition Therapeutics, Inc. Prior to joining Cognition in October 2023, she provided tactical support and strategic counsel to pre-commercial, public and private life sciences companies through Scienta Communications, LLC, an independent communications consultancy established in 2010. Previously, Ms. Sherwood worked at a series of global and boutique public and investor relations agencies where she provided support for companies developing therapeutics in a variety of indications. Earlier in her career, she managed corporate communications for The Liposome Company, which had developed and commercialized a liposomal formulation of amphotericin B. Before transitioning to industry, Ms. Sherwood worked in research laboratories at Princeton University and Thomas Jefferson University. She earned a Bachelor of Science in biochemistry and classical civilizations from Beloit College.Douglas P. Morris. Mr. Morris is a co-founder of Bio-Path and has served as a director of Bio-Path since 2007 and served as an officer from 2007 to June 2014. Mr. Morris also currently serves as the Director of Investor Relations and the Secretary of Bio-Path. Mr. Morris previously served as a co-founder, Managing Member, and Secretary of nCAP Holdings, LLC (nCAP), a privately held technology based company from September 2013 to January 2016. Between 1993 and 2010, Mr. Morris was an officer and director of Celtic Investment, Inc., a financial services company. Mr. Morris owned and operated Hyacinth Resources, LLC (\u201cHyacinth\u201d), a business-consulting firm, from 1990 until September 2018, and is also a Managing Member of Sycamore Ventures, LLC, a privately held consulting firm. Mr. Morris has a B.A. from Brigham Young University, and attended the University of Southern California Master\u2019s program in public administration.Board of DirectorsOur operations are managed under the broad supervision of the Board, which has ultimate responsibility for the establishment and implementation of our general operating philosophy, objectives, goals and policies. Our Board is currently comprised of three independent directors and two non-independent directors. The Board has determined that current directors Heath W. Cleaver, Paul D. Aubert and Aline B. Sherwood are \u201cindependent\u201d as independence is defined under the listing standards for The Nasdaq Stock Market. The Board based these determinations primarily on a review of the responses our directors provided to questions regarding employment and compensation history, affiliations and family and other relationships.Codes of EthicsWe have adopted the Employee Code of Business Conduct and Ethics, which applies to all of our employees, including our executive officers, and the Code of Business Conduct and Ethics for Members of the Board, which applies to members of the Board.Board CommitteesThe Board has a standing audit committee (the \u201cAudit Committee\u201d), compensation committee (the \u201cCompensation Committee\u201d) and nominating/corporate governance committee (the \u201cNominating/Corporate Governance Committee\u201d), each of which is governed by a charter. The Board may also establish other committees from time to time as necessary to facilitate the management of the business and affairs of the Company. In 2020, the Board formed a business development committee (the \u201cBusiness Development Committee\u201d) that assists the Board by advising management on its plans for business development, licensing opportunities and business partnership opportunities. In addition to these committees, we also have a Scientific Advisory Board that serves an advisory role to management and the Board. The information below summarizes the functions of each of the committees and the Scientific Advisory Board.65",
            "type": "paragraph"
        },
        {
            "id": 74,
            "context": "| \u25cf | financial statements, including management\u2019s discussion and analysis thereof; |\n| \u25cf | financial information in any annual information form, proxy statement, prospectus or other offering document, material change report, or business acquisition report; |\n| \u25cf | press releases regarding annual and interim financial results or containing earnings guidance; |\n| \u25cf | internal controls; |\n| \u25cf | audits and reviews our financial statements; and |\n| \u25cf | filings with securities regulators containing financial information, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. |",
            "type": "table"
        },
        {
            "id": 75,
            "context": "| \u25cf | evaluating, identifying and recommending nominees to the Board; |\n| \u25cf | considering written recommendations from our stockholders for nominees to the Board; |\n| \u25cf | recommending directors to serve as committee members and chairs; |\n| \u25cf | reviewing and developing corporate governance guidelines, policies and procedures for the Board; |\n| \u25cf | reviewing disclosure by the Company of matters within the Nominating/Corporate Governance Committee\u2019s mandate; and |\n| \u25cf | reviewing and evaluating the Nominating/Corporate Governance Committee\u2019s charter and efficacy. |",
            "type": "table"
        },
        {
            "id": 76,
            "context": "request. The current members of the Scientific Advisory Board are Jorge Cortes, M.D, who serves as chairman, D. Craig Hooper, Ph.D., and Jason Fleming, M.D.Availability of Committee Charters and Other InformationThe charters for our Audit Committee, Compensation Committee, and Nominating/Corporate Governance Committee, as well as our Corporate Governance Guidelines, Employee Code of Business Conduct and Ethics and Code of Business Conduct and Ethics for Members of the Board, are available under the section titled \u201cCorporate Governance\u201d on the Investors page of the Company\u2019s website, www.biopathholdings.com. We intend to disclose any changes to or waivers from the Employee Code of Business Conduct and Ethics that would otherwise be required to be disclosed under Item 5.05 of Form 8-K on our website. The information on our website is not, and shall not be deemed to be, a part of this Annual Report on Form 10-K or incorporated into any other filings we make with the SEC.We also make available on our website, free of charge, access to our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports, as well as other documents that we file with or furnish to the SEC pursuant to Sections 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after such documents are filed with, or furnished to, the SEC.Nomination ProcessIt is our Board\u2019s responsibility to nominate members for election to the Board and to fill vacancies on the Board that may occur between annual meetings of stockholders. The Nominating/Corporate Governance Committee assists the Board by identifying and reviewing potential candidates for Board membership consistent with criteria approved by the Board. The Nominating/Corporate Governance Committee also annually recommends qualified candidates (which may include existing directors) for approval by the Board of a slate of nominees to be proposed for election to the Board at the annual meeting of stockholders.In the event of a vacancy on the Board between annual meetings of our stockholders, the Board may request that the Nominating/Corporate Governance Committee identify, review and recommend qualified candidates for Board membership for Board consideration to fill such vacancies, if the Board determines that such vacancies will be filled. Our First Amended and Restated Bylaws (the \u201cBylaws\u201d) allow for up to fifteen directors. The Board is permitted by the Bylaws to change the number of directors by a resolution adopted by the Board.When formulating its recommendations for potential Board nominees, the Nominating/Corporate Governance Committee seeks and considers advice and recommendations from management, other members of the Board and may seek or consider advice and recommendations from consultants, outside counsel, accountants or other advisors as the Nominating/Corporate Governance committee or the Board may deem appropriate.Board membership criteria are determined by the Board, with input from the Nominating/Corporate Governance Committee. The Board is responsible for periodically determining the appropriate skills, perspectives, experiences and characteristics required of Board candidates, taking into account our needs and current make-up of the Board. This assessment should include appropriate knowledge, experience, and skills in areas deemed critical to understanding the Company and our business; personal characteristics, such as integrity and judgment; and the candidate\u2019s commitments to the boards of other companies. Each Board member is expected to ensure that other existing and planned future commitments do not materially interfere with the member\u2019s service as a director and that he or she devotes the time necessary to discharge his or her duties as a director.Stockholder Nominations for DirectorsThe Nominating/Corporate Governance Committee will consider candidates for director nominees that are recommended by our stockholders in the same manner as Board recommended nominees, in accordance with the procedures set forth in our Bylaws. Any such nominations should be submitted to the Nominating/Corporate Governance Committee c/o Secretary, Bio-Path 68",
            "type": "paragraph"
        },
        {
            "id": 77,
            "context": "ITEM 11. EXECUTIVE COMPENSATION The Compensation Committee oversees our compensation programs for executives and all employees. The Compensation Committee understands that for the Company and its stockholders to achieve long-term success, the compensation programs need to attract, retain, develop and motivate a strong leadership team. As a result, our executive compensation programs are designed to pay for performance, enable talent attraction, retain top talent and closely align the interests of our executives with those of our stockholders. All decisions with respect to the compensation of our Chief Executive Officer are determined and approved either solely by the Compensation Committee or together with other independent directors, as directed by the Board. All decisions with respect to non-CEO executive compensation, incentive-compensation and equity-based plans are first approved by the Compensation Committee and then submitted, together with the Compensation Committee\u2019s recommendation, to the members of the Board for final approval.",
            "type": "paragraph"
        },
        {
            "id": 78,
            "context": "This section provides important information on our executive compensation programs and explains the compensation decisions made during 2023 by the Compensation Committee for our named executive officers (\u201cNEOs\u201d). In the fiscal year ended December 31, 2023, our only NEO was Peter H. Nielsen, Chairman of the Board, Chief Executive Officer, Chief Financial Officer and President.",
            "type": "paragraph"
        },
        {
            "id": 79,
            "context": "Compensation Philosophy Our primary objective with respect to executive compensation is to design a reward system that will align executive compensation with our overall business strategies and attract and retain highly qualified executives. We intend to stay competitive in the marketplace with companies of comparable size, industry and complexity. Our compensation philosophy for executives is guided by the following principles:",
            "type": "paragraph"
        },
        {
            "id": 80,
            "context": "69\n\n| \u25cf | Reviewed Annually. The Compensation Committee annually reviews compensation levels to ensure we remain competitive and continue to attract, retain and motivate top-tier talent. |\n| \u25cf | Alignment with Stockholder Interests. Our compensation is intended to closely align the interests of our NEOs with those of our stockholders in an effort to create long-term stockholder value. In developing our compensation philosophy, the Compensation Committee has considered the most recent stockholder advisory vote on executive compensation in which an overwhelmingly positive percentage of the votes cast were in favor of our executive compensation. The Compensation Committee is continuously mindful of stockholders\u2019 views on executive compensation and remains focused on ensuring proper alignment with stockholder interests. |\n| Element | Form of Compensation | Purpose, Basis and Performance Criteria |\n| Base Salary | \u200b | Cash | \u200b | \u25cfBase salary is intended to provide a market competitive level of fixed compensation in recognition of responsibilities, skills, capabilities, experience and leadership.\u25cfBase salary is not generally performance based, but reflective of competencies and experience. | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Annual Performance Incentive Awards (considered \u201cat-risk\u201d compensation) | \u200b | Cash | \u200b | \u25cfAnnual cash performance incentive awards are intended to motivate and reward performance achievement.\u25cfPayments are discretionary and approved annually by the Compensation Committee. | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Long-Term Incentive Awards (considered \u201cat-risk\u201d compensation) | \u200b | Stock Options | \u200b | \u25cfLong-term incentive awards are intended to recognize and reward the achievement of long-term corporate goals and objectives, recognize promotions, motivate retention of our leadership talent and align executives\u2019 interests with our stockholders. \u25cfThe Compensation Committee determines the amount of long-term incentive awards to be granted to each NEO. The Compensation Committee also may make isolated awards to recognize promotions, new hires or individual performance achievements.\u25cfIn 2023, the long-term incentive awards included time-vested equity awards that vest over a four-year period.\u25cfThe Compensation Committee provides time-vested long-term incentives (i) to build a consistent ownership stake and retention incentive, (ii) to create a meaningful tie to the Company\u2019s relative long-term stockholder returns and (iii) to motivate consistent improvement over a longer-term horizon. | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Change of Control Severance | \u200b | Eligible to receive severance payments and post-termination health benefits in connection with involuntary termination within three months before or twelve months after a change of control | \u200b | \u25cfEmployment agreements are intended to provide financial security and an industry-competitive compensation package for NEOs. This additional security helps ensure that NEOs remain focused on our performance and the continued creation of stockholder value throughout any change of control transaction rather than on the potential uncertainties associated with their own employment. | \u200b |",
            "type": "table"
        },
        {
            "id": 81,
            "context": "| \u25cf | the industry of the companies; |\n| \u25cf | the annual revenue, market capitalization and total assets of the companies; |\n| \u25cf | the number of full-time employees of the companies; |\n| \u25cf | the market data sources that are available with respect to the companies; and |\n| \u25cf | the number of peers included in the Industry Peer Group. |\n| \u25cf | Actinium Pharmaceuticals, Inc. (ATNM) |\n| \u25cf | Cellectar Biosciences, Inc. (CLRB) |",
            "type": "table"
        },
        {
            "id": 82,
            "context": "| \u25cf | Cyclacel Pharmaceuticals Inc. (CYCC) |\n| \u25cf | Dare Bioscience, Inc. (DARE) |\n| \u25cf | Diffusion Pharmaceuticals, Inc. (DFFN) |\n| \u25cf | Neurobo Therapeutics Inc. (NRBO) |\n| \u25cf | Ocuphire Pharma, Inc. (OCUP) |\n| \u25cf | PDS Biotechnology Corp. (PDSB) |\n| \u25cf | Soligenix, Inc. (SNGX) |\n| \u25cf | Sonnet Biotherapeutics Holdings, Inc. (SONN) |\n| \u25cf | Xenetic Biosciences Inc. (XBIO) |",
            "type": "table"
        },
        {
            "id": 83,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Option | \u200b | All Other | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Awards | \u200b | Compensation | \u200b | \u200b | \u200b |\n| Name and Principal Position | Year | Salary ($) | Bonus ($) | ($)(1) | ($) | Total ($) |\n| Peter H. Nielsen, CEO, | \u200b | 2023 | \u200b | $ | 575,000 | (2) | $ | 110,000 | (3) | $ | 130,880 | \u200b | $ | 11,237 | (4) | $ | 827,117 |\n| CFO, President, Chairman, Director | 2022 | $ | 555,000 | \u200b | $ | 150,000 | \u200b | $ | 288,669 | \u200b | $ | 17,678 | (5) | $ | 1,011,347 |\n| (1) | The amounts reported in this column reflect the aggregate grant date fair value of equity awards granted during the year computed in accordance with FASB ASC Topic 718. See Note 11 to our consolidated financial statements included in this Annual Report on Form 10-K for assumptions made by us in such valuation. |\n| (2) | Mr. Nielsen voluntarily reduced his base salary for 2023 to $400,000. |\n| (3) | Mr. Nielsen voluntarily elected to forego the entire $110,000 bonus. |\n| (4) | The amounts reported include Medicare premiums of $7,855, insurance copayments of $1,990 and certain other benefits including life insurance premiums paid by the Company for Mr. Nielsen. |\n| (5) | The amounts reported include Medicare premiums of $12,822, insurance copayments of $3,471 and certain other benefits including life insurance premiums paid by the Company for Mr. Nielsen. |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Estimated Future Payouts Under Non-Equity | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Incentive Plan Awards | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | All Other | \u200b | All Other | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Stock | \u200b | Option | \u200b | Exercise or | \u200b | Grant Date |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Awards: | \u200b | Awards: | \u200b | Base | \u200b | Fair Value |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Number of | \u200b | Number of | \u200b | Price of | \u200b | of |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Shares of | \u200b | Securities | \u200b | Option | \u200b | Stock |\n| \u200b | \u200b | Grant | \u200b | Threshold | \u200b | Target | \u200b | Maximum | \u200b | Stock or | \u200b | Underlying | \u200b | Awards | \u200b | Awards |\n| Name | Date | ($) | ($) | ($) | Units (#) | Options (#) | ($/Sh) | ($)(2) |\n| Mr. Nielsen (1) | 5/2/2023 | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | 5,250 | \u200b | $ | 27.80 | \u200b | $ | 25.00 |\n| (1) | Reflects time-vested stock options awarded under the 2022 Stock Incentive Plan. The options vest over a four-year period from the date of grant, with one-fourth (1/4) of the options vesting on the first anniversary of such grant, and the remaining options vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the options over the next three years. |\n| (2) | The amounts in this column reflect the aggregate grant date fair value of equity awards granted during the year computed in accordance with FASB ASC Topic 718. See Note 11 to our consolidated financial statements included in this Annual Report on Form 10-K for assumptions made by us in such valuation. |",
            "type": "table"
        },
        {
            "id": 84,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Equity Incentive | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Number of Securities | \u200b | Number of Securities | \u200b | Plan Awards: | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Underlying Unexercised | \u200b | Underlying Unexercised | \u200b | Number of Securities | \u200b | Option | \u200b | Option |\n| \u200b | \u200b | Options Exercisable | \u200b | Options Unexercisable | \u200b | Underlying Unexercised | \u200b | Exercise | \u200b | Expiration |\n| Name | (#) | (#) | Unearned Options (#) | Price ($) | Date |\n| Mr. Nielsen (1) | \u200b | 138 | \u200b | \u2014 | \u200b | \u2014 | \u200b | $ | 11,000.00 | \u200b | April 2026 |\n| Mr. Nielsen (1) | \u200b | 325 | \u200b | \u2014 | \u200b | \u2014 | \u200b | $ | 736.00 | \u200b | April 2028 |\n| Mr. Nielsen (1) | \u200b | 750 | \u200b | \u2014 | \u200b | \u2014 | \u200b | $ | 368.00 | \u200b | March 2029 |\n| Mr. Nielsen (2) | \u200b | 703 | \u200b | 47 | \u200b | \u2014 | \u200b | $ | 65.00 | \u200b | March 2030 |\n| Mr. Nielsen (3) | \u200b | 3,719 | \u200b | 531 | \u200b | \u2014 | \u200b | $ | 104.20 | \u200b | June 2030 |\n| Mr. Nielsen (4) | \u200b | 3,438 | \u200b | 1,562 | \u200b | \u2014 | \u200b | $ | 140.40 | \u200b | March 2031 |\n| Mr. Nielsen (5) | \u200b | 1,969 | \u200b | 2,531 | \u200b | \u2014 | \u200b | $ | 72.20 | \u200b | March 2032 |\n| Mr. Nielsen (6) | \u200b | \u2014 | \u200b | 5,250 | \u200b | \u2014 | \u200b | $ | 27.80 | \u200b | May 2033 |\n| (1) | All of these options granted are fully vested. |\n| (2) | This option vests over a four-year period from the date of grant, March 28, 2020, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company. |\n| (3) | This option vests over a four-year period from the date of grant, June 16, 2020, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company. |\n| (4) | This option vests over a four-year period from the date of grant, March 31, 2021, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company. |\n| (5) | This option vests over a four-year period from the date of grant, March 23, 2022, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company. |\n| (6) | This option vests over a four-year period from the date of grant, May 2, 2023, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company. |",
            "type": "table"
        },
        {
            "id": 85,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Triggering Event | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Termination without Cause or | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Resignation for Good Reason within | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Termination without Cause or | \u200b | 3 Months Before or 12 Months | \u200b |\n| Name | Benefit | Resignation for Good Reason ($) | Following a Change in Control ($) | \u200b |\n| Peter H. Nielsen | Market Value of Stock Vesting | $ | \u2014 | \u200b | $ | \u2014 | (1) |\n| \u200b | Accrued Vacation Days | \u200b | \u200b | 36,923 | \u200b | \u200b | 36,923 | \u200b |\n| \u200b | Three Months\u2019 Base Salary | \u200b | \u200b | 100,000 | \u200b | \u200b | 100,000 | \u200b |\n| \u200b | Continuation of Benefits | \u200b | \u200b | 1,667 | \u200b | \u200b | 3,334 | \u200b |\n| \u200b | Total | $ | 138,590 | \u200b | $ | 140,257 | \u200b |\n| (1) | Mr. Nielsen\u2019s stock option awards would immediately become vested, and the value of the acceleration would be equal to the vesting shares multiplied by the excess of the then current stock price over the exercise price of the options. For purposes of this table, we have calculated the value of the acceleration using the closing price of our common stock on December 29, 2023, or $9.20 per share. |",
            "type": "table"
        },
        {
            "id": 86,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Fees | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Earned | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | or Paid | \u200b | Option | \u200b | All Other | \u200b | \u200b | \u200b |\n| Name | in Cash | Awards | Compensation | Total |\n| Heath W. Cleaver | $ | 73,000 | (1) | $ | 12,306 | (2) | $ | \u2014 | \u200b | $ | 85,306 |\n| Paul D. Aubert | $ | 61,500 | (1) | $ | 12,306 | (2) | $ | \u2014 | \u200b | $ | 73,806 |\n| Aline B. Sherwood | \u200b | $ | 64,500 | (1) | $ | 12,306 | (2) | $ | \u2014 | \u200b | $ | 76,806 |\n| Douglas P. Morris (3) | $ | \u2014 | \u200b | $ | 16,235 | (4) | $ | 73,744 | (5) | $ | 89,979 |\n| (1) | These amounts reflect cash fees paid to or earned by our non-employee directors for attending Board or committee meetings during the year ended December 31, 2023. |\n| (2) | In May 2023, our non-employee directors who were eligible at such time earned or received an annual grant of an option to purchase 500 shares of our common stock, which was the only grant received by such directors during 2023. The amounts in this column reflect the aggregate grant date fair value of equity awards granted during the year computed in accordance with FASB ASC Topic 718. See Note 11 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for assumptions made by us in such valuation. |\n| (3) | Mr. Morris was hired by the Company in 2016 as the Company\u2019s Director of Investor Relations. Accordingly, Mr. Morris is not considered a non-employee director and does not receive compensation for his services as a member of the Board. |\n| (4) | Option awards granted to Mr. Morris reflect compensation received by Mr. Morris in his capacity as the Company\u2019s Director of Investor Relations. |\n| (5) | This amount reflects compensation received by Mr. Morris in his capacity as the Company\u2019s Director of Investor Relations, which includes base salary and certain other benefits. |\n| \u200b | \u200b | \u200b |\n| \u200b | \u200b | Number of |\n| \u200b | \u200b | shares underlying |\n| Director | outstanding options |\n| Heath W. Cleaver | \u200b | 2,125 |\n| Paul D. Aubert | \u200b | 2,100 |\n| Aline B. Sherwood | \u200b | 1,000 |\n| Douglas P. Morris (1) | \u200b | 2,619 |\n| (1) | Mr. Morris was hired by the Company in 2016 as the Company\u2019s Director of Investor Relations. Accordingly, Mr. Morris is not considered a non-employee director. |",
            "type": "table"
        },
        {
            "id": 87,
            "context": "The chairs of the respective Board committees also received as compensation the following amounts: (i) an annual cash retainer in the amount of $20,000 to the chair of the Audit Committee; (ii) an annual cash retainer in the amount of $10,000 to the chair of the Compensation Committee; (iii) an annual cash retainer in the amount of $8,000 to the chair of the Nominating/Corporate Governance Committee; and (iv) an annual cash retainer in the amount of $8,000 to the chair of the Business Development Committee.Non-chair members of the respective Board committees also received as compensation the following amounts: (i) an annual cash retainer in the amount of $7,500 to each member of the Audit Committee; (ii) an annual cash retainer in the amount of $5,000 to each member of the Compensation Committee; and (iii) an annual cash retainer in the amount of $4,000 to each member of the Nominating/Corporate Governance Committee.In addition to the foregoing cash compensation for Board and committee members, non-employee directors of the Board who spent significant time performing Board or committee service beyond the normal scope of their Board or committee responsibilities could receive up to $2,500 per diem at the discretion of the Chief Executive Officer of the Company.Equity Compensation ProgramEach non-employee director of the Board also received as compensation an annual stock option grant (a \u201cGrant\u201d) of 500 shares of our common stock (the \u201cOption Shares\u201d). The exercise price of the Option Shares was determined by the Board, and the Option Shares vest over a one-year period from the date of the Grant, with the Option Shares vesting in equal monthly increments equal to one-twelfth (1/12) of the Option Shares, based on continuing service to the Company.",
            "type": "paragraph"
        },
        {
            "id": 88,
            "context": "ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS The following table sets forth information regarding shares of our common stock beneficially owned at March 5, 2024 by: (i) our sole NEO and each director; (ii) all executive officers and directors as a group; and (iii) each person known by us to beneficially own 5% or more of the outstanding shares of our common stock. The information in this table is based solely on statements in filings with the SEC or other reliable information.",
            "type": "paragraph"
        },
        {
            "id": 89,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Amount and | \u200b | \u200b |\n| \u200b | \u200b | Nature of | \u200b | \u200b |\n| \u200b | \u200b | Beneficial | \u200b | Percent of |\n| Name of Beneficial Owner | Ownership | Class |\n| Peter H. Nielsen (1) (2) | \u200b | 14,838 | \u200b | 2.35 | % |\n| Douglas P. Morris (1) (3) | \u200b | 2,123 | \u200b | * | \u200b |\n| Heath W. Cleaver (1) (4) | \u200b | 2,119 | \u200b | * | \u200b |\n| Aline B. Sherwood (1) (5) | \u200b | 1,000 | \u200b | * | \u200b |\n| Paul D. Aubert (1) (6) | \u200b | 2,100 | \u200b | * | \u200b |\n| All officers and directors as a group (7) | \u200b | 22,180 | \u200b | 3.48 | % |",
            "type": "table"
        },
        {
            "id": 90,
            "context": "*Less than 1%\n77\n\n| (5) | All 1,000 shares are issuable upon the exercise of options that are exercisable within 60 days. |\n| (6) | All 2,100 shares are issuable upon the exercise of options that are exercisable within 60 days. |\n| (7) | Includes 1,702 shares owned of record and 20,478 shares issuable upon the exercise of options currently exercisable or will be exercisable within 60 days. |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Number of |\n| \u200b | \u200b | Number of | \u200b | \u200b | \u200b | \u200b | shares of |\n| \u200b | \u200b | shares of | \u200b | \u200b | \u200b | \u200b | common stock |\n| \u200b | \u200b | common stock to | \u200b | \u200b | \u200b | \u200b | remaining |\n| \u200b | be issued | \u200b | Weighted-average | \u200b | available for |\n| \u200b | upon exercise of | \u200b | exercise price | \u200b | future issuance |\n| \u200b | outstanding | \u200b | of outstanding | \u200b | under equity |\n| \u200b | options, warrants | \u200b | options, warrants | \u200b | compensation |\n| Plan Category | and rights (1) | and rights | plans (2) |\n| Equity compensation plans approved by stockholders | \u200b | 44 | \u200b | $ | 8.06 | \u200b | 55 |\n| Equity compensation plans not approved by stockholders | \u200b | \u2014 | \u200b | \u200b | \u200b | \u200b | \u2014 |\n| (1) | The shares shown in this column are securities to be issued upon exercise of outstanding options, warrants and rights were subject to outstanding stock option awards as of December 31, 2023 that were granted under each of the 2017 Stock Incentive Plan and the 2022 Stock Incentive Plan and total 32 and 12, respectively. |\n| (2) | The shares shown in this column as remaining available for future issuance as of December 31, 2023 are under each of the 2017 Stock Incentive Plan and the 2022 Stock Incentive Plan and total 1 and 54, respectively. |",
            "type": "table"
        },
        {
            "id": 91,
            "context": "ITEM 13. CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE\nRelated Party Transactions It is our policy that we will not enter into any transactions required to be disclosed under Item 404 of Regulation S-K promulgated by the SEC unless the Audit Committee first reviews and approves the transactions. The Audit Committee is required to review on an ongoing basis, and pre-approve all related party transactions before they are entered into, including those transactions that are required to be disclosed under Item 404 of Regulation S-K. Related party transactions involving a director must also be approved by the disinterested members of the Audit Committee. It is the responsibility of our employees and directors to disclose any significant financial interest in a transaction between the Company and a third party, including an indirect interest. All related party transactions shall be disclosed in our filings with the SEC as required under SEC rules.",
            "type": "paragraph"
        },
        {
            "id": 92,
            "context": "In addition, pursuant to our codes of ethics, all employees, officers and directors of ours and our subsidiaries are prohibited from engaging in any relationship or financial interest that is an actual or potential conflict of interest with us without approval. Employees and officers are required to provide written disclosure to their supervisors as soon as they have any knowledge of a transaction or proposed transaction with an outside individual, business or other organization that would create a conflict of interest or the appearance of one. Directors are required to disclose such information to the Board or as otherwise required by law.",
            "type": "paragraph"
        },
        {
            "id": 93,
            "context": "For our last two fiscal years, there has not been nor is there currently proposed any transaction or series of similar transactions to which we were or are to be a party in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at the end of our last two fiscal years, and in which any of our directors, executive officers, persons who we know hold more than 5% of our common stock, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest other than: (i) compensation agreements and other arrangements, which are described elsewhere in this Annual Report on Form 10-K and (ii) the transactions described in the following paragraph.",
            "type": "paragraph"
        },
        {
            "id": 94,
            "context": "78 We have entered into indemnity agreements with certain of our officers and directors which provide, among other things, that we will indemnify such officer or director, under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under applicable law, our Certificate of Incorporation and our Bylaws.Director IndependenceThe following members of the Board have been identified as independent under the standards of The Nasdaq Stock Market: Heath W. Cleaver, Paul D. Aubert and Aline B. Sherwood. Presently, there are no directors on our Audit Committee, Nominating/Corporate Governance Committee or Compensation Committee who are not independent under the standards of The Nasdaq Stock Market.",
            "type": "paragraph"
        },
        {
            "id": 95,
            "context": "ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES For the fiscal years ended December 31, 2023 and December 31, 2022, Ernst & Young LLP (\u201cEY\u201d), as our independent registered public accounting firm during such time, billed the approximate fees set forth in the table below. The Board has considered the services provided by EY and has concluded that such services are compatible with the independence of EY as our principal accountants during such periods.",
            "type": "paragraph"
        },
        {
            "id": 96,
            "context": "The table below sets forth the aggregate fees billed to the Company by EY for services rendered in the fiscal years ended December 31, 2023 and December 31, 2022 (in thousands).\n\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | December 31, | \u200b | December 31, |\n| \u200b | \u200b | 2023 | 2022 |\n| Audit fees (1) | $ | 445 | \u200b | $ | 336 |\n| Audit-related fees (2) | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 |\n| Tax fees (3) | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 |\n| All other fees (4) | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 |\n| Total | $ | 445 | \u200b | $ | 336 |",
            "type": "table"
        },
        {
            "id": 97,
            "context": "\u200b\nPre-Approval Policies and Procedures\nThe Audit Committee has not adopted any blanket pre-approval policies and procedures. Instead, the Audit Committee will pre-approve the provision of all audit or non-audit services.\n79\nPART IV\nITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES\n\n| ExhibitNumber | Exhibit |\n| 2.1 | \u200b | Agreement and Plan of Merger and Reorganization dated September 27, 2007, by and among the Company, Biopath Acquisition Corp., a Utah corporation and wholly owned subsidiary of the registrant, and Bio-Path, Inc., a Utah corporation (incorporated by reference to Exhibit 2.1 to the Company\u2019s Current Report on Form 8-K filed on September 27, 2007). | \u200b |\n| 3.1 | \u200b | Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company\u2019s Current Report on Form 8-K filed on January 6, 2015). | \u200b |\n| 3.2 | \u200b | Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on February 9, 2018). | \u200b |\n| 3.3 | \u200b | Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on January 16, 2019). | \u200b |\n| 3.4 | \u200b | Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on February 23, 2024). | \u200b |\n| 3.5 | \u200b | First Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on June 7, 2017). | \u200b |\n| \u200b | \u200b | \u200b | \u200b |\n| 3.6\u200b | \u200b | Amendment No. 1 to the First Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on December 8, 2023). | \u200b |\n| 4.1 | \u200b | Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company\u2019s Annual Report on Form 10-K filed on March 16, 2015). | \u200b |\n| 4.2 | \u200b | Form of Warrant issued to Maxim Group LLC, Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K on January 21, 2014). | \u200b |\n| 4.3 | \u200b | Form of Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on June 29, 2016). | \u200b |\n| 4.4 | \u200b | Form of Warrant issued to H.C. Wainwright & Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.5 to the Company\u2019s Quarterly Report on Form 10-Q filed on August 9, 2016). | \u200b |\n| 4.5 | \u200b | Form of New Warrant (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on May 22, 2017). | \u200b |\n| 4.6 | \u200b | Form of Warrant Amendment (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on June 19, 2017). | \u200b |\n| 4.7 | \u200b | Form of Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on November 6, 2017). | \u200b |\n| 4.8 | \u200b | Form of Warrant issued to Roth Capital Partners, LLC (incorporated by reference to Exhibit 4.9 to the Company\u2019s Annual Report on Form 10-K filed on April 2, 2018). | \u200b |\n| 4.9 | \u200b | Form of Series A Warrant issued to certain investors (incorporated by reference to Exhibit 4.2 to the Company\u2019s Current Report on Form 8-K filed on September 21, 2018). | \u200b |\n| 4.10 | \u200b | Form of Warrant issued to H.C. Wainwright & Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.3 to the Company\u2019s Quarterly Report on Form 10-Q filed on November 14, 2018). | \u200b |\n| 4.11 | \u200b | Form of Underwriter Warrant issued to H.C. Wainwright & Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on January 16, 2019). | \u200b |",
            "type": "table"
        },
        {
            "id": 98,
            "context": "80\n\n| 4.12 | \u200b | Form of Series A Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on January 22, 2019). | \u200b |\n| 4.13 | \u200b | Form of Warrant issued to H.C. Wainwright & Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.15 to the Company\u2019s Annual Report on Form 10-K filed on March 19, 2019). | \u200b |\n| 4.14 | \u200b | Form of Warrant issued to H.C. Wainwright & Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on March 13, 2019). | \u200b |\n| 4.15 | \u200b | Form of Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on November 22, 2019). | \u200b |\n| 4.16 | \u200b | Form of Warrant issued to H.C. Wainwright & Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.2 to the Company\u2019s Current Report on Form 8-K filed on November 22, 2019). | \u200b |\n| 4.17 | \u200b | Description of Bio-Path Holdings, Inc.\u2019s Securities Registered under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.17 to the Company's Annual Report on Form 10-K filed on March 5, 2020). | \u200b |\n| 4.18 | \u200b | Form of Common Warrant (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on November 9, 2022). | \u200b |\n| 4.19 | \u200b | Form of Common Warrant (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023). | \u200b |\n| 4.20 | \u200b | Warrant Agency Agreement, dated as of August 7, 2023, by and between the Company and Equiniti Trust Company, LLC (incorporated by reference to Exhibit 4.2 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023). | \u200b |\n| \u200b | \u200b | \u200b | \u200b |\n| 10.1+ | \u200b | Employment Agreement \u2013 Peter H. Nielsen (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on February 19, 2008). | \u200b |\n| 10.2+ | \u200b | Amended 2007 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-8 filed on December 10, 2008). | \u200b |\n| 10.3+ | \u200b | First Amendment to First Amended 2007 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Quarterly Report on Form 10-Q filed on August 14, 2013). | \u200b |\n| 10.4 | \u200b | Form of Securities Purchase Agreement by and between the Company, Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on January 21, 2014). | \u200b |\n| 10.5 | \u200b | Form of Waiver, Consent and Amendment to that certain Securities Purchase Agreement by and between Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K on January 21, 2014). | \u200b |\n| 10.6+ | \u200b | First Amendment to Employment Agreement, dated March 26, 2014 \u2013 Peter H. Nielsen (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on March 26, 2014). | \u200b |\n| 10.7 | \u200b | Lease Agreement dated April 16, 2014 by and between the Company and Pin Oak North Parcel TT, LLC (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on April 18, 2014). | \u200b |\n| 10.8 | \u200b | Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on April 16, 2015). | \u200b |\n| 10.9 | \u200b | Controlled Equity OfferingSM Sales Agreement, dated June 24, 2015, by and between the Company and Cantor Fitzgerald & Co. (incorporated by reference to Exhibit 1.1 to the Company\u2019s Current Report on Form 8-K filed on June 25, 2015). | \u200b |\n| 10.10 | \u200b | Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on June 29, 2016). | \u200b |\n| 10.11 | \u200b | Form of Warrant Exercise Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on May 22, 2017). | \u200b |\n| 10.12 | \u200b | Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on November 6, 2017). | \u200b |\n| 10.13 | \u200b | Form of Leak-Out Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K filed on November 6, 2017). | \u200b |\n| 10.14+ | \u200b | Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017). | \u200b |\n| 10.15 | \u200b | Form of Incentive Stock Option Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017). | \u200b |",
            "type": "table"
        },
        {
            "id": 99,
            "context": "| 10.16 | \u200b | Form of Non-Qualified Stock Option Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017). | \u200b |\n| 10.17 | \u200b | Form of Restricted Share Unit Award Agreement (Time-Vested) under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017). | \u200b |\n| 10.18 | \u200b | Form of Restricted Share Unit Award Agreement (Performance-Based) under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017). | \u200b |\n| 10.19 | \u200b | Form of Restricted Share Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017). | \u200b |\n| 10.20 | \u200b | Form of Stock Appreciation Right Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017). | \u200b |\n| 10.21 | \u200b | Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on September 21, 2018). | \u200b |\n| 10.22 | \u200b | Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on January 22, 2019). | \u200b |\n| 10.23 | \u200b | Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on March 13, 2019). | \u200b |\n| 10.24 | \u200b | First Amendment to Lease Agreement dated April 16, 2014 by and between the Company and Pin Oak North Parcel TT, LLC (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on June 4, 2019). | \u200b |\n| 10.25 | \u200b | Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on November 22, 2019). | \u200b |\n| 10.26+ | \u200b | First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on December 23, 2019). | \u200b |\n| 10.27+ | \u200b | Second Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Quarterly Report on Form 10-Q filed on May 16, 2022). | \u200b |\n| 10.28 | \u200b | Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on November 9, 2022). | \u200b |\n| 10.29+ | \u200b | Bio-Path Holdings, Inc. 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022). | \u200b |\n| 10.30 | \u200b | Form of Incentive Stock Option Award Agreement under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022). | \u200b |\n| 10.31 | \u200b | Form of Non-Qualified Stock Option Award Agreement under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022). | \u200b |\n| 10.32 | \u200b | Form of Restricted Share Unit Award Agreement (Time-Vested) under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022). | \u200b |\n| 10.33 | \u200b | Form of Restricted Share Unit Award Agreement (Performance-Based) under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022). | \u200b |\n| 10.34 | \u200b | Form of Restricted Share Award Agreement under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022). | \u200b |\n| 10.35 | \u200b | Form of Stock Appreciation Right Award Agreement under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022). | \u200b |\n| 10.36 | \u200b | Placement Agency Agreement, dated as of August 3, 2023, by and between the Company and Roth Capital Partners, LLC (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023). | \u200b |\n| 10.37 | \u200b | Form of Securities Purchase Agreement, dated as of August 3, 2023, by and between the Company and certain purchasers (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023). | \u200b |\n| 10.38 | \u200b | Form of Warrant Amendment Agreement, dated as of August 3, 2023, by and between the Company and certain warrant holders (incorporated by reference to Exhibit 10.3 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023). | \u200b |",
            "type": "table"
        },
        {
            "id": 100,
            "context": "| 21.1 | \u200b | Subsidiaries of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed on March 5, 2020). | \u200b |\n| 23.1* | \u200b | Consent of Ernst & Young LLP. | \u200b |\n| 31* | \u200b | Certification of Principal Executive Officer/Principal Financial Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 Sarbanes Oxley Act of 2002. | \u200b |\n| 32** | \u200b | Certification of Principal Executive Officer/Principal Financial Officer pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. | \u200b |\n| 97* | \u200b | Executive Compensation Recoupment Policy. | \u200b |\n| 101* | \u200b | The following financial statements from the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Inline XBRL: (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Statements of Cash Flows; (iv) Consolidated Statements of Shareholders\u2019 Equity; and (v) Notes to the Consolidated Financial Statements, tagged as blocks of text and including detailed tags. | \u200b |\n| 104* | \u200b | The cover page from the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Inline XBRL (included as Exhibit 101). | \u200b |\n| * | Filed herewith. |\n| ** | Furnished herewith. |",
            "type": "table"
        },
        {
            "id": 101,
            "context": "| BIO-PATH HOLDINGS, INC. |\n| Dated: March 7, 2024 | By: | /s/ Peter H. Nielsen |\n| Peter H. Nielsen |\n| President |\n| Chief Executive Officer |\n| Chief Financial Officer |\n| Principal Accounting Officer |\n| Date | Title | Signature |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| March 7, 2024 | \u200b | President/Chief Executive Officer/ Chief Financial Officer/ | \u200b | /s/ Peter H. Nielsen | \u200b |\n| \u200b | \u200b | Principal Accounting Officer/Director | \u200b | Peter H. Nielsen | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| March 7, 2024 | \u200b | Director | \u200b | /s/ Heath W. Cleaver | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Heath W. Cleaver | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| March 7, 2024 | \u200b | Director | \u200b | /s/ Paul D. Aubert | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Paul D. Aubert | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| March 7, 2024 | \u200b | Director | \u200b | /s/ Aline B. Sherwood | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Aline B. Sherwood | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| March 7, 2024 | \u200b | Director | \u200b | /s/ Douglas P. Morris | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Douglas P. Morris | \u200b |",
            "type": "table"
        },
        {
            "id": 102,
            "context": "| Bio-Path Holdings, Inc. Financial Statements | Page |\n| Reports of Independent Registered Public Accounting Firms (PCAOB ID: 42 ) | \u200b | F-2 | \u200b |\n| Consolidated Balance Sheets | \u200b | F-4 | \u200b |\n| Consolidated Statements of Operations | \u200b | F-5 | \u200b |\n| Consolidated Statements of Cash Flows | \u200b | F-6 | \u200b |\n| Consolidated Statements of Shareholders\u2019 Equity | \u200b | F-7 | \u200b |\n| Notes to Consolidated Financial Statements | \u200b | F-8 | \u200b |",
            "type": "table"
        },
        {
            "id": 103,
            "context": "Report of Independent Registered Public Accounting FirmTo the Shareholders and the Board of Directors of Bio-Path Holdings, Inc.Opinion on the Financial StatementsWe have audited the accompanying consolidated balance sheets of Bio-Path Holdings, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, shareholders\u2019 equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the \u201cconsolidated financial statements\u201d). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.The Company\u2019s Ability to Continue as a Going ConcernThe accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company\u2019s ability to continue as a going concern. Management\u2019s evaluation of the events and conditions and management's plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.Basis for OpinionThese financial statements are the responsibility of the Company\u2019s management. Our responsibility is to express an opinion on the Company\u2019s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company\u2019s internal control over financial reporting. Accordingly, we express no such opinion.Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.Critical Audit MatterThe critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosure to which it relates.F-2",
            "type": "paragraph"
        },
        {
            "id": 104,
            "context": "| Prepaid or Accrued Research and Development Expenses |\n| Description of the Matter | During 2023, the Company incurred $11.6 million for research and development expenses and as of December 31, 2023 recorded prepaid clinical trial expenses of $0.9 million and accrued clinical trial expense of $0.8 million. As disclosed in Note 2 to the consolidated financial statements, research and development costs are charged to expense when the related goods are delivered, or services are performed. The Company estimated its clinical trial expense based on a cost per patient calculation, which is derived from estimated start-up costs, clinical trial costs based on the number of patients and length of treatment and clinical study report costs. The Company recorded an accrual or prepaid for clinical trial expenses based on its estimated clinical trial expense as compared to payments made to the Company\u2019s third-party clinical research organization, laboratories and clinical investigation sites. Auditing the Company\u2019s accrued and prepaid research and development expenses is complex due to significant judgment and estimates made by management in determining the clinical trial expenses incurred, which include inputs such as number of patients, length of treatment and clinical study report costs, compared to payments the Company has made. |\n| How We Addressed the Matter in Our Audit | To test the prepaid research and development expenses for significant clinical trials, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating the significant assumptions that are used by management to estimate the recorded prepayments. To test the significant assumptions, we corroborated the patient enrollment, length of treatment, trial timeline and progress of research and development activities through discussion with the Company\u2019s research and development personnel that oversee the research and development projects, inspected the Company\u2019s contracts with third parties and any pending change orders to assess the impact on amounts recorded, and obtained information directly from vendors of their costs incurred to date. We tested a sample of transactions and compared the costs against related invoices and contracts. We also performed analytics over fluctuations in accruals or prepaid balances by trial throughout the year and tested subsequent payments to evaluate the completeness of the research and development expenses recognized. |",
            "type": "table"
        },
        {
            "id": 105,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | As of December 31, | As of December 31, |\n| \u200b | \u200b | 2023 | \u200b | 2022 |\n| Assets | \u200b | \u200b |\n| \u200b | \u200b | \u200b |\n| Current assets | \u200b | \u200b |\n| Cash | \u200b | $ | 1,052 | \u200b | $ | 10,384 |\n| Prepaid drug product | \u200b | 632 | \u200b | 3,587 |\n| Other current assets | \u200b | 1,358 | \u200b | 1,644 |\n| Total current assets | \u200b | 3,042 | \u200b | 15,615 |\n| \u200b | \u200b | \u200b |\n| Fixed assets | \u200b | \u200b |\n| Furniture, fixtures & equipment | \u200b | 1,120 | \u200b | 1,120 |\n| Less accumulated depreciation | \u200b | ( 1,044 ) | \u200b | ( 962 ) |\n| \u200b | \u200b | 76 | \u200b | 158 |\n| \u200b | \u200b | \u200b |\n| Right of use operating assets | \u200b | 102 | \u200b | 198 |\n| \u200b | \u200b | \u200b |\n| Total Assets | \u200b | $ | 3,220 | \u200b | $ | 15,971 |\n| Liabilities & Shareholders' Equity | \u200b | \u200b |\n| Current liabilities | \u200b | \u200b |\n| Accounts payable | \u200b | $ | 457 | \u200b | $ | 667 |\n| Accrued expenses | \u200b | 1,346 | \u200b | 909 |\n| Current portion of lease liabilities | \u200b | 103 | \u200b | 108 |\n| Total current liabilities | \u200b | 1,906 | \u200b | 1,684 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Warrant liability | \u200b | 863 | \u200b | \u2014 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Noncurrent lease liabilities | \u200b | 10 | \u200b | 113 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Total Liabilities | \u200b | 2,779 | \u200b | 1,797 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Shareholders' equity | \u200b | \u200b |\n| Preferred stock, $ .001 par value; 10,000 shares authorized; no shares issued and outstanding | \u200b | \u2014 | \u200b | \u2014 |\n| Common stock, $ .001 par value; 200,000 shares authorized; 618 and 398 shares issued and outstanding, respectively | \u200b | 1 | \u200b | 1 |\n| Additional paid in capital | \u200b | 108,047 | \u200b | 105,702 |\n| Accumulated deficit | \u200b | ( 107,607 ) | \u200b | ( 91,529 ) |\n| Total shareholders' equity | \u200b | 441 | \u200b | 14,174 |\n| Total Liabilities & Shareholders' Equity | \u200b | $ | 3,220 | \u200b | $ | 15,971 |",
            "type": "table"
        },
        {
            "id": 106,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Year Ended December 31, |\n| \u200b | 2023 | 2022 |\n| \u200b | \u200b | \u200b |\n| Operating expenses | \u200b | \u200b |\n| \u200b | \u200b | \u200b |\n| Research and development | \u200b | $ | 11,608 | \u200b | $ | 9,165 |\n| General and administrative | \u200b | 4,235 | \u200b | 4,736 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Total operating expenses | \u200b | 15,843 | \u200b | 13,901 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Net operating loss | \u200b | $ | ( 15,843 ) | \u200b | $ | ( 13,901 ) |\n| \u200b | \u200b | \u200b |\n| Other income (loss) | \u200b | \u200b |\n| Change in fair value of warrant liability | \u200b | \u200b | ( 271 ) | \u200b | \u200b | \u2014 |\n| Interest income | \u200b | 36 | \u200b | 33 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Total other income (loss) | \u200b | ( 235 ) | \u200b | 33 |\n| \u200b | \u200b | \u200b |\n| Net loss | \u200b | $ | ( 16,078 ) | \u200b | $ | ( 13,868 ) |\n| \u200b | \u200b | \u200b |\n| Net loss per share, basic and diluted | \u200b | $ | ( 33.63 ) | \u200b | $ | ( 38.12 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Basic and diluted weighted average number of common shares outstanding | \u200b | 478 | \u200b | 364 |",
            "type": "table"
        },
        {
            "id": 107,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Year Ended December 31, |\n| \u200b | \u200b | 2023 | \u200b | 2022 |\n| Cash flow from operating activities | \u200b | \u200b |\n| \u200b | \u200b | \u200b |\n| Net loss | \u200b | $ | ( 16,078 ) | \u200b | $ | ( 13,868 ) |\n| \u200b | \u200b | \u200b |\n| Adjustments to reconcile net loss to net cash used in operating activities | \u200b | \u200b |\n| \u200b | \u200b | \u200b |\n| Stock-based compensation | \u200b | 734 | \u200b | 851 |\n| Amortization of right of use assets | \u200b | 96 | \u200b | 90 |\n| Depreciation | \u200b | 82 | \u200b | 88 |\n| Change in fair value of warrant liability | \u200b | \u200b | 271 | \u200b | \u200b | \u2014 |\n| (Increase) decrease in operating assets | \u200b | \u200b |\n| Prepaid drug product | \u200b | 2,955 | \u200b | ( 3,064 ) |\n| Other current assets | \u200b | 286 | \u200b | 199 |\n| Increase (decrease) in operating liabilities | \u200b | \u200b |\n| Accounts payable and accrued expenses | \u200b | 227 | \u200b | 700 |\n| Lease liabilities | \u200b | ( 108 ) | \u200b | ( 99 ) |\n| \u200b | \u200b | \u200b |\n| Net cash used in operating activities | \u200b | ( 11,535 ) | \u200b | ( 15,103 ) |\n| \u200b | \u200b | \u200b |\n| Cash flow from investing activities | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Purchases of furniture, fixtures & equipment | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 21 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Net cash used in investing activities | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 21 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Cash flow from financing activities | \u200b | \u200b |\n| \u200b | \u200b | \u200b |\n| Net proceeds from sale of common stock | \u200b | 1,677 | \u200b | 1,734 |\n| Net proceeds from exercise of warrants | \u200b | 526 | \u200b | \u2014 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Net cash provided by financing activities | \u200b | 2,203 | \u200b | 1,734 |\n| \u200b | \u200b | \u200b |\n| Net decrease in cash | \u200b | ( 9,332 ) | \u200b | ( 13,390 ) |\n| \u200b | \u200b | \u200b |\n| Cash, beginning of period | \u200b | 10,384 | \u200b | 23,774 |\n| \u200b | \u200b | \u200b |\n| Cash, end of period | \u200b | $ | 1,052 | \u200b | $ | 10,384 |\n| \u200b | \u200b | \u200b |\n| Supplemental disclosure of non-cash activities | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b |\n| Non-cash operating activities | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Right of use asset recognized in exchange for lease obligation | \u200b | $ | \u2014 | \u200b | $ | 85 |",
            "type": "table"
        },
        {
            "id": 108,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Additional | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Common Stock | \u200b | Paid in | \u200b | Accumulated | \u200b | \u200b |\n| Description | Shares | Amount | Capital | Deficit | Total |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Balance at December 31, 2021 | 358 | \u200b | $ | 1 | \u200b | $ | 103,117 | \u200b | $ | ( 77,661 ) | \u200b | $ | 25,457 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Issuance of common stock, net of fees | 40 | \u200b | \u2014 | \u200b | 1,734 | \u200b | \u2014 | \u200b | 1,734 |\n| Stock-based compensation | \u2014 | \u200b | \u2014 | \u200b | 851 | \u200b | \u2014 | \u200b | 851 |\n| Net loss | \u2014 | \u200b | \u2014 | \u200b | \u2014 | \u200b | ( 13,868 ) | \u200b | ( 13,868 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Balance at December 31, 2022 | 398 | \u200b | $ | 1 | \u200b | $ | 105,702 | \u200b | $ | ( 91,529 ) | \u200b | $ | 14,174 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Balance at December 31, 2022 | 398 | \u200b | $ | 1 | \u200b | $ | 105,702 | \u200b | $ | ( 91,529 ) | \u200b | $ | 14,174 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Issuance of common stock, net of fees | 175 | \u200b | \u2014 | \u200b | 491 | \u200b | \u2014 | \u200b | 491 |\n| Exercise of warrants, net of fees | 45 | \u200b | \u2014 | \u200b | 1,120 | \u200b | \u2014 | \u200b | 1,120 |\n| Stock-based compensation | \u2014 | \u200b | \u2014 | \u200b | 734 | \u200b | \u2014 | \u200b | 734 |\n| Net loss | \u2014 | \u200b | \u2014 | \u200b | \u2014 | \u200b | ( 16,078 ) | \u200b | ( 16,078 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Balance at December 31, 2023 | 618 | \u200b | $ | 1 | \u200b | $ | 108,047 | \u200b | $ | ( 107,607 ) | \u200b | $ | 441 |",
            "type": "table"
        },
        {
            "id": 109,
            "context": "approximately $ 10.4 million in cash on-hand, of which approximately $ 10.1 million was not covered by the FDIC. To date, the Company has not incurred any losses on its cash balances. Furniture, fixtures and equipment \u2014 Furniture, fixtures and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Depreciation expense was $ 0.1 million for each of the years ended December 31, 2023 and 2022, respectively.The estimated useful lives are as follows:Computers and equipment \u2013 3 yearsFurniture and fixtures \u2013 7 yearsScientific equipment \u2013 7 yearsLeasehold improvements \u2013 Lesser of useful life or lease termMajor additions and improvements are capitalized, while costs for minor replacements, maintenance and repairs that do not increase the useful life of an asset are expensed as incurred. Long-Lived Assets \u2014 The Company\u2019s long-lived assets consist of furniture, fixtures and equipment, leasehold improvements and right-of-use operating assets. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the asset is measured by a comparison of the asset\u2019s carrying amount to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Research and Development Costs \u2014 Costs and expenses that can be clearly identified as research and development are charged to expense. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. If the goods will not be delivered, or services will not be rendered, then the capitalized advance payment is charged to expense.The Company estimates its clinical trial expense each period based on a cost per patient calculation which is derived from estimated start-up costs, clinical trial costs based on the number of patients and length of treatment and clinical study report costs. These services are performed by the Company\u2019s third-party clinical research organizations, laboratories and clinical investigative sites. The expense is recorded in research and development expense each period. Amounts that have been prepaid in advance of work performed are recorded in other current assets. Stock-Based Compensation \u2014 The Company records stock-based compensation expense measured using the fair value method. The Company uses the Black-Scholes option valuation model to calculate stock-based compensation at the date of grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. The Company's policy is to estimate forfeitures at the grant date and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Changes in these assumptions can materially affect the fair value estimate. Warrants \u2014 The Company determines whether warrants should be classified as a liability or equity. For warrants classified asliabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fairvalue recorded in the Consolidated Statement of Operations as change in fair value of warrant liability. The estimates invaluation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life ofthe warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially inthe future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes infair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. Net Loss Per Share \u2014 Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Although there were warrants and stock options outstanding during 2023 and 2022, they were not included in the computation of any diluted per-share amount when a loss exists, as it would be anti-dilutive. Consequently, diluted net loss per share as presented in the financial statements is equal to basic net F-9",
            "type": "paragraph"
        },
        {
            "id": 110,
            "context": "| 4. | Other Current Assets |\n| 5. | Property and Equipment |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | December 31, |\n| \u200b | Estimated Useful | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Lives | 2023 | 2022 |\n| \u200b | \u200b | (in years) | \u200b | (in thousands) |\n| Leasehold improvements | 2 to 5 | \u200b | $ | 463 | \u200b | $ | 463 |\n| Computers and office equipment | 3 | \u200b | 83 | \u200b | 83 |\n| Furniture and fixtures | 7 | \u200b | 93 | \u200b | 93 |\n| Scientific equipment | 7 | \u200b | 481 | \u200b | 481 |\n| Total | \u200b | \u200b | \u200b | 1,120 | \u200b | 1,120 |\n| Less: Accumulated depreciation | \u200b | \u200b | \u200b | ( 1,044 ) | \u200b | ( 962 ) |\n| Net property and equipment | \u200b | \u200b | \u200b | $ | 76 | \u200b | $ | 158 |\n| 6. | Accounts Payable |\n| 7. | Accrued Expense |",
            "type": "table"
        },
        {
            "id": 111,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | Fair Value Measurements at | \u200b |\n| \u200b | \u200b | \u200b | December 31, 2023 | \u200b |\n| \u200b | \u200b | \u200b | (in thousands) | \u200b |\n| \u200b | \u200b | \u200b | Level 1 | \u200b | \u200b | Level 2 | \u200b | \u200b | Level 3 | \u200b | \u200b | Total | \u200b |\n| Liabilities: | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Warrant liability | \u200b | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 863 | \u200b | $ | 863 | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Fair Value of |\n| \u200b | \u200b | Warrant |\n| \u200b | \u200b | Liability |\n| \u200b | \u200b | (in thousands) |\n| Balance at December 31, 2022 | \u200b | $ | \u2014 | \u200b |\n| Issuance | \u200b | \u200b | 1,186 | \u200b |\n| Exercises | \u200b | \u200b | ( 594 ) | \u200b |\n| Change in fair value | \u200b | \u200b | 271 | \u200b |\n| Balance at December 31, 2023 | \u200b | $ | 863 | \u200b |",
            "type": "table"
        },
        {
            "id": 112,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | As of |\n| \u200b | \u200b | December 31, |\n| \u200b | 2023 |\n| Risk-free interest rate | \u200b | 3.84 | % |\n| Expected volatility | \u200b | 102 | % |\n| Expected term in years | \u200b | 4.6 |\n| Dividend yield | \u200b | \u2014 | % |\n| \u200b |\n| 10. | Stockholders\u2019 Equity |\n| 11. | Stock-Based Compensation Plan |",
            "type": "table"
        },
        {
            "id": 113,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | 2023 | 2022 |\n| Risk-free interest rate | 3.42 | % | \u200b | 2.43 | % |\n| Expected volatility | 129 | % | \u200b | 127 | % |\n| Expected term in years | 6.0 | \u200b | 6.0 | \u200b |\n| Dividend yield | \u2014 | % | \u200b | \u2014 | % |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | Weighted | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Weighted- | \u200b | Average | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Average | \u200b | Remaining | \u200b | Aggregate |\n| \u200b | \u200b | \u200b | \u200b | Exercise | \u200b | Contractual | \u200b | Intrinsic |\n| \u200b | \u200b | Options | \u200b | Price | \u200b | Term | \u200b | Value |\n| \u200b | \u200b | (in thousands) | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Outstanding at December 31, 2022 | 33 | \u200b | $ | 233.40 | \u200b | \u200b | 7.9 | \u200b | $ | \u2014 |\n| Granted | 11 | \u200b | $ | 27.80 | \u200b | \u200b | 9.3 | \u200b | \u200b |\n| Expired | \u200b | ( 1 ) | \u200b | $ | 1,840.00 | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Outstanding at December 31, 2023 | 43 | \u200b | $ | 161.20 | \u200b | \u200b | 7.6 | \u200b | $ | \u2014 |\n| Vested and expected to vest December 31, 2023 | \u200b | 43 | \u200b | $ | 162.80 | \u200b | \u200b | 7.6 | \u200b | $ | \u2014 |\n| Exercisable at December 31, 2023 | 25 | \u200b | $ | 236.20 | \u200b | \u200b | 6.9 | \u200b | $ | \u2014 |",
            "type": "table"
        },
        {
            "id": 114,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | Weighted | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Weighted- | \u200b | Average | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Average | \u200b | Remaining | \u200b | Aggregate |\n| \u200b | \u200b | \u200b | \u200b | Exercise | \u200b | Contractual | \u200b | Intrinsic |\n| \u200b | \u200b | Options | \u200b | Price | \u200b | Term | \u200b | Value |\n| \u200b | \u200b | (in thousands) | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Outstanding at December 31, 2021 | 24 | \u200b | $ | 291.60 | \u200b | \u200b | 8.4 | \u200b | $ | 7,800 |\n| Granted | 10 | \u200b | 74.20 | \u200b | \u200b | 9.3 | \u200b | \u200b |\n| Expired | ( 1 ) | \u200b | 119.20 | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Outstanding at December 31, 2022 | 33 | \u200b | $ | 233.40 | \u200b | \u200b | 7.9 | \u200b | $ | \u2014 |\n| Vested and expected to vest December 31, 2022 | \u200b | 32 | \u200b | $ | 238.00 | \u200b | \u200b | 7.9 | \u200b | $ | \u2014 |\n| Exercisable at December 31, 2022 | 16 | \u200b | $ | 372.40 | \u200b | \u200b | 7.3 | \u200b | $ | \u2014 |\n| 12. | Warrants |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Warrants Outstanding | \u200b | Warrants Exercisable |\n| \u200b | \u200b | \u200b | \u200b | Weighted | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Average | \u200b | Weighted | \u200b | \u200b | \u200b | Weighted |\n| \u200b | \u200b | \u200b | \u200b | Remaining | \u200b | Average | \u200b | \u200b | \u200b | Average |\n| \u200b | \u200b | Number | \u200b | Contractual | \u200b | Exercise | \u200b | Number | \u200b | Exercise |\n| Year Issued | Outstanding | Life | Price | Exercisable | Price |\n| \u200b | \u200b | \u200b | (in years) | (per share) | \u200b | \u200b | (per share) |\n| 2018 | 6 | 0.2 | \u200b | 384.00 | 6 | \u200b | 384.00 |\n| 2019 | 14 | 0.8 | \u200b | 275.20 | 14 | \u200b | 275.20 |\n| 2022 | 40 | 4.4 | \u200b | 15.20 | 40 | \u200b | 15.20 |\n| 2023 | 130 | 4.6 | \u200b | 12.00 | 130 | \u200b | 12.00 |\n| \u200b | 190 | 4.1 | \u200b | $ | 43.20 | 190 | \u200b | $ | 43.20 |\n| 13. | Commitments and Contingencies |\n| 14. | Leases |",
            "type": "table"
        },
        {
            "id": 115,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, |\n| \u200b | \u200b | 2023 | \u200b | 2022 |\n| \u200b | \u200b | (in thousands) |\n| Assets: | \u200b | \u200b | \u200b |\n| Operating lease assets | \u200b | $ | 102 | \u200b | $ | 198 |\n| \u200b | \u200b | \u200b |\n| Liabilities: | \u200b | \u200b |\n| Current portion of lease liabilities | \u200b | 103 | \u200b | 108 |\n| Noncurrent lease liabilities | \u200b | 10 | \u200b | 113 |\n| Total operating lease liabilities | \u200b | $ | 113 | \u200b | $ | 221 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, |\n| \u200b | \u200b | 2023 | \u200b | 2022 |\n| \u200b | \u200b | (in thousands) |\n| Operating lease costs | \u200b | $ | 113 | \u200b | $ | 115 |\n| Variable lease costs | \u200b | 10 | \u200b | 5 |\n| Total lease costs | \u200b | $ | 123 | \u200b | $ | 120 |",
            "type": "table"
        },
        {
            "id": 116,
            "context": "| \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | As of December 31, 2023 |\n| \u200b | \u200b | (in thousands) |\n| 2024 | $ | 108 |\n| 2025 | \u200b | 11 |\n| Future minimum lease payments | \u200b | 119 |\n| Less: Interest | \u200b | ( 6 ) |\n| Present value of operating lease liabilities | \u200b | $ | 113 |\n| 15. | Benefit Plan |\n| 16. | Income Taxes |",
            "type": "table"
        },
        {
            "id": 117,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, |\n| \u200b | 2023 | 2022 |\n| \u200b | \u200b | (in thousands) |\n| Deferred tax assets \u2013 non-current | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Accrued bonuses | \u200b | $ | 22 | \u200b | $ | 63 |\n| Accrued vacation | \u200b | 24 | \u200b | 28 |\n| Net operating loss (NOL) carryover | \u200b | 18,550 | \u200b | 15,818 |\n| Research & development tax credits | \u200b | 4,769 | \u200b | 2,509 |\n| Share based expense | \u200b | 750 | \u200b | 671 |\n| Other | \u200b | 3 | \u200b | 3 |\n| Right of use lease liability | \u200b | \u200b | 24 | \u200b | \u200b | 46 |\n| Fixed asset depreciation | \u200b | 50 | \u200b | 44 |\n| Total deferred tax asset | \u200b | 24,192 | \u200b | 19,182 |\n| Less: valuation allowance | \u200b | ( 24,171 ) | \u200b | ( 19,140 ) |\n| Net deferred tax asset | \u200b | 21 | \u200b | 42 |\n| Right of use asset | \u200b | ( 21 ) | \u200b | ( 42 ) |\n| Net deferred tax asset | \u200b | $ | \u2014 | \u200b | $ | \u2014 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | December 31, |\n| \u200b | 2023 | 2022 |\n| \u200b | \u200b | (in thousands) |\n| Loss before income taxes | \u200b | $ | ( 16,078 ) | \u200b | $ | ( 13,868 ) |\n| Tax (benefit) at statutory tax rate | \u200b | ( 3,376 ) | \u200b | ( 2,912 ) |\n| Effects of: | \u200b | \u200b | \u200b | \u200b |\n| Exclusion of incentive stock option expense | \u200b | 74 | \u200b | 80 |\n| R&D tax credits | \u200b | ( 2,261 ) | \u200b | 844 |\n| Increase in valuation allowance | \u200b | 5,031 | \u200b | 98 |\n| FMV of warrants | \u200b | \u200b | 57 | \u200b | \u200b | \u2014 |\n| Section 382 limit - NOL | \u200b | \u200b | \u2014 | \u200b | \u200b | 1,890 |\n| Other | \u200b | 475 | \u200b | \u2014 |\n| Provision for income taxes | \u200b | $ | \u2014 | \u200b | $ | \u2014 |",
            "type": "table"
        }
    ],
    "html_tables": [
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Developing prexigebersen for treatment of AML in combination therapies. </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Developing BP1002 for treatment of lymphoma and CLL. </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Developing BP1002 for refractory/relapsed AML patients, including venetoclax-resistant patients. </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Developing BP1003 for pancreatic cancer, NSCLC and AML. </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Developing BP1001-A for treatment of solid tumors. </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Expanding DNAbilize</span><sup style=\"font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;\">\u00ae</sup><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> to evaluate targets beyond cancer. </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Establishing DNAbilize</span><sup style=\"font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;\">\u00ae</sup><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> as the antisense drug delivery method of choice by forming partnerships with pharmaceutical and academic clinical research labs.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:28.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Peripheral or bone</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:28.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">marrow blast %</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Off-</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Reason</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Cycles</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Patients</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Diagnosis</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Baseline</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Nadir</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Tx</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Discontinued</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Completed</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">CML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 51</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">No</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 97</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">DLT</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">&lt;1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">6</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 15</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 2</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 5</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">5</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">7</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">MDS</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 8</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 4</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 6</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">5</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">10</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 23</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 10</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 10</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">11</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">CML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 7</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">No</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 50</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">14</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 48</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 5</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 21</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">15</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 54</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 31</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 72</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">20</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 76</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 5</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 63</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">21</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 71</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 43</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 74</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">2</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">22</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 1</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 1</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">2</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">23</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">MDS</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">NE</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">NE</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">NE</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">24</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">MDS</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">5</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">25</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 10</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 3</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 19</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">2</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">26</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 11</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">No</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 80</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">27</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 93</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">No</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 97</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">28</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 96</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 93</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 98</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">29</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 35</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 7</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 24</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">30</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 51</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 17</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 82</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">31</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 17</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">No</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 17</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">32</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 24</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 22</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 22</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">2</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">34</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 66</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">ND</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">ND</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">35</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 17</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 2</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 2</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">CRi</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">37</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 25</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 33</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">ND</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">PD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">1</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">38</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 23</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 2</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 3</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">CR</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">5</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">39</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 36</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 16</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 58</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">SD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">3</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">40</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 31</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 2</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 2</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">CR</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">3</p></td></tr><tr><td style=\"vertical-align:bottom;width:32.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">41</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">AML</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 18</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 9</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> 14</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">SD</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">3</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Patent No.</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Title</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Date Issued </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">US 9,744,187</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">August 29, 2017</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">US 10,335,428</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">July 2, 2019</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">US 10,898,506</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">January 26, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">SG 11201802718P</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">May 12, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">EA 038277</p><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">August 4, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">AU 2016340123</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">January 5, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">MX 403603</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">June 20, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">IN 472686</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">November 24, 2023</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Patent No.</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Title</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Date Issued </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">US 10,927,379</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">February 23, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">US 11,041,153</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">June 22, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">EP 3 512 525</p><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;\">(in force in DE, ES, FR, GB, and NL)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">July 27, 2022</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">JP 7132911</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">August 30, 2022</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">JP 7186721</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for IGF-1R inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 1, 2022</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">CN ZL 201880033244.6</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 16, 2022</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">EA 041953</p><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;\">(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 19, 2022</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">JP 7237009</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">March 2, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">EA 042663</p><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;\">(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">March 9, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">HK 400 11951</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">April 6, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">JP 7284709</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for BCL2 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">May 23, 2023</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">EA 044637</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for BCL2 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">September 19, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">MX 408790</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 7, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">MX 408785</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for BCL2 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 7, 2023</p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">significantly greater capital, technical and human resources than we have and may be better equipped to discover, develop, manufacture and commercialize drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">more experience in drug discovery, development and commercialization, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">drug candidates that have been approved or are in late-stage clinical development; and/or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">collaboration arrangements in our target markets with leading companies and research institutions.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">completion of preclinical laboratory tests, animal studies and formulation studies according to FDA\u2019s Good Laboratory Practice regulations;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">submission of an IND, which must become effective before human clinical trials may begin and which must include approval by an institutional review board at each clinical site before the trials are initiated;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">performance of adequate and well-controlled human clinical trials according to FDA\u2019s Good Clinical Practice (\u201cGCP\u201d) regulations to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">submission to, and acceptance by, the FDA of a new drug application (an \u201cNDA\u201d);</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice (\u201ccGMP\u201d) regulations to assure that the facilities, methods and controls are adequate to preserve the drug\u2019s identity, strength, quality and purity; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">FDA review and approval of the NDA.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Phase 1: </i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The drug candidate is initially introduced into human subjects or patients with the disease and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some drug candidates for severe or life-threatening diseases, the initial human testing is often conducted in patients.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Phase 2:</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> Involves studies in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the drug candidate for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Phase 3:</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, typically at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the drug candidate and provide, if appropriate, an adequate basis for product labeling.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">record-keeping requirements;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reporting of adverse experiences with the drug;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">providing the FDA with updated safety and efficacy information;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">drug sampling and distribution requirements;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">notifying the FDA and gaining its approval of specified manufacturing or labeling changes;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">complying with certain electronic records and signature requirements; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">complying with FDA promotion and advertising requirements.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\"></td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">us to potential criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Inadequate funding for the FDA, the SEC and other government agencies, or a work slowdown or stoppage at those agencies as part of a broader federal government shutdown, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Our business and operations have been affected by and could be materially and adversely affected in the future by the effects of health epidemics and pandemics, including the evolving and ongoing effects of the COVID-19 pandemic.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Unstable market and economic conditions may have serious adverse effects on our ability to raise funds, which may cause delays, restructuring or cessation of our operations. </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We must complete extensive clinical trials to demonstrate the safety and efficacy of our drug candidates. If we are unable to demonstrate the safety and efficacy of our drug candidates, we will not be successful.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Delays in the commencement of clinical trials of our drug candidates could result in increased costs to us and delay our ability to generate revenues.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Delays in the completion of, or the termination of, clinical trials of our drug candidates could result in increased costs to us and could delay or prevent us from generating revenues.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">If we are unable to obtain U.S. and/or foreign regulatory approval, we will be unable to commercialize our drug candidates.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">In addition to regulations in the U.S., we may be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products, if approved.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Changes in existing laws and regulations affecting the healthcare industry could increase our costs and otherwise adversely affect our business.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We rely on third parties to conduct clinical trials for our drug candidates, and their failure to timely and properly perform their obligations may result in costs and delays that prevent us from obtaining regulatory approval or successfully commercializing our drug candidates.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We may not be able to obtain or maintain orphan drug exclusivity for our product candidates.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We rely on third parties for manufacturing of our clinical drug supplies; our dependence on these manufacturers may impair the development of our drug candidates.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">There are underlying risks associated with the manufacture of our drug candidates, which have never been manufactured in large scale. Furthermore, we anticipate continued reliance on third-party manufacturers if we are successful in obtaining marketing approval from the FDA or other regulatory agencies for any of our drug candidates.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Identification of previously unknown problems with respect to a drug candidate, manufacturer or facility may result in restrictions on the drug candidate, manufacturer or facility.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We may experience delays in the development of our drug candidates if the third-party manufacturers of our drug candidates cannot meet FDA requirements relating to current Good Manufacturing Practices.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may not generate product revenue.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">If our future drugs do not achieve market acceptance, we may be unable to generate significant revenue, if any.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">If third-party payors do not adequately reimburse patients for any of our drug candidates that are approved for marketing, they might not be purchased or used, and our revenues and profits will not develop or increase.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">If our patent position does not adequately protect our drug candidates, others could compete against us more directly, which would harm our business.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">If any third-party owners of intellectual property we may license in the future do not properly maintain or enforce the patents underlying such licenses, our competitive position and business prospects will be harmed.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Litigation regarding patents, intellectual property and other proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing drug candidates to market and harm our ability to operate.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Raising additional capital may cause dilution to existing stockholders, restrict our operations or require us to relinquish rights. Additionally, sales of a substantial number of shares of our common stock or other securities in the public market could cause our stock price to fall.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We may issue additional shares of our common stock in accordance with our equity incentive plans or upon exercise or conversion of outstanding securities that are exercisable for or convertible into shares of our common stock, which may cause dilution to existing stockholders.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The trading price of our common stock has been volatile and is likely to be volatile in the future.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Our common stock is thinly traded and in the future may continue to be thinly traded, and our stockholders may be unable to sell at or near asking prices or at all if they need to sell their shares to raise money or otherwise desire to liquidate such shares.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Our certificate of incorporation grants our Board of Directors the power to designate and issue additional shares of common and/or preferred stock.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We do not anticipate paying cash dividends, and accordingly stockholders must rely on stock appreciation for any return on their investment in us.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Our management is required to devote substantial time and incur additional expense to comply with public company regulations.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on the price of our common stock.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:36pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Our common stock may be delisted from The Nasdaq Capital Market which could negatively impact the price of our common stock and our ability to access the capital markets.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the rate of progress, results and costs of completion of ongoing clinical trials of our drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the rate of progress, results and costs of completion of ongoing preclinical testing of our drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the size, scope, rate of progress, results and costs of completion of any potential future clinical trials and preclinical tests of our drug candidates that we may initiate;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the costs to obtain adequate supply of the compounds necessary for our drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the costs of obtaining regulatory approval of our drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the scope, prioritization and number of drug development programs we pursue;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the costs for preparing, filing, prosecuting, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the extent to which we acquire or in-license other products and technologies and the costs to develop those products and technologies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the costs of future commercializing activities, including product sales, marketing, manufacturing and distribution, of any of our drug candidates or other products for which marketing approval has been obtained;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our ability to establish strategic collaborations and licensing or other arrangements on terms favorable to us; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">competing technological and market developments.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delay, reduce the scope of or eliminate one or more of our drug development programs;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">relinquish, license or otherwise dispose of rights to technologies, drug candidates or products that we would otherwise seek to develop or commercialize ourselves at an earlier stage or on terms that are less favorable than might otherwise be available; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">liquidate and dissolve the Company.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">significantly greater capital, technical and human resources than we have and may be better equipped to discover, develop, manufacture and commercialize drug candidates;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">more experience in drug discovery, development and commercialization, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">drug candidates that have been approved or are in late-stage clinical development; and/or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">collaboration arrangements in our target markets with leading companies and research institutions.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">inability to integrate the resources or capabilities of collaborators;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">collaborators may prove difficult to work with or less skilled than we originally expected;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">disputes may arise with respect to the ownership of rights to technology developed with collaborators;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">disagreements with collaborators could delay or terminate the research, development or commercialization of products or result in litigation or arbitration;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">difficulty enforcing our arrangements if one of our collaborators fails to perform;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">termination of our collaboration arrangements by collaborators, which could make it difficult for us to attract new collaborators or adversely affect the perception of us in the business or financial communities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">collaborators may have considerable discretion in electing whether to pursue the development of any additional drug candidates and may pursue technologies or products either on their own or in collaboration with our competitors that are similar to or competitive with our technologies; and</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">limitations on our stockholders\u2019 ability to call special meetings of stockholders;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">an advance notice requirement for stockholder proposals and nominations for members of our Board;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the authority of our Board to determine the number of director seats on our Board;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the authority of our Board to fill vacancies occurring on the Board;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the authority of our Board to issue preferred stock with such terms as our Board may determine.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which may be pursued through civil whistleblower or qui tam actions, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or other third-party payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">federal criminal statutes under the Health Insurance Portability and Accountability Act of 1996, which prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the federal transparency requirements under The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (known collectively as the \u201cAffordable Care Act\u201d), including the provision commonly referred to as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies for which payment is available under Medicare, Medicaid or the Children\u2019s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">State law equivalents of each of the healthcare laws described above, some of which may be broader in scope and apply regardless of the type of payor, such as state anti-kickback statutes and false claims acts, and state pricing, marketing, and transparency statutes that require us to adopt compliance programs, report pricing information, or disclose payments or other transfers of value to physicians or other covered recipients.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">demonstrating sufficient safety and efficacy in past clinical trials to obtain regulatory approval to commence a further clinical trial;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">convincing the FDA that we have selected valid endpoints for use in proposed clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reaching agreements on acceptable terms with prospective contract manufacturers for manufacturing sufficient quantities of our drug candidates; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">obtaining institutional review board approval to conduct a clinical trial at a prospective site.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulators or institutional review boards may not authorize us to commence or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our preclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical testing or clinical trials or we may abandon projects that we expect may not be promising;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">we might have to suspend or terminate our clinical trials if the participating patients are being exposed to unacceptable health risks;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the cost of our clinical trials may be greater than we currently anticipate and we may lack adequate funding to continue the clinical trial;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the timing of our clinical trials may be longer than we currently anticipate;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner (including delays or inability to manufacture or obtain sufficient quantities of materials for use in clinical trials);</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">inadequacy of or changes in our manufacturing process or compound formulation;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">slower than expected rates of patient recruitment and enrollment or lower than expected patient retention rates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the effects of our drug candidates may not be the desired effects or may include undesirable side effects or our drug candidates may have other unexpected characteristics;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">changes in applicable regulatory policies and regulations;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays in identifying and reaching agreement on acceptable terms with prospective clinical trial sites;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">uncertainty regarding proper dosing;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">failure of our clinical research organizations to comply with all regulatory and contractual requirements or otherwise fail to perform their services in a timely or acceptable manner;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">scheduling conflicts with participating clinicians and clinical institutions;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">failure to construct appropriate clinical trial protocols;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">insufficient data to support regulatory approval;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">inability or unwillingness of medical investigators to follow our clinical protocols; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the timing of discussions and meetings with the FDA or other regulatory authorities regarding the scope or design of our clinical trials.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the drug candidate may not prove to be sufficiently efficacious;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the drug candidate may not prove to be safe;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the drug candidate may not be readily co-administered or combined with other drugs or drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the results may not confirm the positive results from earlier preclinical studies or clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the results may not meet the level of statistical significance required by the FDA or other regulatory agencies; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or other regulatory agencies may require us to carry out additional studies.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">new laws, regulations, or judicial decisions related to healthcare availability or the payment for healthcare products and services, including prescription drugs, that would make it more difficult for us to market and sell products once they are approved by the FDA or foreign regulatory agencies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">changes in FDA and foreign regulations that may require additional safety monitoring prior to or after the introduction of new products to market, which could materially increase our costs of doing business; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">changes in FDA and foreign current cGMP that would make it more difficult for us to manufacture our drug candidates in accordance with cGMP.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reliance on third-party manufacturers for regulatory compliance and quality assurance;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the possibility of breach of the manufacturing agreement by the third-party manufacturer because of factors beyond our control;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the possibility of termination or nonrenewal of our manufacturing agreement by the third-party manufacturer at a time that is costly or inconvenient for us;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the potential that third-party manufacturers will develop know-how owned by such third-party manufacturer in connection with the production of our drug candidates that is necessary for the manufacture of our drug candidates; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reliance on third-party manufacturers to assist us in preventing inadvertent disclosure or theft of our proprietary knowledge.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the timing of market introduction of competitive drugs;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the demonstrated clinical safety and efficacy of our drug candidates compared to other drugs and other drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the suitability of our drug candidates to be co-administered or combined with other drugs or drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the durability of our drug candidates in their ability to prevent the emergence of drug-resistant viral mutants;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the convenience and ease of administration of our drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the existence, prevalence and severity of adverse side effects;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">other potential advantages of alternative treatment methods;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the effectiveness of marketing and distribution support;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the cost-effectiveness of our drug candidates; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the availability of reimbursement from managed care plans, the government and other third-party payors.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">unforeseen complications arise with respect to the use of our products; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">sufficient third-party insurance coverage or reimbursement does not remain available.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a covered benefit under its health plan;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">safe, effective and medically necessary;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">appropriate for the specific patient;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">cost effective; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">neither experimental nor investigational.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Patent No.</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Title</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Date Issued </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">US 9,744,187</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">August 29, 2017</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">US 10,335,428</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">July 2, 2019</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">US 10,898,506</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">January 26, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">SG 11201802718P</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">May 12, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">EA 038277</p><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">August 4, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">AU 2016340123</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">January 5, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">MX 403603</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">June 20, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:20.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">IN 472686</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">P-ethoxy nucleic acids for liposomal formulation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">November 24, 2023</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Patent No.</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Title</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Date Issued </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">US 10,927,379</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">February 23, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">US 11,041,153</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">June 22, 2021</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">EP 3 512 525</p><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;\">(in force in DE, ES, FR, GB, and NL)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">July 27, 2022</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">JP 7132911</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">August 30, 2022</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">JP 7186721</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for IGF-1R inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 1, 2022</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">CN ZL 201880033244.6</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 16, 2022</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">EA 041953</p><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;\">(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 19, 2022</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">JP 7237009</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">March 2, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">EA 042663</p><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;\">(in force in AM, AZ, BY, KG, KZ, RU, TJ, TM)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">March 9, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">HK 400 11951</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Combination therapy with liposomal antisense oligonucleotides</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">April 6, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">JP 7284709</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for BCL2 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">May 23, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">EA 044637</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for BCL2 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">September 19, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">MX 408790</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for STAT3 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 7, 2023</p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">MX 408785</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:54.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">P-ethoxy nucleic acids for BCL2 inhibition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">December 7, 2023</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the patentability of our inventions relating to our drug candidates; and/or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the enforceability, validity or scope of protection offered by our patents relating to our drug candidates.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">incur substantial monetary damages;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">encounter significant delays in bringing our drug candidates to market; and/or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">be precluded from participating in the manufacture, use or sale of our drug candidates or methods of treatment requiring licenses.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the denial or delay of regulatory approvals of our drug candidates or receipt of regulatory approval of competing products;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our ability to accomplish clinical, regulatory and other drug development milestones;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the ability of our drug candidates, if they receive regulatory approval, to achieve market success;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the performance of third-party manufacturers and suppliers;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">developments with respect to patents and other intellectual property rights;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">sales of common stock or other securities by us or our stockholders in the future;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">additions or departures of key scientific or management personnel;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">trading volume of our common stock;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">investor perceptions about us and our industry;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">public reaction to our press releases, other public announcements and SEC and other filings;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the failure of analysts to cover us, or changes in analysts\u2019 estimates or recommendations;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the failure by us to meet analysts\u2019 projections or guidance;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the other factors described elsewhere in this \u201cItem 1A. Risk Factors\u201d or the section titled \u201cRisk Factors\u201d contained in our other public filings.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">expenses related to research and development personnel, including salaries and benefits, travel and stock-based compensation;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, clinical investigative sites, laboratories, manufacturing organizations and consultants; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">costs of materials used during research and development activities.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the rate of progress, results and costs of completion of ongoing clinical trials of our drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the size, scope, rate of progress, results and costs of completion of any potential future clinical trials and preclinical tests of our drug candidates that we may initiate;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">competing technological and market developments;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the performance of third-party manufacturers and suppliers;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the ability of our drug candidates, if they receive regulatory approval, to achieve market success;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our drug candidates; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the impact, risks and uncertainties related to global pandemics and actions taken by governmental authorities or others in connection therewith.</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Year ended </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Research and development expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 11,425</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 8,969</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Non-cash stock-based compensation expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 183</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 196</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total research and development expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 11,608</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 9,165</span></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Year ended </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">General and administrative expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,684</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 4,081</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Non-cash stock-based compensation expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 551</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 655</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Total general and administrative expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 4,235</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 4,736</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:40.02%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:48.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:40.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Name</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Age</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:48.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Position - Committee</b></p></td></tr><tr><td style=\"vertical-align:top;width:40.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Peter H. Nielsen</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 75</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:48.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Chief Executive Officer; President; Chief Financial Officer; Treasurer; Chairman of the Board; Director \u2013 Business Development Committee</p></td></tr><tr><td style=\"vertical-align:top;width:40.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:48.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:top;width:40.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Heath W. Cleaver, CPA</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 50</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:48.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Director \u2013 Audit Committee (Chair); Compensation Committee; Nominating/Corporate Governance Committee (Chair)</p></td></tr><tr><td style=\"vertical-align:top;width:40.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:48.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:40.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Paul D. Aubert</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:top;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 54</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;width:48.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Director \u2013 Audit Committee; Compensation Committee (Chair); Nominating/Corporate Governance Committee</p></td></tr><tr><td style=\"vertical-align:top;width:40.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:48.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:40.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Aline B. Sherwood</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 54</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:48.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Director \u2013 Audit Committee; Compensation Committee; Nominating/Corporate Governance Committee; Business Development Committee (Chair)</p></td></tr><tr><td style=\"vertical-align:top;width:40.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:48.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:40.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Douglas P. Morris</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:top;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 68</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;width:48.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Director \u2013 Business Development Committee; Director of Investor Relations; Secretary</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">financial statements, including management\u2019s discussion and analysis thereof;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">financial information in any annual information form, proxy statement, prospectus or other offering document, material change report, or business acquisition report;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">press releases regarding annual and interim financial results or containing earnings guidance;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">internal controls;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">audits and reviews our financial statements; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">filings with securities regulators containing financial information, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">evaluating, identifying and recommending nominees to the Board;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">considering written recommendations from our stockholders for nominees to the Board;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">recommending directors to serve as committee members and chairs;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reviewing and developing corporate governance guidelines, policies and procedures for the Board;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reviewing disclosure by the Company of matters within the Nominating/Corporate Governance Committee\u2019s mandate; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reviewing and evaluating the Nominating/Corporate Governance Committee\u2019s charter and efficacy.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Reviewed Annually</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">. The Compensation Committee annually reviews compensation levels to ensure we remain competitive and continue to attract, retain and motivate top-tier talent.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Alignment with Stockholder Interests</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">. Our compensation is intended to closely align the interests of our NEOs with those of our stockholders in an effort to create long-term stockholder value. In developing our compensation philosophy, the Compensation Committee has considered the most recent stockholder advisory vote on executive compensation in which an overwhelmingly positive percentage of the votes cast were in favor of our executive compensation. The Compensation Committee is continuously mindful of stockholders\u2019 views on executive compensation and remains focused on ensuring proper alignment with stockholder interests.</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:32.46%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:22.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:39.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:32.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Element</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Form of Compensation</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;width:39.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Purpose, Basis and Performance Criteria</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:top;width:32.46%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">Base Salary</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:22.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Cash</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:39.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;\">Base salary is intended to provide a market competitive level of fixed compensation in recognition of responsibilities, skills, capabilities, experience and leadership.</span></div></div></div><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;\">Base salary is not generally performance based, but reflective of competencies and experience.</span></div></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:32.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:39.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:32.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">Annual Performance Incentive Awards (considered \u201cat-risk\u201d compensation)</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:22.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Cash</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:39.22%;background:#cceeff;margin:0pt;padding:0pt;\"><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;\">Annual cash performance incentive awards are intended to motivate and reward performance achievement.</span></div></div></div><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;\">Payments are discretionary and approved annually by the Compensation Committee.</span></div></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:32.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:39.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:32.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">Long-Term Incentive Awards (considered \u201cat-risk\u201d compensation)</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:22.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Stock Options</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:39.22%;background:#cceeff;margin:0pt;padding:0pt;\"><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;\">Long-term incentive awards are intended to recognize and reward the achievement of long-term corporate goals and objectives, recognize promotions, motivate retention of our leadership talent and align executives\u2019 interests with our stockholders. </span></div></div></div><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;\">The Compensation Committee determines the amount of long-term incentive awards to be granted to each NEO. The Compensation Committee also may make isolated awards to recognize promotions, new hires or individual performance achievements.</span></div></div></div><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;\">In 2023, the long-term incentive awards included time-vested equity awards that vest over a four-year period.</span></div></div></div><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;\">The Compensation Committee provides time-vested long-term incentives (i) to build a consistent ownership stake and retention incentive, (ii) to create a meaningful tie to the Company\u2019s relative long-term stockholder returns and (iii) to motivate consistent improvement over a longer-term horizon.</span></div></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:32.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:39.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:32.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">Change of Control Severance</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:22.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Eligible to receive severance payments and post-termination health benefits in connection with involuntary termination within three months before or twelve months after a change of control</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:39.22%;background:#cceeff;margin:0pt;padding:0pt;\"><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;\">Employment agreements are intended to provide financial security and an industry-competitive compensation package for NEOs. This additional security helps ensure that NEOs remain focused on our performance and the continued creation of stockholder value throughout any change of control transaction rather than on the potential uncertainties associated with their own employment.</span></div></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the industry of the companies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the annual revenue, market capitalization and total assets of the companies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the number of full-time employees of the companies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the market data sources that are available with respect to the companies; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the number of peers included in the Industry Peer Group.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Actinium Pharmaceuticals, Inc. (ATNM)</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Cellectar Biosciences, Inc. (CLRB)</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Cyclacel Pharmaceuticals Inc. (CYCC)</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Dare Bioscience, Inc. (DARE)</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Diffusion Pharmaceuticals, Inc. (DFFN)</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Neurobo Therapeutics Inc. (NRBO)</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Ocuphire Pharma, Inc. (OCUP)</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">PDS Biotechnology Corp. (PDSB)</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Soligenix, Inc. (SNGX)</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Sonnet Biotherapeutics Holdings, Inc. (SONN)</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:54pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Xenetic Biosciences Inc. (XBIO)</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:42.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:42.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Option</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">All Other</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:42.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Awards</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Compensation</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:42.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Name and Principal Position</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Year</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Salary ($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Bonus ($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)(1)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total ($)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:42.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Peter H. Nielsen, CEO,</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 575,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(2)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 110,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(3)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 130,880</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 11,237</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(4)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 827,117</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:42.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">CFO, President, Chairman, Director</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 555,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 150,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 288,669</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 17,678</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(5)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,011,347</span></p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The amounts reported in this column reflect the aggregate grant date fair value of equity awards granted during the year computed in accordance with FASB ASC Topic 718. See Note 11 to our consolidated financial statements included in this Annual Report on Form 10-K for assumptions made by us in such valuation.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(2)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Mr. Nielsen voluntarily reduced his base salary for 2023 to $400,000.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(3)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Mr. Nielsen voluntarily elected to forego the entire $110,000 bonus.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(4)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The amounts reported include Medicare premiums of $7,855, insurance copayments of $1,990 and certain other benefits including life insurance premiums paid by the Company for Mr. Nielsen.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(5)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The amounts reported include Medicare premiums of $12,822, insurance copayments of $3,471 and certain other benefits including life insurance premiums paid by the Company for Mr. Nielsen.</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.58%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;white-space:nowrap;width:29.31%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"6\" style=\"vertical-align:bottom;white-space:nowrap;width:28.56%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Estimated Future Payouts Under Non-Equity</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"6\" style=\"vertical-align:bottom;white-space:nowrap;width:28.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Incentive Plan Awards</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:29.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">All Other</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">All Other</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Stock</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Option</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Exercise or</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Grant Date</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Awards:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Awards:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\"> Base</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\"> Fair Value</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\"> Price of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">of</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Shares of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Securities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\"> Option</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Stock</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Grant</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Threshold</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Target</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Maximum</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Stock or</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Underlying</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\"> Awards</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Awards</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:29.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Name</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Date</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Units (#)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Options (#)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($/Sh)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)(2)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:29.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Mr. Nielsen (1)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">5/2/2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,250</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 27.80</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 25.00</span></p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Reflects time-vested stock options awarded under the 2022 Stock Incentive Plan. The options vest over a four-year period from the date of grant, with one-fourth (1/4) of the options vesting on the first anniversary of such grant, and the remaining options vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the options over the next three years.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(2)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The amounts in this column reflect the aggregate grant date fair value of equity awards granted during the year computed in accordance with FASB ASC Topic 718. See Note 11 to our consolidated financial statements included in this Annual Report on Form 10-K for assumptions made by us in such valuation.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Equity Incentive</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';\">\u00a0</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of Securities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of Securities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Plan Awards:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Underlying Unexercised</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Underlying Unexercised</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of Securities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Option</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Option</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Options Exercisable</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Options Unexercisable</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Underlying Unexercised</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Exercise</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Expiration</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Name</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">(#)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">(#)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Unearned Options (#)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Price ($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Date</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Mr. Nielsen (1)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 138</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 11,000.00</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">April 2026</p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Mr. Nielsen (1)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 325</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 736.00</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">April 2028</p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Mr. Nielsen (1)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 750</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 368.00</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 2029</p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Mr. Nielsen (2)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 703</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 47</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 65.00</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 2030</p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Mr. Nielsen (3)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,719</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 531</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 104.20</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">June 2030</p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Mr. Nielsen (4)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,438</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,562</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 140.40</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 2031</p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Mr. Nielsen (5)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,969</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,531</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 72.20</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 2032</p></td></tr><tr><td style=\"vertical-align:bottom;width:28.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Mr. Nielsen (6)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,250</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 27.80</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">May 2033</p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">All of these options granted are fully vested.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(2)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">This option vests over a four-year period from the date of grant, March 28, 2020, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(3)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">This option vests over a four-year period from the date of grant, June 16, 2020, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(4)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">This option vests over a four-year period from the date of grant, March 31, 2021, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(5)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">This option vests over a four-year period from the date of grant, March 23, 2022, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(6)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">This option vests over a four-year period from the date of grant, May 2, 2023, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:26.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:45.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Triggering Event</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:20.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:22.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Termination without Cause or</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:20.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:22.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Resignation for Good Reason within</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:20.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Termination without Cause or</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:22.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">3 Months Before or 12 Months</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Name</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Benefit</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:20.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Resignation for Good Reason ($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:22.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Following a Change in Control ($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Peter H. Nielsen</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Market Value of Stock Vesting</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(1)</p></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Accrued Vacation Days</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 36,923</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 36,923</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Three Months\u2019 Base Salary</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 100,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 100,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Continuation of Benefits</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,667</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,334</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:26.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:23.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Total</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:19.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 138,590</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 140,257</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Mr. Nielsen\u2019s stock option awards would immediately become vested, and the value of the acceleration would be equal to the vesting shares multiplied by the excess of the then current stock price over the exercise price of the options. For purposes of this table, we have calculated the value of the acceleration using the closing price of our common stock on December 29, 2023, or $9.20 per share.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:49.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:49.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Fees</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:49.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Earned</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:49.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">or Paid</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Option</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">All Other</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:49.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Name</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">in Cash</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Awards</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Compensation</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:49.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Heath W. Cleaver</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 73,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(1)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 12,306</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(2)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 85,306</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:49.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Paul D. Aubert</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 61,500</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(1)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 12,306</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(2)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 73,806</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:49.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Aline B. Sherwood</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 64,500</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(1)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 12,306</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(2)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 76,806</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:49.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Douglas P. Morris (3)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 16,235</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(4)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 73,744</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">(5)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 89,979</span></p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">These amounts reflect cash fees paid to or earned by our non-employee directors for attending Board or committee meetings during the year ended December 31, 2023.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(2)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">In May 2023, our non-employee directors who were eligible at such time earned or received an annual grant of an option to purchase 500 shares of our common stock, which was the only grant received by such directors during 2023. The amounts in this column reflect the aggregate grant date fair value of equity awards granted during the year computed in accordance with FASB ASC Topic 718. See Note 11 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for assumptions made by us in such valuation.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(3)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Mr. Morris was hired by the Company in 2016 as the Company\u2019s Director of Investor Relations. Accordingly, Mr. Morris is not considered a non-employee director and does not receive compensation for his services as a member of the Board.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(4)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Option awards granted to Mr. Morris reflect compensation received by Mr. Morris in his capacity as the Company\u2019s Director of Investor Relations.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(5)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">This amount reflects compensation received by Mr. Morris in his capacity as the Company\u2019s Director of Investor Relations, which includes base salary and certain other benefits.</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:82.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:82.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:82.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">shares underlying</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:82.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Director</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">outstanding options</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:82.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Heath W. Cleaver</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,125</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:82.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Paul D. Aubert</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,100</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:82.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Aline B. Sherwood</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,000</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:82.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Douglas P. Morris (1)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,619</span></p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Mr. Morris was hired by the Company in 2016 as the Company\u2019s Director of Investor Relations. Accordingly, Mr. Morris is not considered a non-employee director.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Amount and</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Nature of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Beneficial</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Percent of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Name of Beneficial Owner</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Ownership</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Class</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Peter H. Nielsen (1) (2)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 14,838</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2.35</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Douglas P. Morris (1) (3)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,123</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">*</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Heath W. Cleaver (1) (4)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,119</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">*</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Aline B. Sherwood (1) (5)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">*</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Paul D. Aubert (1) (6)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,100</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">*</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">All officers and directors as a group (7)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 22,180</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3.48</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(5)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">All 1,000 shares are issuable upon the exercise of options that are exercisable within 60 days.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(6)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">All 2,100 shares are issuable upon the exercise of options that are exercisable within 60 days.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(7)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Includes 1,702 shares owned of record and 20,478 shares issuable upon the exercise of options currently exercisable or will be exercisable within 60 days.</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">shares of</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">shares of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">common stock</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">common stock to</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">remaining</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">be issued</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Weighted-average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">available for</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">upon exercise of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">exercise price</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">future issuance</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">outstanding</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">of outstanding</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">under equity</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">options, warrants</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">options, warrants</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">compensation</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Plan Category</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">and rights (1)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">and rights</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">plans (2)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Equity compensation plans approved by stockholders</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 44</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 8.06</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 55</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Equity compensation plans not approved by stockholders</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The shares shown in this column are securities to be issued upon exercise of outstanding options, warrants and rights were subject to outstanding stock option awards as of December 31, 2023 that were granted under each of the 2017 Stock Incentive Plan and the 2022 Stock Incentive Plan and total 32 and 12, respectively.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(2)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The shares shown in this column as remaining available for future issuance as of December 31, 2023 are under each of the 2017 Stock Incentive Plan and the 2022 Stock Incentive Plan and total 1 and 54, respectively.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Audit fees (1)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 445</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 336</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Audit-related fees (2)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Tax fees (3)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">All other fees (4)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Total</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 445</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 336</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:87.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Exhibit</b><b style=\"font-weight:bold;\"><br/></b><b style=\"font-weight:bold;\">Number</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;width:87.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Exhibit</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000101619307000027/ex2-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">2.1</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000101619307000027/ex2-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Agreement and Plan of Merger and Reorganization dated September 27, 2007, by and among the Company, Biopath Acquisition Corp., a Utah corporation and wholly owned subsidiary of the registrant, and Bio-Path, Inc., a Utah corporation (incorporated by reference to Exhibit 2.1 to the Company\u2019s Current Report on Form 8-K filed on September 27, 2007).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420415000776/v398162_ex3-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">3.1</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420415000776/v398162_ex3-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company\u2019s Current Report on Form 8-K filed on January 6, 2015).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418006765/tv485337_ex3-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">3.2</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418006765/tv485337_ex3-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on February 9, 2018).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417031532/v468617_ex3-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">3.3</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex3-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on January 16, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837024001573/bpth-20240221xex3d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">3.4</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837024001573/bpth-20240221xex3d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on February 23, 2024).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td rowspan=\"2\" style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex3-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">3.5</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td rowspan=\"2\" style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417031532/v468617_ex3-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">First Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on June 7, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"display:none;vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"display:none;vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837023019691/bpth-20231207xex3d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">3.6</span></a></p><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837023019691/bpth-20231207xex3d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amendment No. 1 to the First Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company\u2019s Current Report on Form 8-K filed on December 8, 2023).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420415016335/v404039_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.1</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420415016335/v404039_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company\u2019s Annual Report on Form 10-K filed on March 16, 2015).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.2</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to Maxim Group LLC, Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K on January 21, 2014).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420416110666/v443292_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.3</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420416110666/v443292_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on June 29, 2016).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420416117698/v445454_ex4-5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.4</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420416117698/v445454_ex4-5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.5 to the Company\u2019s Quarterly Report on Form 10-Q filed on August 9, 2016).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417028733/v467559_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.5</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417028733/v467559_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of New Warrant (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on May 22, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.6</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417033064/v469208_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant Amendment (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on June 19, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.7</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on November 6, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418018611/tv488319_ex4-9.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.8</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418018611/tv488319_ex4-9.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to Roth Capital Partners, LLC (incorporated by reference to Exhibit 4.9 to the Company\u2019s Annual Report on Form 10-K filed on April 2, 2018).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418050410/tv503304_ex4-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.9</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418050410/tv503304_ex4-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Series A Warrant issued to certain investors (incorporated by reference to Exhibit 4.2 to the Company\u2019s Current Report on Form 8-K filed on September 21, 2018).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418059966/tv506222_ex4-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.10</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418059966/tv506222_ex4-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.3 to the Company\u2019s Quarterly Report on Form 10-Q filed on November 14, 2018).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.11</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Underwriter Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on January 16, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419002290/tv511350_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.12</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419002290/tv511350_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Series A Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on January 22, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419014855/tv515879_ex4-15.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.13</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419014855/tv515879_ex4-15.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.15 to the Company\u2019s Annual Report on Form 10-K filed on March 19, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419013721/tv516100_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.14</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419013721/tv516100_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on March 13, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.1</span></a><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">5</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on November 22, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.1</span></a><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">6</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.2 to the Company\u2019s Current Report on Form 8-K filed on November 22, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465920029711/tm205374d1_ex4-17.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.17</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465920029711/tm205374d1_ex4-17.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Description of Bio-Path Holdings, Inc.\u2019s Securities Registered under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.17 to the Company's Annual Report on Form 10-K filed on March 5, 2020).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922116216/tm2230081d1_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.18</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922116216/tm2230081d1_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Common Warrant (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on November 9, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.19</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Common Warrant (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td rowspan=\"2\" style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex4-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">4.20</span></a></p></td><td rowspan=\"2\" style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td rowspan=\"2\" style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex4-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Warrant Agency Agreement, dated as of August 7, 2023, by and between the Company and Equiniti Trust Company, LLC (incorporated by reference to Exhibit 4.2 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"display:none;vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"display:none;vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"display:none;vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000093173108000021/ex10-1nielsen.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.1+</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000093173108000021/ex10-1nielsen.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Employment Agreement \u2013 Peter H. Nielsen (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on February 19, 2008).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000101619308000054/ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.2+</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000101619308000054/ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amended 2007 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-8 filed on December 10, 2008).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420413045992/v352628_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.3+</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420413045992/v352628_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">First Amendment to First Amended 2007 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Quarterly Report on Form 10-Q filed on August 14, 2013).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.4</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement by and between the Company, Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on January 21, 2014).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.5</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Waiver, Consent and Amendment to that certain Securities Purchase Agreement by and between Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K on January 21, 2014).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414017895/v372789_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.6+</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414017895/v372789_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">First Amendment to Employment Agreement, dated March 26, 2014 \u2013 Peter H. Nielsen (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on March 26, 2014).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414023522/v375097_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.7</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420414023522/v375097_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Lease Agreement dated April 16, 2014 by and between the Company and Pin Oak North Parcel TT, LLC (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on April 18, 2014).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420415023271/v407464_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.8</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420415023271/v407464_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on April 16, 2015).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420415039030/v413299_ex1-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.9</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420415039030/v413299_ex1-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Controlled Equity OfferingSM Sales Agreement, dated June 24, 2015, by and between the Company and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.1 to the Company\u2019s Current Report on Form 8-K filed on June 25, 2015).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420416110666/v443292_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.10</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420416110666/v443292_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on June 29, 2016).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417028733/v467559_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.11</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417028733/v467559_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant Exercise Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on May 22, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.12</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on November 6, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.13</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Leak-Out Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K filed on November 6, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.14+</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.15</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Incentive Stock Option Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.16</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Non-Qualified Stock Option Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-4.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.17</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-4.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Restricted Share Unit Award Agreement (Time-Vested) under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.18</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Restricted Share Unit Award Agreement (Performance-Based) under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-6.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.19</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-6.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Restricted Share Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-7.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.20</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-7.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Stock Appreciation Right Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Company\u2019s Current Report on Form 8-K filed on December 27, 2017).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418050410/tv503304_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.21</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420418050410/tv503304_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on September 21, 2018).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419002290/tv511350_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.22</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419002290/tv511350_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on January 22, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419013721/tv516100_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.23</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419013721/tv516100_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on March 13, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419029728/tv522895_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.24</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000114420419029728/tv522895_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">First Amendment to Lease Agreement dated April 16, 2014 by and between the Company and Pin Oak North Parcel TT, LLC (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on June 4, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.25</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on November 22, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919075627/tm1926828d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.26</span></a>+</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"http://www.sec.gov/Archives/edgar/data/1133818/000110465919075627/tm1926828d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on December 23, 2019).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837022008980/bpth-20220331xex10d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.27</span></a>+</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837022008980/bpth-20220331xex10d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Second Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Quarterly Report on Form 10-Q filed on May 16, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922116216/tm2230081d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.28</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922116216/tm2230081d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on November 9, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.29+</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Bio-Path Holdings, Inc. 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.30</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Incentive Stock Option Award Agreement under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.31</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Non-Qualified Stock Option Award Agreement under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-4.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.32</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-4.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Restricted Share Unit Award Agreement (Time-Vested) under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.33</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Restricted Share Unit Award Agreement (Performance-Based) under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-6.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.34</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-6.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Restricted Share Award Agreement under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-7.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.35</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-7.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Stock Appreciation Right Award Agreement under 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Company\u2019s Current Report on Form 8-K filed on December 20, 2022).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.36</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Placement Agency Agreement, dated as of August 3, 2023, by and between the Company and Roth Capital Partners, LLC (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.37</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement, dated as of August 3, 2023, by and between the Company and certain purchasers (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex10-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">10.38</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465923088389/tm2322973d1_ex10-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant Amendment Agreement, dated as of August 3, 2023, by and between the Company and certain warrant holders (incorporated by reference to Exhibit 10.3 to the Company\u2019s Current Report on Form 8-K filed on August 7, 2023).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:3.5pt;\"><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465920029711/tm205374d1_ex21-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">21.1</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000110465920029711/tm205374d1_ex21-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Subsidiaries of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed on March 5, 2020).</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002730/bpth-20231231xex23d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">23.1*</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002730/bpth-20231231xex23d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Consent of Ernst &amp; Young LLP.</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002730/bpth-20231231xex31.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">31*</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002730/bpth-20231231xex31.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Principal Executive Officer/Principal Financial Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 Sarbanes Oxley Act of 2002.</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002730/bpth-20231231xex32.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">32**</span></a></p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002730/bpth-20231231xex32.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Principal Executive Officer/Principal Financial Officer pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">97*</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002730/bpth-20231231xex97.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Executive Compensation Recoupment Policy.</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">101*</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">The following financial statements from the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Inline XBRL: (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Statements of Cash Flows; (iv) Consolidated Statements of Shareholders\u2019 Equity; and (v) Notes to the Consolidated Financial Statements, tagged as blocks of text and including detailed tags.</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:9.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">104*</p></td><td style=\"vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:87.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">The cover page from the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Inline XBRL (included as Exhibit 101).</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\">*</p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\">Filed herewith.</p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\">**</p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\">Furnished herewith.</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td><td style=\"vertical-align:top;width:3%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td><td style=\"vertical-align:top;width:47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"></td><td colspan=\"2\" style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">BIO-PATH HOLDINGS, INC.</p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:3%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:47%;margin:0pt;padding:0pt;\"></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Dated: March 7, 2024</p></td><td style=\"vertical-align:top;width:3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">By:</p></td><td style=\"vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">/s/ Peter H. Nielsen</p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:3%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Peter H. Nielsen</p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:3%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">President</p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:3%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Chief Executive Officer</p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:3%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Chief Financial Officer</p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:3%;margin:0pt;padding:0pt;\"></td><td style=\"vertical-align:top;width:47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Principal Accounting Officer</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:22.51%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Date</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;width:52.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Title</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Signature</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:52.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:22.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">March 7, 2024</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">President/Chief Executive Officer/ Chief Financial Officer/</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">/s/ Peter H. Nielsen</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Principal Accounting Officer/Director</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:22.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Peter H. Nielsen</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:22.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">March 7, 2024</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">/s/ Heath W. Cleaver</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:22.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Heath W. Cleaver</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:22.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">March 7, 2024</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">/s/ Paul D. Aubert</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:22.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Paul D. Aubert</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:22.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">March 7, 2024</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">/s/ Aline B. Sherwood</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:22.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Aline B. Sherwood</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:22.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">March 7, 2024</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">/s/ Douglas P. Morris</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:18.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:52.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:22.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Douglas P. Morris</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:93.18%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:93.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Bio-Path Holdings, Inc. Financial Statements</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Page</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:93.18%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\"><a href=\"#ReportofIndependentRegisteredPublicAccou\"><span style=\"font-style:normal;font-weight:normal;\">Reports of Independent Registered Public Accounting Firms</span></a> (PCAOB ID:  42 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:4.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">F-2</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:93.18%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\"><a href=\"#CONSOLIDATEDBALANCESHEETS_364028\"><span style=\"font-style:normal;font-weight:normal;\">Consolidated Balance Sheets</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">F-4</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:93.18%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\"><a href=\"#CONSOLIDATEDSTATEMENTSOFOPERATIONS_93856\"><span style=\"font-style:normal;font-weight:normal;\">Consolidated Statements of Operations</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">F-5</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:93.18%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\"><a href=\"#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_773775\"><span style=\"font-style:normal;font-weight:normal;\">Consolidated Statements of Cash Flows</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">F-6</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:93.18%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\"><a href=\"#CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHO\"><span style=\"font-style:normal;font-weight:normal;\">Consolidated Statements of Shareholders\u2019 Equity</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">F-7</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:93.18%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\"><a href=\"#NotestoConsolidatedFinancialStatements_6\"><span style=\"font-style:normal;font-weight:normal;\">Notes to Consolidated Financial Statements</span></a></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">F-8</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:top;width:14%;margin:0pt;padding:0pt 0pt 12pt 0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0pt 3.5pt 12pt 0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td><td style=\"vertical-align:top;width:84%;margin:0pt;padding:0pt 0pt 12pt 0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:top;width:14%;margin:0pt;padding:0pt 0pt 12pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0pt 3.5pt 12pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:top;width:84%;margin:0pt;padding:0pt 0pt 12pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-style:italic;font-weight:bold;\">Prepaid or Accrued Research and Development Expenses</span></p></td></tr><tr><td style=\"vertical-align:top;width:14%;margin:0pt;padding:0pt 0pt 12pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><i style=\"font-style:italic;\">Description of the Matter</i></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0pt 3.5pt 12pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:top;width:84%;margin:0pt;padding:0pt 0pt 12pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;\">During 2023, the Company incurred $11.6 million for research and development expenses and as of December 31, 2023 recorded prepaid clinical trial expenses of $0.9 million and accrued clinical trial expense of $0.8 million. As disclosed in Note 2 to the consolidated financial statements, research and development costs are charged to expense when the related goods are delivered, or services are performed. The Company estimated its clinical trial expense based on a cost per patient calculation, which is derived from estimated start-up costs, clinical trial costs based on the number of patients and length of treatment and clinical study report costs. The Company recorded an accrual or prepaid for clinical trial expenses based on its estimated clinical trial expense as compared to payments made to the Company\u2019s third-party clinical research organization, laboratories and clinical investigation sites. </p><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Auditing the Company\u2019s accrued and prepaid research and development expenses is complex due to significant judgment and estimates made by management in determining the clinical trial expenses incurred, which include inputs such as number of patients, length of treatment and clinical study report costs, compared to payments the Company has made.</p></td></tr><tr><td style=\"vertical-align:top;width:14%;margin:0pt;padding:0pt 0pt 18pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><i style=\"font-style:italic;\">How We Addressed the Matter in Our Audit</i></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0pt 3.5pt 18pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:top;width:84%;margin:0pt;padding:0pt 3.5pt 18pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">To test the prepaid research and development expenses for significant clinical trials, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating the significant assumptions that are used by management to estimate the recorded prepayments. To test the significant assumptions, we corroborated the patient enrollment, length of treatment, trial timeline and progress of research and development activities through discussion with the Company\u2019s research and development personnel that oversee the research and development projects, inspected the Company\u2019s contracts with third parties and any pending change orders to assess the impact on amounts recorded, and obtained information directly from vendors of their costs incurred to date. We tested a sample of transactions and compared the costs against related invoices and contracts. We also performed analytics over fluctuations in accruals or prepaid balances by trial throughout the year and tested subsequent payments to evaluate the completeness of the research and development expenses recognized.</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">As of December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">As of December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Assets</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Current assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Cash</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,052 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10,384 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Prepaid drug product </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  632 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,587 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Other current assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,358 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,644 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Total current assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,042 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15,615 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Fixed assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Furniture, fixtures &amp; equipment</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,120 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,120 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Less accumulated depreciation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 1,044 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 962 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  76 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  158 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Right of use operating assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  102 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  198 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\"><b style=\"font-weight:bold;\">Total Assets</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,220 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15,971 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Liabilities &amp; Shareholders' Equity</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Current liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Accounts payable</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  457 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  667 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Accrued expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,346 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  909 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Current portion of lease liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  103 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  108 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Total current liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,906 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,684 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> Warrant liability</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  863 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Noncurrent lease liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  113 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\"><b style=\"font-weight:bold;\">Total Liabilities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,779 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,797 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Shareholders' equity</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Preferred stock, $ .001  par value;  10,000  shares authorized; no shares <span style=\"-sec-ix-hidden:Hidden_q_jy8UHjO0-NoeqlKmaMKg;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">issued</span></span> and <span style=\"-sec-ix-hidden:Hidden_6J5g629dpkKVhXhTEYkzIg;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">outstanding</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"-sec-ix-hidden:Hidden_Oqf00wUTlUaYcv9WNenpJA;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> \u2014</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"-sec-ix-hidden:Hidden_jAqBt4kk2kKjCz5xntirmw;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> \u2014</span></span></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Common stock, $ .001  par value;  200,000  shares authorized;  618  and  398  shares <span style=\"-sec-ix-hidden:Hidden_JOhMniS3NU2FgB8GzFokyA;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">issued</span></span> and <span style=\"-sec-ix-hidden:Hidden_OT5fiVi8WUy7bQs-VDxOHQ;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">outstanding</span></span>, respectively</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\">Additional paid in capital</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  108,047 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  105,702 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\">Accumulated deficit</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 107,607 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 91,529 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Total shareholders' equity</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  441 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  14,174 </p></td></tr><tr><td style=\"vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total Liabilities &amp; Shareholders' Equity</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,220 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15,971 </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Year Ended December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Operating expenses</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Research and development</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  11,608 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  9,165 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">General and administrative</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,235 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,736 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Total operating expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15,843 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  13,901 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net operating loss</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 15,843 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 13,901 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Other income (loss)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Change in fair value of warrant liability</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 271 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Interest income</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  36 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  33 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total other income (loss)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 235 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  33 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net loss</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 16,078 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 13,868 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net loss per share, basic and diluted</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"-sec-ix-hidden:Hidden_ByQS2t1eY0CmlmgjnTszpA;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">$</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 33.63 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"-sec-ix-hidden:Hidden_J69EyTJ8P0Wa2ydBcAyr7A;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">$</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 38.12 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Basic and diluted weighted average number of common shares outstanding</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  478 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  364 </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Year Ended December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Cash flow from operating activities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Net loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 16,078 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 13,868 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Adjustments to reconcile net loss to net cash used in operating activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Stock-based compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  734 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  851 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Amortization of right of use assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  96 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  90 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Depreciation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  82 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  88 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Change in fair value of warrant liability</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  271 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">(Increase) decrease in operating assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\">Prepaid drug product </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,955 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 3,064 )</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\">Other current assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  286 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  199 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Increase (decrease) in operating liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\">Accounts payable and accrued expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  227 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  700 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\">Lease liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 108 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 99 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\">Net cash used in operating activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 11,535 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 15,103 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Cash flow from investing activities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Purchases of furniture, fixtures &amp; equipment</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 21 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\">Net cash used in investing activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 21 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Cash flow from financing activities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Net proceeds from sale of common stock</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,677 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,734 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Net proceeds from exercise of warrants</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  526 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\">Net cash provided by financing activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,203 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,734 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net decrease in cash</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 9,332 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 13,390 )</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Cash, beginning of period</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10,384 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  23,774 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Cash, end of period</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,052 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10,384 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Supplemental disclosure of non-cash activities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Non-cash operating activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Right of use asset recognized in exchange for lease obligation </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  85 </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:16.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Additional</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:16.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Common Stock</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Paid in</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Accumulated</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Description</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Shares</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Amount</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Capital</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Deficit</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:middle;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance at December 31, 2021</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  358 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  103,117 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 77,661 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  25,457 </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">Issuance of common stock, net of fees</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  40 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,734 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1,734 </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">Stock-based compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  851 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  851 </p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">Net loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 13,868 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 13,868 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance at December 31, 2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  398 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  105,702 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 91,529 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  14,174 </b></p></td></tr><tr><td style=\"vertical-align:middle;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance at December 31, 2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  398 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  105,702 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 91,529 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  14,174 </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">Issuance of common stock, net of fees</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  175 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  491 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  491 </p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">Exercise of warrants, net of fees</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  45 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,120 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,120 </p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">Stock-based compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  734 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  734 </p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">Net loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 16,078 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 16,078 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:51.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance at December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  618 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  108,047 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 107,607 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  441 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">4.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Other Current Assets</b></p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">5.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Property and Equipment</b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:17.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Estimated Useful</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Lives</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr style=\"height:0pt;visibility:hidden;\"><td colspan=\"9\" style=\"padding:0pt;\"></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in years)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:17.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Leasehold improvements</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"> 2  to  5 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  463 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  463 </p></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Computers and office equipment</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"> 3 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  83 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  83 </p></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Furniture and fixtures</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"> 7 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  93 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  93 </p></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Scientific equipment</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"> 7 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  481 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  481 </p></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,120 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,120 </p></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Less: Accumulated depreciation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 1,044 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 962 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Net property and equipment</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  76 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  158 </p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">6.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Accounts Payable</b></p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">7.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Accrued Expense</b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:middle;width:41.76%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:2.49%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:9.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:2.5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:9.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:2.5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:9.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:2.5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:9.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:2.46%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"10\" style=\"vertical-align:bottom;white-space:nowrap;width:51.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Fair Value Measurements at</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"10\" style=\"vertical-align:bottom;white-space:nowrap;width:51.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"10\" style=\"vertical-align:bottom;white-space:nowrap;width:51.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:41.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 1</b></p></td><td style=\"vertical-align:middle;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 2</b></p></td><td style=\"vertical-align:middle;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 3</b></p></td><td style=\"vertical-align:middle;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td><td style=\"vertical-align:middle;width:2.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Liabilities:</b></p></td><td style=\"vertical-align:middle;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:41.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Warrant liability</p></td><td style=\"vertical-align:middle;width:2.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:middle;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:middle;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:middle;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> 863 </p></td><td style=\"vertical-align:middle;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:middle;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> 863 </p></td><td style=\"vertical-align:middle;width:2.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:58.48%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:middle;width:79.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:middle;width:2.67%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:79.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"3\" style=\"vertical-align:bottom;white-space:nowrap;width:17.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Fair Value of</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:79.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"3\" style=\"vertical-align:bottom;white-space:nowrap;width:17.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Warrant</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:79.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"3\" style=\"vertical-align:bottom;white-space:nowrap;width:17.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Liability</b></p></td></tr><tr><td style=\"vertical-align:middle;width:79.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"3\" style=\"vertical-align:middle;width:17.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td></tr><tr><td style=\"vertical-align:middle;width:79.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Balance at December 31, 2022</p></td><td style=\"vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:middle;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:79.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Issuance</p></td><td style=\"vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,186 </p></td><td style=\"vertical-align:middle;width:2.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:79.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Exercises</p></td><td style=\"vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 594 )</p></td><td style=\"vertical-align:middle;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:79.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Change in fair value</p></td><td style=\"vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  271 </p></td><td style=\"vertical-align:middle;width:2.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:middle;width:79.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Balance at December 31, 2023</p></td><td style=\"vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  863 </p></td><td style=\"vertical-align:middle;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:56.78%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:78.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"3\" style=\"vertical-align:bottom;white-space:nowrap;width:19.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">As of</b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:78.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"3\" style=\"vertical-align:bottom;white-space:nowrap;width:19.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"3\" style=\"vertical-align:bottom;white-space:nowrap;width:19.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:78.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Risk-free interest rate</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3.84 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Expected volatility</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  102 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:78.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Expected term in years</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  4.6 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Dividend yield</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:3pt;padding-right:3pt;width:30.09%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:top;width:3.87%;margin:0pt;padding:0pt 3pt 0pt 3pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:top;width:21.53%;margin:0pt;padding:0pt 3pt 0pt 3pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td><td style=\"vertical-align:top;width:74.58%;margin:0pt;padding:0pt 3pt 0pt 3pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">10.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Stockholders\u2019 Equity</b></p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">11.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Stock-Based Compensation Plan</b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;\">Risk-free interest rate</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3.42 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2.43 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;\">Expected volatility</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  129 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  127 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;\">Expected term in years</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6.0 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6.0 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;\">Dividend yield</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted-</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Remaining</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Aggregate</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Exercise</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Contractual</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Intrinsic</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Options</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Price</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Term</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Value</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Outstanding at December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  33 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  233.40 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 7.9 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Granted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  11 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  27.80 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 9.3 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Expired</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 1 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,840.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Outstanding at December 31, 2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  43 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  161.20 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 7.6 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Vested and expected to vest December 31, 2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  43 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  162.80 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 7.6 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Exercisable at December 31, 2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  25 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  236.20 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 6.9 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted-</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Remaining</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Aggregate</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Exercise</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Contractual</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Intrinsic</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Options</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Price</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Term</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Value</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Outstanding at December 31, 2021</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  24 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  291.60 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 8.4 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  7,800 </p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Granted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  74.20 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 9.3 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Expired</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 1 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  119.20 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Outstanding at December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  33 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  233.40 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 7.9 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Vested and expected to vest December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  32 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  238.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 7.9 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:59.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Exercisable at December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  16 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  372.40 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 7.3 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">12.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Warrants</b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:52.98%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"6\" style=\"vertical-align:bottom;white-space:nowrap;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Warrants Outstanding</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Warrants Exercisable</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Remaining</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Number</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Contractual</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Exercise</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Number</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Exercise</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Year Issued</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Outstanding</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Life</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Price</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Exercisable</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Price</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in years)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(per share)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(per share)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">2018</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  0.2 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  384.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  384.00 </p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">2019</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  14 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  0.8 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  275.20 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  14 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  275.20 </p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  40 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4.4 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15.20 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  40 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15.20 </p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  130 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4.6 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  12.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  130 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  12.00 </p></td></tr><tr><td style=\"vertical-align:bottom;width:52.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  190 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4.1 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  43.20 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  190 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  43.20 </p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">13.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Commitments and Contingencies</b></p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">14.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Leases</b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr style=\"height:0pt;visibility:hidden;\"><td colspan=\"7\" style=\"padding:0pt;\"></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Assets:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Operating lease assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  102 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  198 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Liabilities:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Current portion of lease liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  103 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  108 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Noncurrent lease liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  113 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Total operating lease liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  113 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  221 </p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:25.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr style=\"height:0pt;visibility:hidden;\"><td colspan=\"7\" style=\"padding:0pt;\"></td></tr><tr><td style=\"vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:25.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Operating lease costs</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  113 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  115 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Variable lease costs</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  5 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Total lease costs</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  123 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  120 </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.84%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:78.45%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;width:17.42%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:78.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">As of December 31, 2023</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:78.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:78.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">2024</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;width:17.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  108 </p></td></tr><tr><td style=\"vertical-align:bottom;width:78.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">2025</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  11 </p></td></tr><tr><td style=\"vertical-align:bottom;width:78.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Future minimum lease payments</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:17.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  119 </p></td></tr><tr><td style=\"vertical-align:bottom;width:78.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Less: Interest</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 6 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:78.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Present value of operating lease liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;width:17.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  113 </p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">15.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Benefit Plan</b></p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:10.1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">16.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Income Taxes</b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr style=\"height:0pt;visibility:hidden;\"><td colspan=\"7\" style=\"padding:0pt;\"></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Deferred tax assets \u2013 non-current</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Accrued bonuses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  22 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  63 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Accrued vacation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  24 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  28 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Net operating loss (NOL) carryover</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  18,550 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  15,818 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Research &amp; development tax credits</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  4,769 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  2,509 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Share based expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  750 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  671 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Other</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  3 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  3 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Right of use lease liability</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  24 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  46 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Fixed asset depreciation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  50 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  44 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total deferred tax asset</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  24,192 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  19,182 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Less: valuation allowance</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 24,171 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 19,140 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Net deferred tax asset</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  21 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  42 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Right of use asset</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 21 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 42 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Net deferred tax asset</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  \u2014 </p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:74.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr style=\"height:0pt;visibility:hidden;\"><td colspan=\"7\" style=\"padding:0pt;\"></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(in thousands)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Loss before income taxes</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 16,078 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 13,868 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Tax (benefit) at statutory tax rate</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 3,376 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 2,912 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Effects of:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Exclusion of incentive stock option expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  74 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  80 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">R&amp;D tax credits</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 2,261 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  844 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Increase in valuation allowance</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  5,031 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  98 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">FMV of warrants</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  57 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  \u2014 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Section 382 limit - NOL</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  1,890 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Other</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  475 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  \u2014 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Provision for income taxes</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.3pt 0.05pt 0pt;\">  \u2014 </p></td></tr></table>"
    ]
}